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Impact statement 
 
This work is the first to demonstrate that pre-pubertal females are inherently more primed to 
respond to virus than males. It is the first to report that the production of interferon alpha 
(IFNα) after toll-like receptor 7 (TLR7) stimulation was higher in females, regardless of puberty, 
but also higher after puberty, regardless of sex. Through the investigation of a unique cohort 
of healthy and transgender young people, as well as young girls with Turner’s syndrome (TUS), 
a unique model was built that uncouples serum sex hormones and the number of X 
chromosomes for the first time in humans. Through this, novel associations between X 
chromosome number, and serum sex hormone have been demonstrated in the innate anti-
viral immune system which may contribute to the sex differences seen in viral infection, 
vaccination and autoimmunity. 
The unique group of young people who showed such interest and willingness to be involved in 
this study, provide a glimpse into these relationships in a manner that was previously only 
possible in murine experiments. These data not only highlight the importance of sex as an 
under-represented variable in immunology, but also highlight the importance of pubertal 
development in the immune system.  
This research aimed to address one of the main research questions that young people at the 
ARUK Centre for Adolescent Rheumatology wanted investigated: ‘Why me?’. These data start 
to answer that question for young women with juvenile onset SLE (jSLE) which is more 
common in young women after puberty.  These are some of the first data reporting changes in 
the immune system in young people who undergo gender switching and are important in the 
care of transgender young people.  
These data reveal novel themes in the immune-pathogenesis of jSLE. TLR7, TLR9 and the 
endogenous retroelement LINE1 emerge as targets for future research.  A novel correlation 
between tetherin protein expression and IFN gene expression signature is described that may 
be explored further as a clinical biomarker. The importance of stratifying jSLE by IFN gene 
expression has been highlighted here, as well as the novel method of controlling for IFN gene 
expression when measuring the expression of individual genes in jSLE.  
Custom flow cytometry panels were designed and optimised, and a specific Nanostring Plexset 
technique (that has not been previously performed in the UK) was painstakingly optimised for 
this project. This serves as an affordable and fast platform to perform gene expression in jSLE 
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Abstract  
Type 1 IFNs are an antiviral cytokine family, important in jSLE which is more common in 
females, around puberty. It is reported here that plasmacytoid dendritic cells (pDC) from 
healthy females were more activated than males, and expressed more of the anti-viral surface 
protein, tetherin than males, suggesting that they are more primed to react to viral ligand. In 
healthy volunteers, females produced more type 1 IFN after TLR7 stimulation than males, 
regardless of puberty. There was however an increased production of type 1 IFN after TLR7 
stimulation in post pubertal volunteers, regardless of sex. A unique human model including 
transgender volunteers and young women with TUS revealed that TLR7 induced type 1 IFN 
production related to X chromosome number, and serum testosterone concentration, in a 
manner which differed depending on the number of X chromosomes present. Female 
peripheral blood mononuclear cells (PBMC) expressed more of the genes coding for RNA-
sensors RIG-1 and MDA5 regardless of puberty, and TLR7 gene expression was increased in 
post pubertal females. Therefore, females were inherently more primed to respond to viral or 
endogenous RNA ligand than males, and produced more type 1 IFN after TLR7 stimulation, 
which associated with puberty in a manner that may partly explain why a type 1 IFN mediated 
autoimmune disease like jSLE is more common in females after puberty. Indeed, in this study, 
young people with jSLE had a diminished production of IFNα after TLR9 stimulation and a 
decreased gene expression of TLR9. Conversely, TLR7 induced IFNα production was unchanged 
and TLR7 gene expression was increased in jSLE patients with evidence of a high background 
IFN. Stratifying low disease activity patients with jSLE revealed that approximately half of these 
patients had an upregulated IFN score, which is less than previously reported in higher disease 
activity and may better represent the baseline. Stratifying by IFN score revealed that the gene 
expression of the endogenous retroelement LINE1 was relatively upregulated in jSLE as 
compared to healthy volunteers. These findings highlight the importance of TLR7 in the female 
predisposition toward jSLE, especially after puberty, and reveal TLR7 and LINE1 as potential 
targets for future investigation. 
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Chapter 1: Introduction 
 
Sex differences exist in the prevalence and severity of many immune mediated human 
diseases, including infections, malignancies, and autoimmune diseases (2, 3). Systemic lupus 
erythematosus (SLE) is perhaps the most obvious immune disease that is highly skewed 
towards the female sex(4). The sex difference in juvenile onset SLE (jSLE) is further skewed 
after puberty, leading to the hypothesis that female sex and puberty associate with changes in 
the immune system which predispose females to develop jSLE. Specifically, as type 1 interferon 
(IFN) is a cytokine family associated with SLE, and it is known that the toll-like receptor (TLR) 7 
mediated production of IFNα is higher in females, this thesis aims to explore whether TLR7 
mediated IFNα production changes over puberty in a manner which may predispose females 
to develop jSLE. Importantly, unique human models are required to further investigate the 
underlying contributions of X chromosome number and serum sex hormone concentration to 
the sex and pubertal differences in IFN pathway.  
Sex and puberty are basic biological variables. Despite this, there are very little data regarding 
the influence of sex and puberty on the immune system which could help to explain the sex 
and developmental differences seen in immune related disease phenotypes.  
In this introduction, the basic and more detailed concepts and literature around sex, puberty 
and the immune system will be described, with a specific focus on type 1 IFN and jSLE to 
develop the hypothesis that puberty associates with an increased TLR7 mediated type 1 IFNα 
production in females, which, if true, may predispose them to the development of jSLE. 
1.1.1. The immune system  
The immune system is the defence mechanism of any organism against disease. It is composed 
of processes and structures which essentially protect an organism from pathogens. These 
pathogens are varied, rapidly evolve and adapt to evade the immune system in a continuous 
evolutionary arms race.  
In humans and other vertebrates, exposure to a new pathogen or antigen (any molecule that 
can be bound by a major histocompatibility complex (MHC) and presented to a T cell receptor) 
triggers both the innate and adaptive immune system. The innate response is rapid, with 
recognition of non-specific pathogen associated molecular patterns (PAMPS) by pattern 
recognition receptors (PRR). PRR activation results in a rapid and potent early alarm response. 
If the pathogen is not eliminated by this early innate response, the adaptive immune system is 
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recruited. Antigen presenting cells (APC) migrate to lymphoid organs to present the antigen to 
naïve T and B cells that recognise the antigen via their specific receptors. This results in the 
clonal expansion and differentiation of these cells into effector cells, which, in addition to 
eliminating the pathogen, confer long lasting memory immunity to the organism.  
Below, a brief overview will be provided of the adaptive immune system, before focussing 
more on the innate immune system, specifically the anti-viral, type 1 IFN mediated response. 
1.1.1.1. The adaptive immune system-brief overview 
The adaptive immune system is the newer system in evolutionary terms and exists only in 
vertebrates. The adaptive immune system can adapt to varied challenges and develop a lasting 
immune memory that will protect the organism against the same pathogen in its lifetime.  T 
cells are lymphocytes that develop in the thymus. They recognise antigen via membrane 
bound T cell receptors (TCR). These TCR recognise short peptide fragments of antigen, 
presented to them via MHC on an APC. The TCR is restricted to recognise both a particular 
peptide sequence and the particular MHC upon which is presented. Antigen presented on 
MHCI complex is recognised by the CD8 co-receptor on cytotoxic T cells, whereas antigen on 
MHCII is recognised by the CD4 co-receptor on helper T cells. Cytotoxic T cells largely recognise 
viral peptide presented via MHCI and result in the killing of the infected presenting cell. All 
nucleated cells express MHCI and therefore can be effectively killed. Helper CD4 T cells are 
capable of killing the presenting cell, but also capable of further modulating the immune 
response via the activation of B cells, dendritic cells and macrophages(5).   
B cells produce immunoglobulins. Immunoglobulins that are bound to the B cell membrane are 
effectively B cell receptors (much like TCR), and the soluble immunoglobulins released by B 
cells are known as antibodies. Antibodies bind antigen in the extra cellular spaces of the body 
and mark the antigen (and associated pathogen) for destruction by other cells. Antibodies may 
also undergo secondary diversification via somatic hyper-mutation, gene conversion and class 
switching.  
Each human has an immensely diverse repertoire of TCR and antibody due to somatic VD(J) 
recombination under the guidance of recombination activation gene enzymes (RAG). In the 
thymus, the autoimmune regulator (AIRE) protein is responsible for the specific deletion of 
self-reactive T cells(5).  
In the adaptive immune system, there is an initial maturation of response after the first 
exposure to a pathogen, and a rapid, specific and effective response upon subsequent 
exposures, swiftly eliminating the pathogen before it can establish infection.  
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Many of the discoveries of the immune system come from the study of diseases with 
abnormalities in the immune response. Charles Janeway Jr., the author of the famous 
Janeway’s Immunobiology textbook, in one of his final papers, reminisced about how his 
father, an Immunologist, described the emergence of a clinical syndrome in infants lacking 
immunoglobulin, after the advent of penicillin, where previously they would not have 
survived(6, 7). The discovery of this immune abnormality, along with others, has shaped of our 
knowledge about how the immune system works, and this theme will be echoed throughout 
the introduction. In the same paper, Janeway commented that the adaptive immune system 
was solely responsible for diseases manifesting with immune deficiency and autoimmunity(6). 
In recent years, as more of the innate immune system is discovered, it is emerging that the 
distinction between the two is probably more blurred than was previously thought. With the 
emergence of transcriptome and genome sequencing, as discussed later, it is becoming clear 
that many of the diseases that were thought to be largely due to dysfunction of the adaptive 
immune system, like SLE, may have a more innate basis(1).  
1.1.1.2. The innate immune system-brief overview 
The innate immune system is the more recently discovered, although more evolutionarily 
ancient, arm of immune defence. It is based on the principle that there are conserved non-self-
molecules that trigger a non-specific alarm via germ line encoded PRR. This principle of 
‘pattern recognition’ was proposed by the same Charles Janeway Jr. at a symposium in 1989, 
and describes two features of innate immunity: the ability to distinguish between self and 
pathogen non-self and the ability to activate the adaptive immune responses to non-self (8, 9). 
His co-author, Ruslan Medzhitov, his student at the time, published a follow on 20 years later, 
showing that Janeway’s pattern recognition hypothesis has subsequently been proven correct, 
and in addition to suggesting a general principle of innate immune recognition, provided a 
conceptual framework for the integration of innate and adaptive immunity(10).  
The PRR are classified into five families based on protein domain homology(8). These five 
families consist of the TLRs, C-type lectin receptors (CLRs), nucleotide-binding domain, leucine-
rich repeat (LRR)-containing (or NOD-like) receptors (NLRs), RIG-I-like receptors (RLRs), and the 
AIM2-like receptors (ALRs) (Table 1-1). 
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PRR Members Shared domains Receptor 
location 
TLR 1–10 in humans, 
1–9 and 11–13 
mice 
LRR, TIR Cell surface, 
endosomal 
compartments 
CLR Dectin-1, Dectin-
2, DC-SIGN, 
mannose 
receptor, CLECSF 
8 etc  
C-type lectin Cell surface 
NLR NOD1 (NLRC1), 
NOD2 (NLRC2), 
NLRC3–5, 
NLRP1–9 and 11–
14, NAIP1, -2, -5, 
-6 
Nucleotide 
binding, LRR 
Cytoplasm, 
plasma, and 
endosomal 
membrane 
associated 
RLR RIG-I, MDA5, 
LGP2 
DExD/H helicase Cytoplasm 
ALR AIM2, IFI16 PYRIN, HIN-200 Cytoplasm, 
nucleus (IFI16) 
Table 1-1. Pattern recognition receptors (adapted from Brubaker et al(8)). AIM, absent in 
melanoma; ALR, AIM2-like receptor; CARD, caspase recruitment domain; CLR, C-type lectin 
receptor; IFI, IFN, γ-inducible; LGP, laboratory of genetics and physiology; LRR, leucine-rich 
repeat; MDA, melanoma differentiation gene; NAIP, NLR family, apoptosis inhibitory protein; 
NLR, nucleotide-binding oligomerization domain receptor; NLRC, NLR family CARD domain 
containing; NLRP, NLR family PYD domain containing; NOD, nucleotide-binding oligomerization 
domain; RIG-I, retinoic acid–inducible gene I; RLR, RIG-I-like receptor; TIR, Toll/IL-1 
receptor/resistance; TLR, Toll-like receptor. 
PRR signal via downstream adaptor proteins. Importantly, these adaptor proteins may receive 
signals from multiple PRR (e.g. myeloid differentiation primary response protein 88 (MyD88) 
acts as an adaptor protein for multiple TLR). These adaptors must interact with an upstream 
and downstream signalling protein(8). There are numerous adaptor proteins described as 
summarised in Table 1-2.   
28 
 
 
 
 
 
 
 
 
 
 
 
Table 1-2. Pattern recognition receptor downstream adaptor proteins (as adapted from 
Brubaker et al(8).ASC, apoptosis-associated speck-like protein containing a CARD; CARD, 
caspase recruitment domain; MAVS, mitochondrial antiviral signalling protein; RHIM, RIP 
homotypic interaction motif; TIR, Toll/IL-1 receptor/resistance; TIRAP, TIR-containing adaptor 
protein; TRAF, TNF receptor–associated factor; TRAM, TRIF-related adaptor molecule; TRIF, TIR 
domain–containing adaptor-inducing IFNβ. 
1.1.1.2.3. Toll like receptors  
 Perhaps the best described PRR are the TLR. As they shall be important in this thesis, I shall 
specifically highlight their structure and pathway as an example of innate immune functioning. 
Toll is a receptor that was discovered in Drosophilia where it was found to be essential for 
establishing dorsoventral polarity during embryogenesis (11). Subsequently TLR were also 
found to play an important role in the immune system of insects, leading to their study in 
vertebrate immunology (12). TLR are essentially glycoproteins, consisting of a leucine rich 
repeat  (LRR) and a Toll/IL1-receptor/resistance (TIR) cytoplasmic domain(Fig. 1-1)(13). The 
LRR forms a horse-shoe like shape which is provides a concave binding surface for the binding 
of various pathogen ligands. Each TLR has a specific pathogen ligand that it recognises. The 
cellular location of the TLR is also important in defining what it binds to and what it defines as 
non-self. The various TLR ligands are summarised in Table 1-3(14).  
 
Adapter 
protein  
Upstream 
receptor 
interaction  
Downstream 
signalling 
interaction 
Location 
TIRAP/MyD88 TIR domain Death domain Cell surface, 
endosomal 
compartments 
TRAM/TRIF TIR domain TRAF binding, 
RHIM domain 
Cell surface, 
endosomal 
compartments 
MAVS CARD domain Proline-rich 
region, TRAF 
binding 
Mitochondrial, 
peroxisomal, 
and 
mitochondria-
associated 
membranes 
ASC PYRIN CARD domain Cytosol, 
mitochondria 
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Table 1-3. TLR ligands and their origin (adapted from Akira et al(14)). TLR-Toll like 
receptor,RSV-respiratory syncytial virus. TLR-Toll like receptor 
 
 
 
 
 
 
Figure 1-1. Toll like receptor (TLR) basic structure (adapted from Akira et al(14)) .TLR have a 
leucine rich repeat (LRR) end and an intracellular TIR( Toll/IL-1 receptor/resistance) domain. 
 
TLR Ligand Pathogenic origin  
TLR 1 Tri-acyl lipopeptides Bacteria and mycobacteria 
TLR2 Lipoprotein, peptidoglycan, lipoteichoic 
acid, glycolipids, porins, atypical 
lipopolysaccharide(among others) 
Gram positive bacteria, 
mycobacteria, Neisseria, fungi 
TLR3 Double stranded RNA Viruses 
TLR4 Lipopolysaccharide  Gram negative bacteria, RSV 
TLR5 Flagellin Bacteria 
TLR6 Diacyl lipopeptides, lipoteichoic acid, 
zymosan 
Mycoplasma, gram positive 
bacteria, fungi 
TLR7 Single stranded RNA Virus 
TLR8 Single stranded RNA Virus 
TLR9 CpG containing DNA Virus and bacteria 
TLR10 Not defined  
TLR11  Not defined  
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Downstream of the various adaptor proteins, there are further complex signalling pathways, 
including interleukin 1 associated receptor family (IRAK), TNF receptor associated factor (TRAF) 
and IκB kinase (IKK) mediated phosphorylation and ubiquitination and ultimately nuclear 
factor-κB (NF-κB) transcription or IFN regulatory factor (IRF) activation. These pathways all 
differ slightly, depending on the TLR, and ultimately give rise to the transcription of specific 
inflammatory genes, and ultimately a specific cell phenotype in response to the particular 
ligand(15).  
The focus of this shall be on the specific anti-viral arm of the innate immune system that has 
evolved to respond to viral and non viralnucleic acid ligands.  
1.1.1.3. The innate antiviral immune system  
There is a rapid and potent response to viral infection in the innate immune system. Viruses 
are particularly adept at rapid mutation and adaptation, and therefore the innate immune 
system has had to develop a robust non-specific response to early viral infection. Viral diseases 
display a sex difference in clinical phenotype, and innate response (16, 17). In addition, SLE has 
been described as a disease that resembles a viral infection, without any identifiable virus, in 
that it has a type 1 IFN transcription signature, an idea which shall be further explored later(1). 
For these reasons, the specific type 1 IFN antiviral innate response will be described in detail 
here.  
1.1.1.3.1. Type 1 IFN  
The type 1 IFN family is a class of cytokines, named for their ability to interfere with the 
replication of virus in vivo and in vitro(18). The family consists of IFNα and IFNβ as well as IFNε, 
IFNκ and IFNω.  For the purposes of this thesis, IFNα and IFNβ will be the focus, as these have 
been the best described in relation to SLE. IFNα has 13 subtypes, and both IFNα and IFNβ are 
coded for on chromosome 9. Nearly every cell can produce type 1 IFN but, during the course of 
an infection, pDC are the chief producers of type 1 IFN (19).  
1.1.1.3.2. Type 1 IFN signalling 
All type 1 IFNs signal via the IFN receptor (IFNΑR) which has 2 subunits (Fig. 1-2(20)). Each type 
1 IFN subtype binds to the receptor subunits with different affinities, and different IFNΑR 
densities exist in different tissue types, causing slightly different upregulation of IFN stimulated 
gene (ISG) transcription and subsequent anti-viral response depending on subtype and tissue 
type(21). 
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Figure 1-2. (From Randall et al(20)) The type 1 IFN receptor consist of 2 subunits. IFNΑR-IFN 
receptor. 
When type 1 IFN binds to the IFNΑR, the receptor subunits are endocytosed and activate 
tyrosine kinases (Tyk)2 and janus kinase (Jak)1. This results in the phosphorylation of signal 
transducer and activator of transcription (STAT) 1 and 2, with complex formation with IRF9, 
resulting in the IFN stimulated gene factor 3 (ISGF3) complex. ISGF3 translocates to the 
nucleus, where it binds IFN stimulated regulatory elements (ISRE) in the promoter regions of 
ISG (Fig. 1-3(22)). 
 Figure 1-3. Type 1 IFN leads to transcription of ISG (From Michalska et al(22)). IFN-IFN, IFNΑR-
IFN receptor, JAK-janus kinase, TYK-tyrosine kinase, IRF-IFN regulation factor, STAT- signal 
transducer and activator of transcription, ISGF3- IFN stimulated gene factor 3, ISRE-IFN specific 
response element, ISG-IFN stimulated genes. 
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1.1.1.3.3. Type 1 IFN function and IFN inducible genes 
Type 1 IFNs cause cells to behave in a typical antiviral manner. They are pro-apoptotic and 
cytostatic, and induce the transcription of potent viral restrictor proteins(18). Type 1 IFN has 
been shown to increase activation of monocytes and dendritic cells, increase chemotaxis, 
antigen presentation and T cell activation(23). Type 1 IFN enhances T cell survival, activation 
and clonal expansion, promotes B cell antibody production and class switching(23). As will be 
shown later, many of these type 1 IFN induced anti-viral immune functions are similar to the 
immune abnormalities seen in SLE. It is important to note that the type 1 IFN response may 
have developed to detect and respond to viral nucleic acid ligand, but is not specific to nucleic 
acids of viral origin. 
ISG display a large variety of anti-viral functions. ISG include genes encoding for PRR such as 
TLR9, RIG-1, STING, MAVS and cGAS (among many others). Many ISG encoded proteins are 
potent antiviral effectors. These include inhibitors of viral entry (e.g. MX1, IFITM, TRIM), 
inhibitors of viral translocation and replication (e.g. IFIT, ISG15) and inhibitors of viral assembly 
and shedding (e.g. tetherin and viperin) (Fig. 1-4(24)). ISG also include transcription factors 
such as IRF7 and IRF3. . 
 Included in the ISG, are genes involved in regulation of IFN response, such as SOCS, a JAKSTAT 
inhibitor and USP18, which maintains long term desensitisation to IFN(25). 
ISG indirectly measure for the presence and action of type 1 IFN, by measuring the genes that 
type 1 IFNs upregulate. ISG can be measured using a single gene, commonly MX1, or by 
measuring multiple genes, which are used to build a type 1 IFN score (26). Measuring gene 
expression may be complex and relatively time consuming. Very early data is emerging that 
the expression of the protein encoded by certain ISG (e.g. tetherin) on cell surfaces closely 
correlates to the gene expression and may serve as an more easily measurable proxy measure 
for type 1 IFN activity(27), although it is not known whether surface tetherin expression 
accurately correlates with ISG score.  
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 Figure 1-4. Direct anti-viral effector IFN stimulated genes (ISG) ( From Schneider et al(24)). ISG 
are specific genes, upregulated by type I IFN which code for proteins that directly inhibit viral 
entry, fusion, uncoating, transcription, replication, translation and release. ISG are represented 
by stars in the figure above which shows the effector function of a few of the ISG. 
1.1.1.3.4. Nucleic acid sensing and type 1 IFN production  
Type 1 IFNs are produced when cells sense viral (or endogenous) RNA or DNA through specific 
cytoplasmic or endosomal nucleic acid PRR. Endosomal TLRs 3, 7 and 9 sense nucleic acids. 
TLR3 senses double stranded RNA (DsRNA), and signals via the adaptor protein TRIF (TIR 
domain–containing adaptor-inducing IFNβ) to induce type 1 IFN production.  
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TLR7 specifically senses single stranded RNA (ssRNA), while TLR9 senses DNA with a CpG motif. 
TLR7 and TLR9 are transported to appropriate intracellular compartments by UNC93B1 and 
require cleavage to recruit MyD88. All TLR7 and 9 signalling requires MyD88, but additional 
factors determine whether TLR7 or 9 engagement will result in the production of type I IFNs 
(IFNs) or pro-inflammatory cytokines. These factors include the mode of ligand entry and the 
intracellular compartment in which the TLR encounters its ligand. DNA and RNA viruses, CpG 
ODNs and small DNA/RNA immune complexes enter pDCs through endocytosis. If adaptor 
protein 3 (AP3) or microtubule-associated protein 1A/1B-light chain 3 (LC3) are recruited then 
the IFN-regulatory factor 7 (IRF7) endosome forms, leading to type I IFN production. Several 
molecules and pathways are involved in this process including IκB kinase-α (IKKα), osteopontin 
(OPN), SLC15A4, Bruton's tyrosine kinase (BTK), BLOC1, BLOC2, DOCK2, PACSIN1 (protein 
kinase C and casein kinase substrate in neurons protein), phospholipid scramblase 1 (PLSCR1), 
viperin, SCARB2 and the mammalian target of rapamycin (mTOR) pathway. This ultimately 
leads to the phosphorylation of IRF7 and transcription of type 1 IFN. Alternatively, TLR 7 and 9 
containing compartments can form NF-κB endosomes, resulting in the production of pro-
inflammatory cytokines and chemokines (e.g. interleukins-IL6, IL12 and tumour necrosis factor-
TNF). This process requires IRF5, BTK and Solute Carrier Family 15 Member 4 (SLC15A4)(28). 
TLR9 signalling is represented in Fig. 1-5(28), and TLR7 signalling follows a very similar path, 
except that ssRNA is the ligands that acts as the trigger. 
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Figure 1-5. Toll like receptor (TLR)9 signalling in Plasmacytoid dendritic cells (pDC) (From 
Sweicki et al(28)). In TLR9 signalling, CpG containing DsDNA or a synthetic CpG ligand enter the 
endosome directly or via immune complex and activate TLR9 signalling. This occurs via an IRF7 
or NF-κβ endosome to result in the production of type 1 IFN or other cytokines respectively. IC-
immune complex, AP3-adaptor protein 3, MyD88 myeloid differentiation primary response 
protein 88, IRF-IFN regulatory factor, SLC 15A4-Solute Carrier Family 15 Member 4, BTK- 
Bruton's tyrosine kinase, PACSIN1 -protein kinase C and casein kinase substrate in neurons 
protein,PLSCR1- phospholipid scramblase 1, mTOR-mammalian target of rapamycin, IKKα- IκB 
kinase-α,OPN- osteopontin, BLOC- biogenesis of lysosome-related organelles complex, DOCK- 
dedicator of cytokinesis, SCARB2- scavenger receptor class B member 2. 
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In addition to the endosomal sensors in pDC, there are intra-cytoplasmic nucleic acid sensors 
capable of inducing type 1 IFN production.  
DsRNA sensors are retinoic acid-inducible gene (RIG)-like receptors (RLR): RIG-1, melanoma 
differentiation-associated protein 5 (MDA5) and LGP2. After recognition of dsRNA, RIG-1 and 
MDA-5 undergo conformational changes, resulting in the exposure of caspase activation and 
recruitment domains (CARD) in the N-terminal. This then interacts with the CARD of the 
mitochondrial antiviral signalling protein (MAVS), an adaptor protein, in the outer membrane 
of mitochondria (29). MAVS forms aggregates in the outer membrane of mitochondria, which 
interact with downstream signalling proteins, IKK complex-NF-κ and TBK1/IKKi-IRF3, resulting 
in the expression pro-inflammatory and type I IFN genes, respectively. LGP2 is thought to 
regulate RIG-I- and MDA5-mediated antiviral responses (29). 
Intracellular DNA is derived from viruses, bacteria, and mitochondria, and is recognized by 
cytoplasmic DNA PRR, including cyclic GMP-AMP synthase(cGAS), AIM2, DEAD-box helicase 41 
(DDX41) and IFN alpha-inducible protein 6 (IFI16). These result in the production of type 1 IFN 
and other cytokines. cGAS is a newly discovered potent DNA sensor that signals via stimulator 
of IFN genes (STING)(30, 31). 
1.1.1.3.5. Interferon regulatory factors  
IRF are important in the interferon signalling pathway s of all 3 types of IFN(32). Briefly, IRF are 
a family of 9 factors, which are involved as transcription factors in the interferon signalling 
pathways. In addition, they play a role in immune cell development, regulation of immune 
response, oncogenesis and metabolism(32). IRF function differently in all 3 classes of IFN. In 
type 1 IFN via TLR 7 or 9 stimulation, IRF7 and to a lesser extent, IRF are important in the 
downstream transcription of type 1 IFN(33). IRF7, IRF5 and IRF3 are essential in the RIG-
1/MDA5 mediated production of type 1 IFN, whereas IRF8 may play a regulatory role(33). 
 
1.1.1.3.6. Plasmacytoid dendritic cells-brief overview 
As pDC are the chief cell that produce type 1 IFN(34, 35), they will briefly be described here .In 
general, dendritic cells(DCs) act as a bridge between the innate and adaptive arms of the 
immune system.  They are able to respond to molecular PAMPS and present antigen to the 
specific T cells in the adaptive immune system. DC are divided by the nature of the pathogen 
that they are primed to respond to and include the subtypes plasmacytoid DC (pDC) and 
conventional DC (cDC) 1 and 2(36). pDC develop from common lymphoid progenitors under 
the influence of E2-2, a basic haemophagocytic lymphohystiocytosis protein and the relative 
lack of ID2, an inhibitor of DNA binding(36). Growth factors GM‐CSF (acting through STAT5) 
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and Flt3L (acting through STAT3) respectively inhibit or enhance pDC development by 
modulating the expression of ID2 and E2‐2.  .pDC specialise in the innate anti-viral response by 
producing type 1 IFN after the sensing of cytoplasmic or endosomal nucleic acid(28). Human 
pDCs do not express the lineage-associated markers CD3, CD19, CD14, CD16 and CD11c(37). 
They are characterised by the expression of BDCA2 (also known as CLEC4C), CD123 and the 
immunoglobulin superfamily receptor immunoglobulin-like transcript 7 (ILT7; also known as 
LILRA4)(37). Although most cells can produce type 1 IFN after TLR7 and TLR9 stimulation, pDC 
are known to produce by far the most, in the order of 1000 times more than any other cell 
type. Upon stimulation with TLR7 or TLR9 ligands, pDC downregulate their expression of 
BDCA2(38). 
1.1.1.4. Summary 
In this brief overview, the overall scheme and functioning of the highly complex immune 
system has been described, with a specific focus on the type 1 IFN related, innate, anti-viral 
immune system, which has a relevance to sex and jSLE. In the next section, the concepts of sex 
and puberty will be described and the limited data about their role in immune development 
and functioning will be summarised.  
1.1.2.  Sex  
Sex is a biological construct defined by chromosomes, sex organs and hormones. Gender is 
defined by behaviours and activities influenced by society and culture. Sex is an important and 
neglected biological variable, especially within the immune system. Unfortunately, 
immunology ranks among the lowest of the scientific disciplines for the reporting of sex based 
differences(39). There was a perception in early research that female animals introduced 
monthly variability into data and therefore many preclinical studies included male animals 
only(40). The Food and Drug Administration in the 1970s recommended that females of 
reproductive age be excluded from clinical studies, and therefore females have been 
historically under-represented in pre-clinical and clinical research(3). Sex is an important 
biological variable that may provide insights into disease pathogenesis, especially in diseases 
with a strong sex bias, such as SLE. Recently the National Institute of Health and other 
Canadian and European agencies have issued a call for sex differences to be represented in 
clinical and pre-clinical studies(3). A brief summary of the literature regarding the role of sex in 
the immune system is given below. 
1.1.2.1. Sex and the immune system  
Sex, as a biological variable influences the immune system in anatomical and physiological 
terms, in the transmission of, exposure to, clearance of and subsequent immunity to, micro-
organisms. The psychosocial variable, gender, may influence the immune system in that it 
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influences societal behaviours, environmental exposures and health seeking. For the purpose 
of this thesis, sex will be referred to as a biological variable, with the  recognition that gender 
also influences immunity, although not discussed further here(3).  
1.1.2.1.1. Sex and disease 
As mentioned before, disease states often highlight underlying physiological processes. Many 
diseases display a sex bias in terms of incidence and prevalence as well as severity and 
outcome. A non-exhaustive summary is provided in Fig. 1-6 from an excellent review on the 
subject by Klein et al(3). The general trend that emerges is that females seem to mount an 
enhanced immune response to most pathogens when compared to males. This offers females 
relative protection from infection and some cancers, while increasing their risk of 
autoimmunity and morbidity in viral disease where a hyper-active response may be 
detrimental (e.g. HIV, influenza).  
 
Figure 1-6. Summary of sex differences in disease manifestations (From Klein et al(3)). 
Generally, females show an increased susceptibility to autoimmune disease whereas males 
bias toward non-reproductive cancers. There are also differences in susceptibility to infectious 
diseases. HIV-human immunodeficiency virus, MERS-middle east respiratory syndrome. 
It appears that these sex differences in disease occur at all ages. New-born males have a higher 
rate of death from infection than new-born females(41). In developing countries, male 
children have higher rates of malaria, trematode and nematode infections(42). In adults, 
human immunodeficiency virus (HIV) infected women have a higher CD8+ T cell activation, 
when adjusted for viral load, and less circulating viral RNA than men. Despite this, women have 
a 1.6 fold higher risk of progressing to advanced immune deficiency syndrome(AIDS) at the 
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same viral load as men(43). Prevalence of infection with influenza virus is higher in men, but 
death following influenza infection is higher in women. Tuberculosis and Cryptococcus 
infection are more common in men, along with hepatitis B infection(3). Men are more likely to 
die of sepsis than females(44). 
It is well established that females are more prone to develop almost all types of autoimmune 
disease. The exception to this rule (which is not included in Fig 1-6) is HLAB27 mediated 
disease such as ankylosing spondylitis and juvenile onset enthesitis related arthritis, which are 
more common in males after puberty.  
Sex differences have also been described in vaccine response (45, 46) (Figure 1-7). 
Consistently, females mount a ‘stronger’ response than males, achieving higher titres of 
antibody post-vaccination. In addition, it has been shown that females are more likely to suffer 
adverse events secondary to immunisation than men (i.e. vaccine side effect), but less likely to 
contract the disease in the future (i.e. vaccine failure)(46). Indeed, in dose response studies in 
influenza vaccine, women who received half the dose of inactivated influenza vaccine than 
men achieved equivalent protective antibody titres(47). 
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 Figure 1-7. Sex differences in response to vaccination (From Klein et al(3)). Td/Tdap-tetanus, 
diphtheria and pertussis 
Cancers occurring outside of the reproductive tract show a bias towards males (48). Males 
have double the risk of mortality than females from all types of malignancy(49). Immune based 
cancer therapies, such as programmed cell death 1 ligand 1 specific monoclonal antibodies 
have been reported to be more effective in females than males with malignant melanoma (3, 
50). Therefore, an enhanced immune response in females may offer better immune 
surveillance of tumour cells.  
In summary, sex differences in disease phenotypes generally seem to indicate that females at 
all ages have an ‘enhanced’ immune reaction to infection than males.  
1.1.2.1.2. Sex and the adaptive immune system  
Compared to the overall volume of immunology research, research that includes sex as a 
variable in immunology is rare. Despite this, from the research that is available, it is clear that 
sex affects most arms of the immune system, as will be summarised here. The general trend 
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mirrors the findings in disease phenotype, in that females tend to produce an enhanced or 
exaggerated response as compared to men.   
From the earliest screening of self-reactive T cells in thymic tissue by the autoimmune 
regulator (AIRE), sex differences are present in the immune system. AIRE gene expression has 
been shown to be decreased in female thymic tissue in two separate recent studies (51, 52). 
Dragin and colleagues associated diminished AIRE expression with oestrogen-associated gene 
methylation, while Zhu and colleagues demonstrated that the androgen receptor bound 
the AIRE promoter region and increased AIRE expression. Both demonstrated  that 
AIRE expression affected thymic expression of tissue-specific antigens and, using murine 
models of multiple sclerosis and thyroiditis, found that altering sex steroid production 
influenced susceptibility to autoimmunity in an AIRE-dependent manner(53). 
CD4+ T cells have been widely shown to be increased in healthy female adults and children, 
when compared to males (54-56). Interestingly, even in the context of HIV infection, which 
depletes CD4 T cells, female new-borns, children and adults have been reported to have an 
increased percentage of CD4 T cells in peripheral blood mononuclear cells (PBMC) when 
compared to males (57-59). Female T cells have been shown to have an improved cytotoxic 
activity and upregulation of inflammatory genes, and almost half of the activated genes in 
human T cells have an oestrogen response element in their promoter region(60). Evidence 
suggests that males have more T-regulatory cells (Treg) than females(61).B cells in females 
have been shown to be increased in number and produce more immunoglobulin than in 
men(54, 62). The described sex differences in the immune system are summarised below in 
Table 1-4. 
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Table 1-4. Reported sex differences in the immune system (from Klein et al) (3). IFN-IFN, Treg-T 
regulatory cell, TLR-toll like receptor, TNF-tumour necrosis factor, Il-interleukin. 
1.1.2.1.3. Sex and the innate immune system  
There is very little data that investigates sex differences in the innate immune system. From 
what exists, it seems that males seem better primed immunologically to respond to bacterial 
PAMPs. PBMC from human males produce more tumour necrosis factor alpha (TNFα) after 
lipopolysaccharide (LPS) stimulation than females (63). Male neutrophils have been shown to 
express more TLR4 than females (64, 65). Recent data from the Human Functional Genomics 
Project, a large project that assessed the variability of human cytokine responses to a large 
panel of microbial and metabolic stimuli in a group of 500 healthy volunteers; female sex was 
associated with higher circulating levels of IL-1Ra, lower IL-18 binding protein (IL-18BP), and 
did not associate with  IL-6(66, 67). Spontaneous neutropil apoptosis has been shown to be 
delayed in women compared to men(67). 
This is not the case in the type 1 IFN, anti-viral innate immune system, where there is good 
evidence that females have a more robust response than males as I will demonstrate in detail 
later(16, 68, 69).  
 Female Male 
CD4 T cells ↑CD4 number 
↑activation 
↑IFNɤ 
↑IL17 production 
 
CD8 T cells ↑cytotoxic activity 
↑antiviral gene transcription(RIG, IFNG, 
IFI6) 
 
Treg cells  ↑Treg numbers 
B cells ↑B cell number 
↑Basal levels Immunoglobulin 
↑ antibody responses 
 
Antigen presenting 
cells 
↑phagocytic activity 
↑antigen presentation 
Neutrophils-↑TLR4 and 
TNF 
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1.1.2.2. Summary 
The difference in immune disease phenotype between sexes highlights the importance of sex 
as a variable when studying the immune system. The data are relatively scarce, but indicate 
that females, in general, display an enhanced immune response when compared to males. 
Males and females differ by sex chromosome and sex hormone. These concepts will now be 
described and what is known about how they associate with the immune system will be 
summarised.  
1.1.3. Sex Chromosomes  
Females have two X chromosome and males have a single X and Y chromosome. Females 
however express genes from only one of their X chromosomes.  X gene dosage compensation 
is achieved, at least partially, through random X chromosome inactivation(XCI) (70). The choice 
of which chromosome is silenced occurs early in cell development and randomly results in an 
inactivated X (Xi) and an active X (Xa). The Xi has an exclusion of RNA polymerase II and 
transcription factors as well as epigenetic modifications to repress the Xi(71). This leads to a 
natural mosaicism in females, where cells express either a maternal or paternal derived Xa 
chromosome. This natural mosaicism protects against the effects of X-linked deleterious 
deletions and provides an added diversity in the immune response(72). XCI relies on the 
expression of X-inactive-specific-transcript (Xist), a long, non-coding RNA that is essential for 
female survival(73). Xist is mono-allelically upregulated on an X chromosome and triggers that 
X to become transcriptionally silenced(73). 
Up to 15% of Xi genes in female humans escape XCI (74) with wide variation between gene loci 
and individuals. These regions are known as pseudo-autosomal genes(75).   
1.1.3.1. X chromosome related immune disease 
As mentioned before, immune associated disease often directs our understanding of the 
functioning of the immune system. An indication of the importance of the X chromosome in 
immunity is the clinical manifestation of X-linked immune disorders which will be briefly 
summarised here. The prototypic hereditary autoimmune disease, immune-dysregulation, 
poly-endocrinopathy, enteropathy, X linked syndrome (IPEX) is among these and results from a 
mutation in FOXP3 and a subsequent deficiency or absence of T-regs, manifesting as early 
onset life-threatening autoimmunity.  Bianchi et al (76) have compiled a table (Table 1-5) of 
the other X linked immune diseases, which manifest mostly as immune deficiency, but may 
have autoimmune manifestations. This serves to highlight how the X chromosome has an 
abundance of genes encoding for immune function which will be discussed in the next section.  
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Table 1-5. Summary of X linked immune deficiency syndromes as per Bianchi et al (76). IBD-
inflammatory bowel disease, HA- haemolytic anaemia, DLE-discoid lupus erythematosus, SLE- 
systemic lupus erythematosus, ITP-idiopathic thrombocytopenic purpura 
 
 
Disease Gene X 
chromosome 
location 
Major autoimmune features 
X-linked hyper-IgM syndrome 
(HIGM) 
CD40L Xq26 Sero-negative arthritis, 
hypothyroidism, hepatitis, IBD 
X linked 
agammaglobulinemia (XLA) 
BTK Xq21.3-q22 Arthritis, Diabetes, HA, 
Scleroderma, Alopecia 
Immunodysregulation, 
polyendocrinopathy and 
enteropathy, X-linked 
syndrome (IPEX) 
FOXP3 Xp11.23-
q13.3 
Serum autoantibodies against 
different organs including gut, 
liver, skin, pancreases, kidney. 
Wiskott-Aldrich syndrome 
(WAS) 
WAS Xp11.23-
p11.22 
Vasculitis, uveitis, renal 
disease, Henoch-Schönlein–
like purpura, IBD, cerebral 
vasculitis, neutropenia, 
dermatomyositis, recurrent 
angioedema 
X-linked neutropenia and 
myelodysplasia 
WAS Xp11.23-
p11.22 
Severe neutropenia 
Chronic Granulomatous 
Disease 
CYBB Xp21.1 Sarcoidosis, Crohn’s disease, 
Rheumatoid Arthritis, DLE, SLE, 
ITP, Kawasaki disease, Behchet 
syndrome 
X linked severe combined 
immune deficiency (SCIDX1) 
IL2RG Xq13 Skin Rash, HA 
Anhidrotic ectodermal 
dysplasia with immune 
deficiency NEMO/IKKγ 
deficiency 
IKBKG Xq28 IBD, Arthritis, Autoimmune HA 
X linked lymphoproliferative 
syndrome 
SHD2D1A 
(1) 
XIAP (2) 
Xq25 
Xq25 
Hemophagocytic Syndrome, 
Necrotizing Vasculitis, 
Nephritis 
45 
 
1.1.3.2. X chromosome related immune genes.  
The X chromosome codes for about 1200 genes, including a remarkable number of  immune 
associated genes (Fig. 1-8(77)). The dogma is that females express only 1 copy of most of the X 
chromosome encoded genes, as the Xi is ‘switched off’. In the immune system, data is 
emerging which shows that this may not always be true. Given the large number of immune 
encoded genes on the X chromosome, it is a reasonable extension, that if females were to 
express more of these genes than males, it may explain some of the sex differences seen in 
immune disease phenotype and immune function.  
It was recently shown that in human B and T cells, there is a lack of co-localisation of Xist RNA 
to the Xi as seen in other somatic cells (78). In addition, the Xi in naïve B and T cells, lacks the 
epigenetic histone modifications present in somatic cells. This paper described the Xi as acting 
in a euchromatic manner in human lymphocytes. They show that human female B cells contain 
regions along the X that are expressed at higher levels when compared with male cells, and 
that these regions contain immunity-related genes (e.g. CXCR3 and FOXP3)(78).   Using a 
sequencing technique to map open chromatin sites, predicted transcription factor finding, 
and  nucleosome position, or  ‘personal regulome’ mapping, Qu et al found that sex was the 
largest influence on the variability of the ‘regulome’ of CD4 T cells, with a majority of the 
variability in regulatory elements mapping to the X chromosome(79) . 
Therefore, there is emerging evidence that there may be variable inactivation and regulation 
of the Xi in immune cells specifically and subsequent bi-allelic expression of X encoded 
immune genes in females.  
 In addition, there should be a steady and predetermined mosaicism of paternal and maternal 
Xa expression in tissues in females(77). In acute inflammation or challenge, there may be 
proliferation of a certain subset of cells, resulting in skewing of the natural mosaicism of X 
chromosome expressed genes. In addition, there is an increased skewing of blood and immune 
cells with age in women, which may lead to an over-expression of certain X-linked alleles(80). 
Therefore, the dogma that only one copy of an immune gene is always expressed in females is 
being challenged. In addition, the natural heterogeneity enjoyed by females through 
mosaicism may not be constant and may skew under various conditions resulting in over- 
expression of deleterious alleles. This may explain why females may have an enhanced 
immune response, if they have bi-allelic expression of certain X linked immune genes.  
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Figure 1-8. Genes on the X chromosome encoding proteins with immune function. (From 
Spolarics et al(77)) 
Most studies exploring the reasons for sex difference in immune diseases such as SLE, focus on 
the hormonal differences between males and females. X chromosome number and the 
expression of X chromosome associated genes is an important and neglected variable in the 
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study of the immune system. Part of the reason for this, is the difficulty separating out the 
individual contribution of X chromosome number and sex hormone environment in sexually 
mature, human adult volunteers, as they are inherently linked and naturally confound each 
other. This has been possible in mouse models as will be shown later, but not in humans. In 
this project, unique human volunteers have been recruited to be able to investigate the effects 
of X chromosome number and sex hormone individually.  
1.1.3.3. Turner’s syndrome 
Turner’s syndrome (TUS) is a disorder of the X chromosome. It is one of the commonest 
chromosomal disorders and affects up to 1in 2500 female infants(81). TUS describes a clinical 
phenotype in females, with associated complete or partial absence of the second X 
chromosome, with or without cell line mosaicism(82). Young people with TUS may present 
with lymphoedema, typical dysmorphic features, short stature, recurrent otitis media, 
congenital heart defects (bicuspid aortic valve and aortic coarctation), primary amenorrhoea, 
delayed puberty and infertility among other clinical presentations(83).  
Approximately half of TUS manifests as a true 45 X aneuploidy. It may also be due to structural 
abnormalities in the second X chromosome. These include an isochrome of the long arms of 
the second X chromosome (46, X,i(X)q), which essentially manifests as an X short arm 
monosomy. In addition, portions of the long or short arm may be missing (Xq or Xp). A ring 
chromosome X (rX) may form if part of the end of both the short and long arms are missing-
functionally similar to an Xp deletion(84). Any of these forms may exist with various levels of 
mosaicism. In addition, structural anomalies can exist in mosaic form alongside karyotypes 
45,X or 46,XX(83). More complex karyotypes include chromosomal translocations and 
45,X/47,XXX mosaics(83). 
Essentially however, whatever the genotype, the phenotype is produced when insufficient X 
chromosome material is available(82). These young patients are treated individually based on 
their particular disease manifestation and may require growth promotion with growth 
hormone therapy and pubertal induction with oestrogen therapy.  
Young females with TUS may provide an interesting model therefore of a phenotype with 
effectively one X chromosome but no Y chromosome, and potentially normal female hormone 
environment if treated with exogenous oestradiol.  
1.1.3.4. Summary  
The X chromosome is associated with immune-based disease and harbours many immune 
genes. Data is emerging that the X chromosome, or portions thereof, may escape inactivation 
in some immune cells.  It is a difficult to study this in humans, as the number of X 
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chromosomes present corresponds to the sex hormone environment and these confound each 
other. Young females with TUS may provide a model which enables us to explore this further. 
In the next section, the effect of sex hormones, and what is known about their association with 
the immune system will be explored. 
1.1.4. Hormones  
Hormones are signalling molecules, classified as proteins, steroid hormones, catecholamines and 
iodothyronines. 
Protein hormones are synthesised as pre-hormones and stored in secretory vesicles. They are 
regulated at the level of secretion and synthesis and often circulate unbound in plasma. They are 
hydrophilic and signal via transmembrane receptors. The gonadotrophins, luteinising hormone (LH) 
and follicle stimulating hormone (FSH) are examples of protein hormones, secreted by the 
hypothalamus. 
 Steroid hormones are derivatives of cholesterol that are synthesised in the adrenal gland 
(corticosteroids), testes or ovaries (sex hormones) or placenta. These all have closely related 
structures based on a cycloperhydropentano-phenanthrene four ring structure (Fig 1-9). 
During steroidogenesis, steroid hormones undergo various enzyme mediated modifications, 
specific to certain tissue/organ sites,  in order to produce a cholesterol derivative that is 
unique to a specific receptor (Table 1-6, Figure 1-9)(85). These steroid hormones are then 
classified into certain subgroups i.e. mineralocorticoid, glucocorticoid, progestin, androgen and 
oestrogen based on site of manufacture and receptor.  
Hormones potently regulate many functions within a cell, including growth, protein 
expression, cell death, genetic and epigenetic changes and many more. Hormone function is 
not ubiquitous on all cell types however, and only certain cell types express receptors for 
certain hormones. 
More specifically, receptors to sex steroid hormones are nuclear hormone receptors. These 
have the ability to enhance or inhibit the rate of expression of various genes, depending on the 
cell type. These receptors contain a hormone response element which acts as a DNA binding 
port, directly before the promoter region of gene that the hormone is acting on to enhance 
transcription. 
Typically, oestradiol is essential for the manifestation of female secondary sexual 
characteristics, whereas testosterone is the male sex steroid. Progesterone plays a role in 
maintaining pregnancy and the menstrual cycle in females, which will be further elaborated 
below.  
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Table 1-6. Steroid hormone family (From Porterfield, Endocrine and Reproductive Physiology 
(85)) 
 
 
 
 
 
 
 
Family No. of 
carbons 
Hormone Primary site of 
synthesis 
Primary receptor 
Progestin 21 Progesterone Ovary/placenta Progesterone 
receptor 
Glucocorticoid 21 Cortisol, 
Corticosterone 
Adrenal Cortex Glucocorticoid 
receptor 
Mineralocorticoid 21 Aldosterone, 11-
deoxycorticosterone 
Adrenal Cortex Mineralocorticoid 
receptor 
Androgen 19 Testosterone, 
dihydrotestosterone 
Testis Androgen 
receptor 
Oestrogen 18 Oestradiol, Oestrone Ovary/placenta Oestrogen 
receptor 
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Figure 1-9. Steroidogenesis pathway (from Koeppen and Stanton 2008 (86))A. Steroid 
hormones all have closely related structures based on a cycloperhydropentano-
phenanthrene four ring structure. B.During steroidogenesis, steroid hormones undergo various 
enzyme mediated modifications, specific to certain tissue/organ sites, in order to produce 
unique steroid hormones. 
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1.1.4.1. Hormones and the immune system  
1.1.4.1.1. Oestradiol  
Oestradiol has long been the hormone of choice when attributing blame for the increased 
immune response in females. It is the obvious choice as it is the hormone that is most 
associated with the female sex. It may not however be solely responsible. Below is a brief 
summary of the known effects of oestradiol on the immune system. 
Many immune cells have been shown to express oestrogen receptors alpha and beta(87). In 
terms of the adaptive immune system, the effect of oestradiol seems to be dose dependant. 
Generally, low doses of oestradiol correspond with a Th1 type responses and cell mediated 
immunity, whereas higher doses of oestradiol, as one would expect in pregnancy, correspond 
to Th2 type responses and humoral immunity (3, 88). Oestradiol has been shown to modulate 
CD4 T cells and CD8 T cells(89). Oestradiol has been shown to bind to oestrogen response 
elements (ERE) in the IFNγ promoter region(90), promote Treg cell expansion in vitro and in 
vivo(91) and decrease TH17 IL17 production(92). Oestradiol has also been associated with 
increased antibody production, somatic hyper-mutation and class switching (93). 
Oestradiol treatment has been shown to increase the number of neutrophils in humans(94). 
Oestradiol at low dose is associated with enhanced monocyte/macrophage cytokine 
production, but at high doses associates with suppression of these responses(95).  
1.1.4.1.2. Testosterone 
Testosterone is generally thought to have immune modulating effects although the data is 
scarce(3). Hypo-androgenism associates with increased inflammatory cytokines, antibody 
titres and CD4/CD8 ratios(3). Gonadotropin releasing hormone (GnRH) antagonism in men 
lowers testosterone levels and associates with a decrease in Treg cells, and an increase in 
natural killer (NK) cells(96). 
1.1.4.2. Summary  
Little data exists regarding the direct role of hormones in the immune system, although 
oestradiol is thought to have a dose dependant effect and testosterone is thought to be 
immune modulatory. A direct extension of this would be to examine if the immune system 
associated with puberty, where there is a massive change in the sex hormone environment. 
Puberty and its associated physical and physiological changes will be discussed below.  
1.1.5. Puberty 
Puberty is characterized by the maturation of gametogenesis, secretion of gonadal hormones, 
and the development of secondary sexual characteristics and reproductive functions. It is a 
period of biological change, starting on average at 11 years old in girls and 12 years old in boys, 
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and lasting approximately 4 years, with a wide variation in the normal age of onset and 
duration(97). Adolescents are defined by the WHO as young people between the ages of 10-
19(98). The term ’adolescence’ is used widely as a synonymous term for puberty, but has a 
wider age range and additional non-biological connotations of cognitive, psychological, and 
social change(99). Adolescents are under-represented in clinical and pre-clinical research 
which focuses either on children or adults. A contributing reason for this may be the great 
variation inherent in this time of change, which involves a cataclysmic shift in the hormonal 
and social functioning of young people. Another reason is the lack of adolescent focussed 
healthcare, with artificial barriers in healthcare between paediatric and adult services. 
Adolescents are therefore an under-utilised source of new information, especially in terms of 
how sex hormones affect the immune system.  
Puberty consists of a series of predictable events that show some variation in timing, onset 
and sequence. In females, these consist of breast development, and the enlargement of the 
internal female organs with the achievement of menstruation (menarche). In males, puberty 
consists of the enlargement of the genitalia and an increase in testicular volume along with the 
breaking of the voice. Both sexes undergo thelarche (development of pubic and axillary hair) 
and a growth spurt. (100) 
Pubertal stages were classified in a widely used classification system by Tanner and Marshall in 
1969 (101).  
The problems with Tanner based staging was that it is quite complex, with 5 different stages, 
that are too descriptive for routine screening of pubertal status. In addition, Tanner staging is 
based on physical phenotype, and requires physical examination. Ethically and practically, it is 
difficult to justify performing physical examination of breasts and genitalia on young people 
routinely. In research involving pubertal development, it is not feasible to perform full Tanner 
staging on large cohorts of healthy young volunteers.  
Therefore, more recently, a simpler method of classifying pubertal phase (to replace stage) has 
been developed to identify young people as either pre-puberty, in puberty or post-
puberty(102). This divides the pubertal phases into 3 simple, easily definable phases, namely, 
pre-puberty, in puberty and completing puberty. In addition, this system uses self-reportable 
criteria, such as menarche, voice deepening and hair growth, to make it more feasible and 
acceptable to young people.  The Royal College of Paediatrics and Child Health (RCPCH) has 
adopted these three pubertal phases in the Childhood and Puberty close monitoring chart, 
shown in Table 1-7 and 1-8 below.  
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Table 1-7. Male pubertal phases (RCPCH Growth Chart(103)) 
Table 1-8. Female pubertal phases (RCPCH Growth Chart(103)).  
There is considerable variation in the timing of puberty, but it usually follows a specific 
sequence. In females, it starts with breast development, followed by pubic and axillary hair 
development and culminates with menstruation. In males, the onset is marked with testicular 
and genital enlargement, followed by pubic hair and axillary development. In addition to the 
variation in the timing of onset, there is a variation in the transit between each stage, although 
there is roughly a year between each Tanner stage(100).  
In the UK, premature puberty in females is defined as the development of secondary sexual 
characteristics before the age of 8 in females and 9 in males. Delayed puberty is defined as the 
absence of secondary sexual characteristics by 13 years in girls, and 14 years in boys(100).  A 
study of 1166 females in the UK showed the median self-reported onset of menarche to be 12 
years and 11 months(104).  
1.1.5.1. Hormonal changes in puberty 
Puberty is initiated by the increase in the pulsatile release of GnRH by the hypothalamus. 
There has been a lot of investigation into the trigger of this event, which is associated with 
genetic, ethnic and social associations, although the exact trigger is unknown (105, 106). The 
increased pulsatile nature of GnRH release leads to an increase in the release of FSH and LH. 
FSH causes maturation of ovarian follicles and release of oestradiol. This, in turn promotes 
Pre-puberty (Tanner stage 1) In puberty (Tanner stage 2-
3) 
Completed puberty (Tanner 
stages 4-5) 
If both of the following:  If any of the following: If any of the following 
No signs of pubertal 
development 
High voice 
Early pubic or armpit hair 
growth 
Enlargement of testes or 
penis 
Voice fully broken 
Moustache and early facial hair 
growth 
Adult size of penis and axillary 
hair 
 
Pre-puberty (Tanner stage 1) 
In puberty (Tanner stage 2-
3) 
Completed puberty (Tanner 
stages 4-5) 
If:  If any of the following: If all of the following 
No signs of pubertal 
development 
 
Any breast enlargement so 
long as nipples enlarged 
Any pubic or axillary hair 
Starting periods (menarche) 
with breast, pubic and axillary 
hair development. 
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breast development, bone growth and maturation, and the eventual achievement of 
menstruation (Fig. 1-10). A mature menstrual cycle consists of a follicular phase, with the 
maturation of a follicle, under the influence of FSH. A mid cycle surge of LH triggers ovulation. 
In the luteal phase, the corpus luteum supports the endometrium with the release of 
progesterone and oestradiol, which eventually decreases in the absence of an implanted 
embryo, resulting in menstruation.  
Male puberty is also initiated by GnRH pulses, leading to an increase in LH, which stimulates 
the Leydig cells of the testes to produce testosterone. This stimulates the growth of the 
seminiferous tubules and increases testicular volume. Testosterone also increases the size of 
the genitalia, deepens the voice, and stimulates growth of hair and muscular development. 
FSH stimulates the growth of the seminiferous tubules, but also stimulates the release of 
inhibin b which inhibits further FSH. There is a peripheral conversion of some testosterone to 
oestradiol, resulting in growth, skeletal maturation and some breast development which may 
occur in males during puberty (Fig. 1-11).  
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Figure 1-11. Normal Puberty in Females. (From Up to Date (107)). GnRH pulses from the 
hypothalamus increase in frequency, triggering release of FSH and LH from the anterior 
pituitary. FSH acts to mature the ovaries and increases the release of oestradiol, along with LH. 
Oestrogens act to increase breast development and growth. There is an eventual maturation 
and co-ordination of this system resulting in ovulation and cyclical menstruation. GnRH-
Gonadotrophin releasing hormone; FSH-follicle stimulating hormone; LH-Luteinising hormone.  
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Figure 1-12. Normal puberty in boys (From Up to Date (107)).  A cyclical increase in GnRH 
triggers the release of FSH and LH, which mature the testes and stimulate the production of 
testosterone. GnRH-gonadotrophin releasing hormone; FSH-follicle stimulating hormone; LH-
luteinising hormone 
1.1.5.2. Mini puberty of infancy   
In young infants, there is a transient activation of the hypothalamic, gonadal pituitary axis in 
what is termed a ‘mini-puberty’ (Fig. 1-12). There is a rise in gonadotrophins after birth which 
peaks at 3 months of age(108). There is a subsequent transient rise in the levels of 
testosterone in boys and oestradiol in girls (109). Levels rise remarkably high, similar to those 
seen in puberty, and can even result in vaginal bleeding in some female infants, and virilisation 
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in some male infants(110). Levels of sex hormone and gonadotrophin thereafter drop to barely 
detectable levels throughout childhood, until the onset of puberty.  
Figure 1-13. The mini-puberty of infancy (From Kuiri-Hänninen et al (110)). There is a mini-
puberty in early infancy that associates with increased levels of gonadotrophins and sex 
steroids in a. male and b. female infants. FSH-follicle stimulating hormone; LH-luteinising 
hormone 
1.1.5.3. Puberty and the immune system   
Very little is known about the development of the immune system specifically over puberty. 
We know that from studying the immune system in children, adults and the elderly that 
changes occur with age and development. New-born babies have immature innate and 
adaptive immune responses which mature over childhood, to ultimately produce an adult 
phenotype. In the elderly, there is an immune senescence that occurs, with weakening of 
many adaptive and innate responses(111).  
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Despite puberty being a time of massive physiological change, there is almost no data about 
whether the immune system changes over these few years. This is probably associated with 
the lack of involvement of adolescents in research, as well as the disconnect between child and 
adult focussed care. This gap in the literature is a lost opportunity, as puberty provides a great 
model for studying the effects of increasing concentrations of sex hormones in males and 
females. Another group of young people who may help us better understand the effects of sex 
hormones and sex chromosomes, are young people with gender dysphoria. 
1.1.5.4. Gender dysphoria  
Gender dysphoria refers to the significant distress experienced by a person with a discordance 
between their assigned and experienced gender (112, 113). Young people with gender 
dysphoria often identify as being ‘transgender’ i.e. trans female/trans girl /trans woman in 
those born phenotypically male and trans male/trans boy/trans man in those born 
phenotypically female.  
The diagnostic and statistical manual of mental disorders version 5(DSMV) , defines gender 
dysphoria as a discordance of an individuals assigned and experienced gender, along with 
significant distress or impairment in everyday functioning for at least 6 months, along with the 
presence of at least 6 of the criteria listed in Table 1-9 below(114). 
Table 1-9. Criteria for the diagnosis of gender dysphoria in children and adolescents (From 
DSMV(114)). The diagnosis of gender dysphoria requires at least 6 of the above criteria, with a 
significant impairment in functioning or distress due to gender dysphoria.  
Referrals of young people  to specialist gender dysphoria clinics are becoming much more 
frequent  in the UK(115), probably due to an increased awareness and acceptance of these 
young people in society.  
Criteria for the diagnosis of gender dysphoria in children and adolescents 
-A strong desire to be of the other gender or an insistence that one is the other gender. 
-A strong preference for wearing clothes typical of the opposite gender. 
-A strong preference for cross-gender roles in make-believe play or fantasy play. 
-A strong preference for the toys, games or activities stereotypically used or engaged in by 
the other gender. 
-A strong preference for playmates of the other gender. 
-A strong rejection of toys, games and activities typical of one’s assigned gender. 
-A strong desire for the physical sex characteristics that match one’s experienced gender. 
-A strong dislike of one’s sexual anatomy. 
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After thorough multidisciplinary assessment, upon reaching Tanner stage 2 of pubertal 
development, young people with gender dysphoria are offered pubertal suppression therapy 
with GnRH agonists(115). This therapy delays their pubertal development as their birth sex and 
prevents the development of irreversible secondary sexual characteristics. It works well as a 
potentially reversible tactic to prevent the development of unwanted characteristics (e.g. 
breast development and voice deepening), while allowing more time for full psychosocial 
evaluation and support prior to deciding about further, irreversible gender transition. It is 
shown that young people with gender dysphoria at presentation have significantly poorer 
psychosocial functioning than gender typical or cisgender young people, but that this improves 
with psychosocial support and even more so with pubertal suppression therapy(116).  
After at least a year on puberty blocking therapy, and after extensive psychosocial input and 
support, young people with the capacity to consent may be offered cross-sex hormone therapy 
(oestrogen in those born phenotypically male and testosterone in those born phenotypically 
female)(115). The cross-sex hormone therapy is introduced slowly in line with standard 
pubertal induction regimens in endocrinology and allows for the induction of trans secondary 
sexual characteristics as well as the pubertal growth spurt. Trans females are usually kept on a 
GnRH agonist during this time, while oestrogen is introduced, as testosterone may not be 
sufficiently suppressed, whereas GnRH agonists may be withdrawn from trans males. Young 
patients are usually referred on to adult services, where further decisions can be made 
regarding full gender affirming surgery.  
The long term biological outcome of transgender people who have received cross-sex therapy 
to induce trans puberty are poorly understood. Of note, there are 2 case reports of the 
development of SLE in trans females receiving oestrogen therapy (117, 118). This however is 
not enough to consider that oestradiol may be a real risk to trans females to develop SLE, and 
probably is in line with background population risk. 
These young people provide an ideal model to investigate the relative contributions of X 
chromosome number and sex hormone environment to a range of biologic variables that show 
sex and pubertal differences. There has been a real interest in studying these young people in 
the fields of metabolic medicine and immunology (119). Just as immune deficiency syndromes 
have helped to demonstrate the inner workings of the immune system, transgender young 
people may provide a model for us to better understand the relative contributions of sex 
hormone and X chromosome number to immune functioning and disease manifestation. 
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1.1.5.5. Summary  
There are massive physiological and hormonal changes that occur over puberty, but there is 
almost no data exploring whether the immune system changes over puberty. This is a lost 
opportunity, in the quest to explore the effects of sex hormones on the immune system. In 
addition, young transgender people may provide a good model of the variation of puberty, 
uncoupling the traditional link between X chromosome number and sex hormone 
environment.  
1.1.6. Sex, puberty, hormone, X chromosome and the TLR7 mediated production 
of type 1 IFN. 
In the preceding sections, the concepts of the immune system, sex, puberty, X chromosomes 
and hormones have been outlined.  The known changes in the adaptive and innate immune 
system with sex or puberty, and highlighted the difficulty examining the underlying causes for 
this have been described.  
The following section will focus specifically on the type 1 IFN, antiviral, innate immune system, 
and explore what is known about how sex, puberty, hormones and X chromosomes affect type 
1 IFN production. As shall be discussed later, type 1 IFN is important in the development of 
SLE, and it can be argued that sex or pubertal differences in type 1 IFN production could help 
explain the increased prevalence of jSLE in females at puberty.  
1.1.6.1. TLR7 mediated IFNα production is higher in females 
It is well established that adult females produce more type 1 IFN after TLR7 signalling when 
compared to males(16). In the first and largest paper to show this in 2006, Berghofer and 
colleagues demonstrated that in 120 adult healthy volunteers, PBMC from females produced 
more IFNα than males, specifically after TLR7 and not TLR9 signalling. Resiquimod (R848) was 
used as a synthetic TLR7 agonist and CpGODN2216 as a synthetic TLR9 agonist. R848 is also an 
agonist of TLR8, although pDC, the chief producers of type 1 IFN do not express TLR8. To 
confirm that this effect was TLR7 specific, in the same paper, the experiment was repeated in a 
separate population of 101 healthy volunteers, using a different TLR7 (and non-TLR8) agonist, 
imiquimod (R837), which confirmed that females produced more IFNα than men after TLR7 
stimulation specifically. They went on to investigate whether these differences were due to 
differences in the numbers of pDC between men and women but found no difference, and 
further showed that purified pDC still produced more IFNα in women than men. In addition, 
they tested for the production of TNFα after TLR7 stimulation, which showed no significant 
differences. They went on to further examine the role of sex hormone and TLR7 gene 
expression in this difference, which I will demonstrate in subsequent sections. 
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 This study was the first of its kind to describe this TLR7 specific sex difference in IFNα 
production. The volunteers assessed were from a wide age range (18-65) which include post-
menopausal volunteers. They did not assess for any differences with age or menopause in this 
population to assess if females still produced more IFNα than men after menopause, to 
establish whether this difference only existed during reproductive maturity, which would imply 
a link with sex hormones. In addition, these ligands, although highly specific, were synthetic, 
and may not represent real life viral scenarios.  
Following on from this, in 2009, Meier and colleagues investigated whether sex differences in 
TLR7 activation by HIV derived ligands might be responsible for the observed sex difference in 
HIV disease(120). For TLR ligands, they used an inactive HIV vesicle control and the HIV derived 
TLR7 agonists, GagRNA1166 and Gp160RNA2093, or TLR9 agonist, CpGODN2219, to stimulate PBMC 
and measured pDC specific IFNα production by flow cytometry in 20 female and 23 male 
adults. They showed that a higher percentage of pDC from females produced IFNα after TLR7 
stimulation, which was not true for TLR9 stimulation or TLR7 induced TNFα production(120). 
This confirmed the findings of Berghofer et al in that females produced more IFNα (and not 
TNFα) after stimulation with a real-life pathogen-derived TLR7 agonist, but not a TLR9 agonist. 
This finding was further confirmed by Seillet and colleagues in 2012 in 20 female and 15 male 
healthy adults(121). 
All of these studies usually used antibodies towards IFNα2, making it unclear if this sex effect 
was subclass specific. Using a different synthetic TLR7 agonist, CLO97, Ziegler et al confirmed 
that there was a significantly higher pDC expression of all 13 IFNα subtypes and IFNβ in adult 
females, compared to males(122) implying that this effect was true for all known type 1 IFN.  
All of these studies only involved adult participants, further highlighting the need to assess for 
these differences outside of sexual maturity, in order to establish if these differences are 
inherent to the female sex or associated with sex hormones. The only exception to this was a 
study in 2012 by Wang et al(123). They used PBMC from 2 month old infants and similarly 
showed that, after R848 stimulation, there was an increased percentage of pDC producing 
IFNα in female when compared to male infants(124).  As discussed earlier however, 2-month-
old infants do not provide a good model if one is trying to exclude the hormonal differences 
between the sexes, as they are going through the ‘mini-puberty’ stage and have high levels of 
sex steroid hormone.  
The data therefore strongly indicates that females produce more IFNα after TLR7 stimulation 
than males. It is however unclear if there is an inherent different between the sexes, or 
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whether this only manifests during sexual maturity, which would a priori imply a hormonal 
basis for this difference. 
1.1.6.2. Oestradiol and TLR7 induced IFNα production 
After it was shown that females produced more IFNα in response to TLR7 stimulation than 
men, Berghofer et al went on to investigate whether varying doses of oestradiol in vitro 
affected the production of IFNα(16). They found that oestradiol and the oestradiol antagonist, 
ICI182780, had no effect on the ability of PBMC to produce IFNα after TLR7 stimulation(16). 
This was an important step in that it implied that the sex difference existed regardless of 
exposure of PBMC to oestradiol during stimulation but did not exclude the constitutive 
oestradiol environment that the cells had originated from.   
In the paper by Meier et al, after it was shown that females produced more IFNα after TLR7 
stimulation, they also reported a non-significant trend toward lower percentages of IFNα 
producing pDCs in response to TLR7 ligands in postmenopausal women compared to 
premenopausal women (mean 16.9% versus 27.6%, p = 0.08)(120). It is difficult to comment on 
this as the effect is not statistically significant, but it does imply a trend towards the effect of 
oestradiol in vivo.  
This led Siellet et al to investigate the effect of oestradiol on TLR7 induced IFNα production in a 
mouse model(121). They found that in sub-lethally irradiated NOD/SCID/β2m−/− mice 
transplanted with female human progenitor cells, female donor human derived pDC produced 
more IFNα in recipient female mice compared to recipient male mice. They concluded from 
this that TLR7 induced pDC IFNα production was oestradiol related. Although this may be true, 
the assumption is flawed in that they only used female human donors, and therefore did not 
fully rule out the effects of X chromosome difference.  In addition, they showed that, in 17 
post-menopausal females, treatment with oestradiol for 3 months increased the percentage of 
pDC producing IFNα after TLR7 signalling. This effect was not specific though, as they also 
showed that there was an increase in pDC TNFα production after TLR7 stimulation, as well as 
an increase in the TLR9 induced IFNα production, which does not mirror the original TLR7 
specific sex effect. Although this study showed that oestradiol may play a role in the sex 
difference seen in TLR7 induced IFNα production, it was not specific to IFNα nor TLR7 and did 
not explore the effect of the X chromosomal origin of the pDC. 
The same group extended these data and in 2014 published a follow up paper(68). Human 
neonatal cord blood from both sexes was transplanted into the same irradiated 
NOD/SCID/β2m−/− recipient mice. After stimulating bone marrow cells with TLR7 agonist R848, 
regardless of the sex of the recipient mouse, pDC from female cord blood donors showed an 
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increased percentage of pDC producing IFNα (and not TNFα). When male recipient mice with 
male recipient pDC received oestradiol, there was a trend towards an increase in the 
percentage of pDC producing IFNα, but this was not significant. These data are important as 
they are the first to try and tease out the separate effects of X chromosome number and sex 
hormone, and show that regardless of hormone, donor pDC with two X chromosomes 
produced more IFNα after TLR7 stimulation. This is important, but it is a highly artificial model, 
with potential confounding factors. Mouse experiments are important in immunology, but do 
not however always reflect human physiology (125).   
Therefore, there is evidence that implies that oestradiol may play a role in the increased TLR7 
mediated production of IFNα, although this is not conclusive. In addition, there is an intriguing 
possibility that X chromosome number may inherently associate with TLR7 induced IFNα 
production. This highlights the need to examine whether young pre-pubertal children, with 
low hormone levels, show the same sex difference in TLR7 mediated IFNα production, and 
whether this changes over puberty. In addition, young transgender people and those with TUS 
may contribute to this model, by providing a human model which uncouples X chromosome 
number and serum sex hormone concentration.  
1.1.6.3.  Testosterone and TLR7 induced IFNα production 
As is usually the case in the data regarding the hormonal differences in the immune system, 
there is fewer data regarding testosterone and its role in the sex difference in TLR7 induced 
IFNα production.  
The only study to explore testosterone as a potential contributor to the sex difference seen in 
TLR7 induced IFNα production was the study by Wang et al, which assessed infants(124). After 
initially showing that TLR7 mediated IFNα production was lower in pDC from male infants, 
compared to females, they postulated that perhaps the ‘mini-puberty’ associated with infancy 
may contribute to this sex difference, specifically due to higher levels of testosterone in male 
infants. They tested this in vitro by pre-stimulating human female pDC with 3 doses of 
dihydrotestosterone (DHT), the active tissue metabolite of testosterone for 1 hour before 
stimulating with R848. Remarkably, they reported a negative correlation between IFNα 
production as measured by enzyme linked immunosorbence assay (ELISA) and DHT dose. This 
correlation with DHT was not seen for the production of TNFα after R848 stimulation but was 
reported for CpG (TLR9) stimulation.  
This in vitro finding was intriguing, as it was not seen when oestradiol was added to the 
experimental system by Berghofer et al(16) and implies that testosterone may associate with a 
decrease in the TLR7 induced IFNα production in females. This further highlights the need to 
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explore the role of oestradiol, testosterone and X chromosome number independently in 
humans, in vivo.  
1.1.6.4. TLR7 is coded on the X chromosome.  
Equally intriguing is the fact that TLR7 is coded for on the X chromosome. It stands to reason 
that perhaps differences in expression of TLR7 gene between males and females could account 
for the increased TLR7 associated IFNα production seen in females. Given the data presented 
above, whereby the X chromosome, or portions thereof could escape X inactivation in some 
immune cells, this stands as a logical possibility.  
With relatively small sample numbers, both Berghofer(16) (n=16) and Laffont(68) (n=10) could 
not demonstrate a sex difference in TLR7 gene expression in pDC from healthy adults when 
analysing expression by PCR. Berghofer et al, using an EBV immortalised B cell line from one 
single female donor, showed that TLR7 did not escape X inactivation in immortalised B cells or 
pDC in that donor(16). As discussed, the X chromosome mosaicism may not be in a steady 
state depending on the tissue type and individual, implying that a single donor and a single cell 
line may not be adequate to exclude the bi-allelic expression of TLR7 in females.   
In contrast to this, Zang et al showed that TLR7 did escape X inactivation in immortalised B 
cells from large datasets containing many individuals(126), highlighting probable inter-
individual heterogeneity and the need for larger sample sizes.  
Interestingly, Souyris et al have recently shown that TLR7 escapes bi-allelic expression in up to 
30% of pDC, B cells and monocytes  from healthy adult women(127). In addition, they have 
demonstrated that males had a lower PBMC protein expression of TLR7 compared to women, 
when analysed by western blot analysis.  
These data are intriguing and imply that TLR7 gene expression may be bi-allelic in different cell 
types, clonal populations, tissues, and even show inter and intra- individual variability. It 
implies that X chromosome bi-allelism may be more dynamic than previously thought, 
especially in the X linked immune genes. This raises the question about whether the 
expression of X linked immune genes, specifically TLR7, may change with puberty and its 
associated hormonal changes, or display a steady expression regardless of sexual maturity.  
1.1.6.5. Summary 
It has been robustly shown that immune cells from adult females produce more type 1 IFN 
after TLR7 stimulation than males. The data suggests that this may be due to X chromosome 
number as well as sex hormone concentration, but this has not been definitively demonstrated 
in humans. There is a need to investigate whether this sex difference exists prior to puberty, 
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and whether it changes over puberty and to specifically assess for the contributions of sex 
hormone number, serum testosterone and oestradiol concentrations. This is particularly 
pertinent in the research of jSLE, a disease that is more common in females, manifests over 
puberty and displays a type 1 IFN transcriptional signature. As will be discussed later, jSLE is 
mediated and perhaps initiated by the type 1 IFN pathway and it therefore stands to reason 
that sex and pubertal differences in this pathway could be linked to the sex and pubertal bias 
seen in jSLE. A clinical overview of jSLE will be provided below in 1.3 before focussing on the 
emerging data that indicate that jSLE may be IFN mediated in 1.4.  
1.3. Juvenile systemic lupus erythematosus.  
Juvenile systemic lupus erythematosus (jSLE) is the prototypical, multisystem autoimmune 
disease characterised by auto-antibodies to nuclear self-antigens.  It has been traditionally 
defined as an autoimmune disease- i.e. predominantly involving the adaptive immune system, 
but as data emerges regarding the importance of the innate immune system in jSLE, it can be 
argued that it has a more autoinflammatory origin, as will be discussed further(1). jSLE is 
defined as SLE with onset before the age of 16, and accounts for approximately 15% of the 
incidence of all SLE(128).  jSLE has a more severe disease phenotype and disproportionately 
affects women and ethnic minorities, and most commonly presents around puberty. A brief 
overview of the epidemiology, clinical features and treatment strategies in jSLE is given below.  
1.3.1. Epidemiology of jSLE  
The incidence and prevalence of jSLE varies around the world from 0.3-0.9/100000, although 
the global data are scarce(4). Regardless of geographical location, the epidemiology of jSLE 
shows a variation with sex, age and ethnicity. In fact, it can be argued that jSLE targets groups 
that are traditionally under-represented in clinical and pre-clinical research, that is, 
adolescents, females and non-white ethnic groups.  
1.3.1.1. Sex  
SLE is more common in females at all ages, but the ratio between males and females varies 
with age. In 2016, Ambrose et al compared 924 individuals with SLE (413 jSLE, 511 adult-onset 
SLE (aSLE) (Fig. 1-14)(4). They report a sex ratio (female: male) of 5:1 in children (<12), 
increasing to 7:1 during adolescence (12-17) and settling at adult ratios of approximately 13:1 
which is widely reported in adult data.  
In the UK jSLE cohort, there are currently upwards of 400 patients enrolled with jSLE. In a 
publication in 2012, the characteristics of 276 of these were described, with a female to male 
ratio of 5.6:1 after 10 years of age and 2.7:1 before 10 years (129). The increase in the female 
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bias after sexual maturity does imply that sex hormones may play a role in the susceptibility to 
jSLE.  
Supporting this observation, in mouse models of SLE, female mice develop SLE more quickly, 
have a more severe disease phenotype and die sooner(130). If these mice undergo ovarectomy 
pre-puberty, the disease is not as severe and develops later. However, if mice undergo 
ovarectomy post-puberty, the disease phenotype is unchanged, implying that puberty itself 
may influence the development of jSLE. In some mouse models, treatment with oestrogen 
antagonism improves disease, whereas oestrogen therapy worsens disease(131). 
Interestingly, men with Klinefelter syndrome (XXY) have been reported to have a similar 
prevalence of aSLE as females (approximately 14 times higher than XY men) (132). 
Furthermore, 7 of 286 men with aSLE were confirmed to have Klinefelter syndrome, which is 
almost ten times higher than the general male population prevalence(133). In relation to the 
discussion above, this implies that having two X chromosomes might also be associated with 
the development of jSLE.  
 
Figure 1-18. The sex ratio of SLE varies with age (From Ambrose et al(4)) 
1.3.1.2. Ethnicity 
 There is a well described ethnic variation in the incidence and prevalence of aSLE. In a review 
of adult jSLE epidemiology studies in the USA, the incidence in white people ranged from 3.3-
5.6 (per 100000 cases), while the prevalence ranged from 43-56 ( per 100000 cases)(134). In 
contrast, incidence African Americans ranged from 8-16, whereas prevalence ranged from 111-
261. In 2016, Rees et al published a retrospective cohort study in the UK, based on 7732 cases 
of aSLE(135).They showed incidence and prevalence in white people at 6.73, and 134 
respectively. In contrast, people of black, Afro-Caribbean origin had an incidence and 
prevalence of 31 and 517 respectively (135). Despite good data from western populations that 
aSLE affects non-white people more frequently, there are almost no good epidemiological  
data from the developing world and Africa(136).  
Studies have persistently shown that non-white aSLE patients are more at risk of developing 
lupus nephritis, neurological lupus, and have a higher mortality(137).  
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The data from children and young people is similar to adults, in that jSLE seems to be more 
common in non-white population groups. In fact, in the LUMINA (LUpus in MInorities: NAture 
versus nurture) study in the US, there was a significantly higher proportion of African American 
patients with jSLE compared to aSLE. It has also been reported in the UK that aSLE patients 
were significantly more likely to be white than jSLE patients (4).The data from the UK jSLE 
cohort study from 2012 is represented in Table 1-10 below, and shows that white children had 
the lowest standardised incidence of jSLE, despite being the most represented in the 
group(138). In addition, it has been shown that non-white patients with jSLE display a worse 
phenotype, with a higher rate of renal and neurological disease, as well as an increased risk of 
having a catastrophic event as a presenting feature (139, 140). Despite this, there is a relative 
under-representation of non-white people in the jSLE research literature. 
Ethnic group No. (%) of patients Standardized incidence per 100,000  
persons per UK ethnic population 
Caucasian 103 (52) 0.1 
Chinese 4 (2) 0.8 
Bangladeshi 5 (2.5) 0.9 
Black Caribbean 8 (4) 0.7 
Indian 18 (9) 0.9 
Black “other” 2 (1) 1 
Pakistani 12 (6) 0.8 
Mixed race 15 (8) 1.1 
Black African 19 (10) 2 
Asian “other” 12 (6) 2.5 
Not stated 0 (0) – 
Table 1-10. Ethnicity of patients in the UK jSLE cohort study(138) 
1.3.1.3. Age  
jSLE accounts for approximately 15% of all SLE(128). There are differences reported in disease 
severity and outcome in jSLE compared to aSLE. In a Korean study of 201 patients, fever, oral 
ulcers, nephritis, anaemia, and thrombocytopenia were more common in jSLE patients than 
aSLE(141). In a Spanish cohort of 3,428 aSLE patients and 484 jSLE patients, jSLE had 
significantly more renal and neurological involvement than aSLE. jSLE patients more frequently 
underwent all SLE-related treatment and procedures, as well as dialysis and kidney 
transplantations(142).In the LUMINA study mentioned above, jSLE was more active than aSLE 
at all timepoints, despite the fact that the young people with jSLE had lower self-reported 
disease activity than their adult counterparts. In addition, the LUMINA cohort showed an 
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increased rate of neurological and renal involvement as well as neurological and renal damage 
in jSLE as compared to aSLE(128). Most disturbingly, the jSLE group had double the mortality 
rate of the aSLE group (128). In the large UK cohort report by Ambrose et al, jSLE had higher 
rates of renal and neurological involvement, as well as almost six times the standardised 
mortality rate of aSLE (Figs. 1-15/16(4)). 
The median age of onset of jSLE in the UK jSLE cohort group was 12.8 years of age in females 
and 11.1 years of age in males(138). In females, this closely approximates to the median age of 
onset of puberty mentioned above. 
Figure 1-15. jSLE has an increased rate of renal involvement than aSLE (From Ambrose et al(4)) 
Figure 1-16. jSLE has a higher reported standardised mortality rate than aSLE (From Ambrose 
et al(4)) 
1.3.2. The clinical manifestations of jSLE 
jSLE is a markedly heterogeneous multisystem disease that is unpredictable in its clinical 
phenotype. Nevertheless, there are certain unifying characteristics which allow for the 
classification of jSLE.  
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1.3.2.1. Classification Criteria  
 Although there are no validated diagnostic criteria for SLE, classification criteria exist, which 
were developed for adult onset SLE. The initial criteria for SLE were the America College of 
Rheumatology (ACR) criteria updated in 1997(143). New Systemic lupus international 
collaborating clinics classification (SLICC) criteria were developed in 2012(144). These are 
summarised below in Table 1-11. These criteria were not developed for jSLE, but they have 
been tested in young people, in a multicentre study where the sensitivity and specificity of the 
ACR criteria were 76.6% and 93.4%, respectively, whereas those of the SLICC criteria were 
98.7% and 85.3%, respectively (145). 
ACR criteria(143) SLICC criteria(144) 
4 out of 11 required for diagnosis of SLE 4 out of 17 required, including at least one clinical criterion 
and one immunological criterion, OR biopsy proven lupus 
nephritis 
Criterion Definition Criterion Definition 
 Clinical criteria 
Malar rash Fixed erythema, flat or raised 
over malar eminences, 
tending to spare nasal folds 
Acute cutaneous lupus Malar rash, bullous lupus, 
photosensitive rash, TEN, 
maculopapular lupus rash 
OR subacute cutaneous 
lupus 
Photosensitivity Skin rash as result of unusual 
reaction to sunlight 
Discoid rash Erythematous raised patches 
with adherent keratotic 
scaling and plugging, 
atrophic scarring may occur 
Chronic cutaneous lupus Discoid, hypertrophic lupus, 
lupus panniculitis, mucosal 
lupus, chilblain lupus 
Non-scarring alopecia Diffuse thinning or hair 
fragility with visible broken 
hairs in the absence of 
another cause 
Oral ulcers Painless oral or 
nasopharyngeal ulcers 
Oral or nasal ulcers Palate, buccal, tongue or 
nasal ulcers in the absence 
of another cause 
Arthritis Non-erosive arthritis 
involving two or more joints 
characterised by tenderness, 
swelling or effusion  
Joint disease Synovitis (swelling)or 
tenderness and morning 
stiffness in two or more 
joints 
Serositis Pleuritis or pericarditis  Serositis Pleuritis or pericarditis 
Renal disorder Proteinuria (>3+ or 
>500mg/24hrs) or cellular 
casts (Red cell, haemoglobin, 
granular, tubular or mixed) 
Renal Proteinuria (Urine protein: 
creatinine ratio or 24 hr 
urine >500mg/24hr) or red 
blood cell casts 
Neurological disorder Seizures or psychosis without 
associated drug or metabolic 
cause 
Neurological  Seizures, psychosis, 
mononeuritis multiplex, 
myelitis, neuropathy or 
acute confusional state in 
the absence of other causes 
Haematological disorder Haemolytic anaemia or 
leukopenia, or lymphopenia 
or thrombocytopenia 
Haemolytic anaemia  
Leukopenia or lymphopenia  
Thrombocytopenia  
 Immunological criteria 
ANA positive  ANA positive  
Immunological disorder Presence of the following 
antibodies; Anti-DsDNA or 
Anti-Smith or 
antiphospholipid antibodies 
Anti-DsDNA  
Anti-Smith  
Antiphospholipid antibodies  
  Low complement  Low C3, low C4 or low CH50 
  Direct Coombs test positive  
Table 1-11. ACR vs SLICC criteria for SLE (adapted from up to Date(146)) 
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A new classification system is under development which attempts to improve the specificity 
and sensitivity of the current systems. This system will be weighted, with each criteria given a 
score, whereas the current criteria are equally represented currently(147).This new 
classification may include constitutive symptoms such as fever, and acknowledge that anti-
nuclear antobody (ANA) positivity may be required for the diagnosis of SLE.  
In any event, the classification criteria give an overview of the most common clinical features 
of the disease and highlights its multisystemic nature. Because virtually any organ may be 
involved in SLE, and its heterogenous nature, it has been given the  moniker, ‘the great 
imitator’(148). As mentioned above, young people are more likely to present with renal 
disease and neurological disease, are more likely to have disease associated damage and 
increased mortality(128). 
1.3.2.2. Measures of disease activity in jSLE 
There are multiple measurements of disease activity that have been developed in SLE. These 
include the SLE disease activity index (SLEDAI)(149), the British Isles lupus assessment group 
index (BILAG)(150)and the systemic lupus activity measure (SLAM)(151). All 3 have been 
shown to be sensitive to change and are sensitive measures of disease activity in children 
(152). SLEDAI is the simplest to use, as it is a simple additive score, and is often used for 
research purposes and clinical monitoring. It consists of 24 outcome measures, including 16 
clinical measures and 8 laboratory measures. The organ measures are weighted differently, for 
example, neurological involvement is scored at 8, kidney involvement at 4 and skin 
involvement at 1. SLEDAI is scored according to the 30 days prior to scoring.  
Clinical biomarkers such as the titre of anti-double stranded DNA antibodies (anti-DsDNA) and 
the complement split products C3 and C4 are routinely used in clinical practise as monitoring 
tools for disease activity, but a review of the literature has failed to show their consistency, or 
ability to predict flares(153). They are however often used by clinicians in association with 
other scoring systems such as the SLEDAI to monitor a patient’s disease.  
Composite scores exist which are routinely used in clinical trials. These include the SLE 
response index (SRI)-4 (154), the SRI-50(155) and the BILAG-Based Composite Lupus 
Assessment (BICLA)(156). 
1.3.3. Treatment of jSLE  
1.3.3.1. General  
Young people with jSLE require specialist multidisciplinary care, appropriate to their 
developmental stage, and with a careful focus on their psychosocial and family context. jSLE is 
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an incurable disease that will have a long-term consequences, either due to disease or therapy, 
and young people need a supportive and professional multi-disciplinary team to manage them 
safely through childhood, adolescence and the transition into adult care. A detailed discussion 
about specific therapies is beyond the scope of this introduction, but the main themes along 
with successes and failures of some of the clinical trials which may give insights into the 
pathogenesis of jSLE will be highlighted here.  
In general, supportive measures are advised, which includes vaccination and avoidance of UV 
exposure, which may trigger disease flares.  
1.3.3.1.1. Anti-malarials  
The most consistently effective drug for SLE currently is hydroxychloroquine (HCQ), a drug 
repurposed from its use as anti-malarial in the Second World War. While more targeted 
therapies have recently failed clinical trials, HCQ has consistently been shown to be an 
effective agent to decrease flares, morbidity and other complications in SLE(157).  
It has been shown that anti-malarials are capable of binding nucleic acid in the endosome, 
thereby masking the TLR binding ligand(158). HCQ has been shown to have many other 
immune modulatory effects, including interfering with cell signalling (159) and lysosomal 
acidification, which interrupts proteolysis, chemotaxis, phagocytosis, antigen presentation and 
macrophage mediated cytokine production (160-162).  
1.3.3.1.2. Glucocorticoids 
Cortisol was the first glucocorticoid isolated from the adrenal gland in the 1940s, and the 
discoverers Kendall, Richstein and Hench were awarded the Nobel prize for this discovery in 
1950(163). Glucocorticoids were rapidly shown to be effective in rheumatoid arthritis and 
asthma, and thereafter shown to be potent in the treatment of SLE(164). They have 
widespread immune suppressive properties, but these come at the price of a poor side effect 
profile. Side effects include hypertension, diabetes, weight gain, striae and Cushingoid 
features, hyperlipidaemia, glaucoma, osteoporosis, myopathy and avascular necrosis. Steroid 
withdrawal may precipitate a life threatening adrenal crisis. In addition, in children specifically, 
steroid therapy interferes with growth, pubertal development, bone density and ultimate 
adult height. This is in addition to the psychological distress a Cushingoid appearance can 
cause an adolescent. Glucocorticoids are so intrinsically linked to adverse events in SLE that it 
is difficult to tell how much damage is disease induced vs steroid induced. In the Systemic 
Lupus International Collaborating Clinics/American College of Rheumatology Damage Index 
(SDI) measurement tool, half of the 12 domains included in the index relate at least in part to 
the damage induced by steroid therapy (165).  
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Glucocorticoids are however lifesaving in SLE and there is no doubt that they have contributed 
to the decrease in mortality over the decades. There is however a need to be mindful of their 
danger when treating a young person, and an urgent need for novel ideas to develop equally 
potent but less toxic drugs for use in SLE.   
1.3.3.1.3. Immunomodulatory drugs in SLE  
Cyclophosphamide, mycophenylate and azathioprine are non-specific immune suppressive 
drugs that are used in SLE(166). They may be used to induce disease remission or maintain 
remission, typically for severe organ involvement, i.e. nephritis or neurological disease and are 
recommended in multicentre jSLE consensus guidelines (167, 168). They do however also have 
their own set of side effects, including lymphopenia, infertility and teratogenicity, all of which 
are difficult to manage in young people.  
1.3.3.1.4. Biologic agents in SLE  
As more data has emerged about the immune system in SLE, there has been an increase in the 
number of targeted monoclonal antibody therapies that have been investigated for SLE (and 
jSLE). Despite promising outcomes reported anecdotally by physicians, these agents have 
largely not succeeded in clinical trials. In fairness, these drugs have been held up to much 
higher levels of scrutiny than corticosteroids or HCQ were when they were first discovered. 
This has led to a situation where only one new agent, belimumab, has been approved for the 
use of SLE in the last 60 years.  
Despite this, clinically important findings have been detected in sub- and post-hoc analyses 
from these “failed” randomised control trials. This has highlighted the limitations in SLE trial 
design, including heterogeneity of disease, inadequate trial size or duration, insufficient dose 
finding prior to enrolment, choice of primary endpoints, under-estimation of placebo effect 
and non-standardized use of background therapy, including corticosteroid dose(169). In an 
excellent review on the subject. Mahieu et al have summarized the major biological therapy 
randomised control trials in Table 1-12(169).  
Of note, recently sifalimumab(170), an IFNα monoclonal antibody and anifrolumab(171), an 
IFNΑR antibody were successful in phase II studies, reaching their primary end points. In 
addition, there was a differential response, based on whether patients displayed an 
upregulated IFN gene signature or not. Despite these data, the company has released an early 
press release reporting that the first arm (multi-dose) has failed to reach primary endpoints 
after 1 year(172). It will still be interesting to see whether there was any differential response 
to these therapies based on stratification by IFN signature when the full results are released.  
 Table 1-12 Summary of drug trials in lupus adapted from Mahieu et al (169) 
Drug Target Mechanism Study Outcome 
Rituximab CD20  Deplete CD20+ B-
cells  
Merrill et al.(173)(EXPLORER) 
Phase II/III RCT 
Moderate-to-severe SLE 
1° endpoints: a) Major or b) partial clinical response at 
52 weeks 
1° endpoints not met 
Pre-specified subgroup analysis found better response in blacks and Hispanic group treated with 
rituximab vs placebo 
Strict definitions for major and partial clinical response 
Amount of background therapy mitigated differences between treatment arms 
Abatacept 
  
CD80/86 
  
  
Inhibit T-cell co-
stimulation 
Merrill et al.(174) 
Phase IIb RCT in mild-to-moderate SLE 
1° endpoint: ≥1 BILAG A or B flare during 52 weeks  
1° endpoint not met; similar flare rates with abatacept and placebo 
Improvements in PROs (health-related quality of life, fatigue, and sleep) with abatacept 
Atacicept 
  
  
  
BAFF/BLyS 
and APRIL 
  
  
Neutralize 
BAFF/BLyS 
(TNFSF13B) and 
APRIL (TNFSF13A) 
   
Isenberg et al. (APRIL-SLE) (175) 
Phase II RCT 
Moderate-to-severe SLE 
1° endpoint: ≥1 BILAG A or B flare during 52 weeks 
1° endpoint not met 
Atacicept 75mg and placebo had similar flare rate 
Atacicept 150mg arm halted for adverse events, but signal of fewer flares relative to placebo 
Belimumab   
  
  
BAFF/BLyS  
  
  
  
  
  
  
Neutralize 
BAFF/BLyS 
(TNFSF13B) 
  
  
  
  
  
  
  
Wallace et al.(176) 
Phase II RCT 
Active SLE 
1° endpoints: a) Change in SELENA-SLEDAI score from 
baseline to 24 weeks and b) time to first flare (SFI) in 
52 weeks 
1° endpoints not met; guided choice of patient selection and endpoints for phase III RCTs 
Serologically active patients (ANA or anti-dsDNA antibody positive) had significant improvement in 
SELENA-SLEDAI and 2° endpoints at week 52 
Led to development of SRI composite endpoint 
Unlimited changes in immunosuppressants and GC confounded results 
1° endpoint met; greater SRI-4 response with belimumab vs placebo in both studies 
 Navarra et al (177). and Furie et al.(178) (BLISS-52 and 
BLISS-76) 
Phase III RCTs 
Moderate-to-severe seropositive SLE 
1° endpoint: SRI-4 response at 52 weeks 
First use of SRI composite endpoint 
Stricter control of GC and immunosuppressants near end of study 
Pre-specified analyses showed improvements in HRQOL, fatigue29 
Pooled post-hoc analysis suggested benefit in renal disease54 
Tabalumab  
  
  
BAFF/BLyS  
  
  
Neutralize 
BAFF/BLyS 
(TNFSF13B) 
  
Isenberg et al.(179) and Merrill et al.(180)(ILLUMINATE 
1 and 2) 
Phase III RCTs 
Moderate-to-severe SLE 
1° endpoint: SRI-5 response at 52 weeks 
ILLUMINATE 1 did not meet 1° endpoint 
ILLUMINATE 2 met 1° endpoint; greater SRI-5 response with tabalumab vs placebo 
Neither study met key secondary endpoints (fatigue, time to flare, GC dose) 
Patients with any change in immunosuppression dose, including decrease, were considered non-
responders 
Development suspended 
Epratuzumab 
   
  
  
  
  
CD22 
  
  
  
  
  
Alter B-cell 
responsiveness 
  
  
  
  
Wallace et al. (181)(ALLEVIATE 1 and 2; SL0006 open 
label extension) 
Phase II RCTs 
Moderate-to-severe SLE 
1° endpoint (modified): BILAG response with no 
treatment failure at week 12 
Enrolment suspended early for low supply of study drug; 1° endpoint evaluated at 12 weeks instead 
of intended 24 weeks 
Greater achievement of 1° endpoint with epratuzumab than placebo 
Improvements in HRQOL and reduced GC doses at 48 weeks34 
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Wallace et al.(182) (EMBLEM) 
Phase IIb dose-ranging study 
Moderate-to-severe SLE 
1° endpoint: BICLA response at 12 weeks 
First use of BICLA composite endpoint 
Not powered for significance, but suggested efficacy and safety of 2400mg combined monthly dose 
More homogeneous patient population than prior RCTs 
Clowse et al(183). (EMBODY 1 and 2) 
Phase III RCT 
Moderate-to-severe SLE 
1° endpoint: BICLA response at 48 weeks 
1° endpoint not met; no difference in BICLA response rate and secondary efficacy measures between 
epratuzumab and placebo 
PF-04236921   IL-6  Neutralize IL-6 Wallace et al.(184) 
 Phase II RCT 
Moderate-to-severe SLE 
1° endpoint: SRI-4 at 24 weeks 
1° endpoint met for 10mg dose; also showed improvements in BICLA and HRQOL (secondary pre-
specified endpoints) 
Reduction of flares (SFI) with 50mg dose 
200mg treatment arm discontinued for serious adverse events 
  
Edratide 
  
  
  
  
Unknown 
  
  
  
  
Unknown 
  
  
  
  
Urowitz et al.(185) 
Phase II RCT 
Mild-to-moderate SLE 
1° endpoint: Reduction in SLEDAI-2K and Adjusted 
Mean SLEDAI (AMS) through 26 weeks 
1° endpoint not met, but significant improvements in BILAG were seen (secondary pre-specified 
endpoint) 
Background GC use may have confounded results  
Sifalimumab  
  
  
IFNα 
  
  
  
Neutralize some 
species of IFN-α 
  
  
  
Khamashta et al.(170) 
Phase IIb RCT 
Moderate-to-severe SLE 
1° endpoint: SRI-4 response at 52 weeks 
Statistical significance set at p<0.098 
1° endpoint met; greater achievement of SRI-4 and improvements in skin disease, joint count, and 
fatigue with sifalimumab compared to placebo 
Anifrolumab Type 1 IFN 
receptor 
Neutralize type 1 
IFN activity 
  
Furie et al.(186) 
Phase II RCT 
Moderate-to-severe SLE 
1° endpoint: SRI-4 response at 24 weeks and sustained 
reduction in GC dose 
1° endpoint met; more SRI-4 responders and reduced GC doses with anifrolumab than placebo 
Effect size greater in patients with high IFN at baseline 
  
Phase III RCT underway (TULIP) 
 
Recent press release –TULIP1 Arm- failed to reach statistically significant decrease in SRI4 at 12 
months(172) 
Ustekinumab IL12/23  Neutralises 
IL12/23 
Van Vollenhoven et al (187) 
Phase IIRCT 
1° endpoint SRI4 at  
1° endpoint achieved. No requirement to reduce GC dose. Not all patients on standard therapy, 
response above standard therapy unclear.  
Baricitinib Jak1 and 2 
inhibitor 
Neutralises jak1 
and 2 and prevent 
STAT 
phosphorylation 
Wallace et al(188) 
Phase II RCT,  
2mg and 4mg groups 
1° endpoint resolution rash/arthritis at week 24 
4mg-1° endpoint met along with reduction in SRI4 at 24 weeks, less flares.  
GC dose high in both groups, tapering not used as an endpoint.  
No stratification.  
 
 1.3.4. Summary  
jSLE is an unpredictable, severe, multisystem disease, that targets females, ethnic minorities 
and is more common around the onset of puberty. Although treatments exist, they are not 
universally effective and have severe side effects. There is an urgent need for novel ideas and 
therapies in the treatment of jSLE. The sex bias in jSLE, as well as the increased onset around 
the age of puberty may provide new insights into disease pathogenesis and potentially inform 
target development.  
1.4. Type 1 IFN in the pathogenesis of jSLE 
 
There is no doubt that SLE is highly heterogeneous and that multiple abnormalities in multiple 
immune compartments contribute to the pathogenesis. There is emerging data that the 
innate, antiviral immune system, specifically the type 1 IFN pathway may contribute to disease 
development in jSLE, with some arguing that it may be the underlying immune-pathogenetic 
mechanism(1). Given the above sex difference described in the TLR7 mediated type 1 IFN 
pathway, one could hypothesise that this may be responsible for the known sex difference 
described in jSLE. As it is unknown whether the type 1 IFN pathway changes with puberty, it is 
unknown whether this may associate with the pubertal association seen in jSLE.  
In working towards developing a hypothesis, the known genetic, transcriptomic and 
epigenomic data in the SLE literature will be summarised, with a focus on how the type 1 IFN 
pathway emerges as an important pathway in the pathogenesis of jSLE. Known abnormalities 
in the adaptive immune system in SLE will then be briefly mentioned, before concentrating in 
more detail on the type 1 IFN pathway.  
With the exception of the important work done by the Pascual group(189), the majority of the 
research regarding type 1 IFN has been performed in aSLE. Therefore, the pathogenesis of SLE 
will be referred to in general, and it shall be specified if a study included patients with jSLE. 
1.4.2. The genetics of SLE 
SLE has a 24% concordance in monozygotic twins, vs a 2% concordance in dizygotic twins(190). 
Genes in the MHC region confer the strongest risk, followed by non-MHC genes. Non MHC 
genes include those involved in immune complex processing, DNA degradation,  apoptosis, 
clearance of cellular debris, neutrophil and monocyte signalling, TLR/type 1 IFN signalling, 
nuclear factor kappa beta activation, B and T cell function and signalling(191)(some examples 
Fig. 1-17(192)). Importantly, more than half of the non-MHC loci are associated directly with 
the IFN pathway, or indirectly in terms of increased availability of DNA/RNA/nuclear cell debris 
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and apoptotic waste.  The number of described polymorphisms continues to increase as more 
studies are done. It has been estimated, in a recent large Taiwanese population study (23 
million participants and 18283 SLE cases), that heritability accounted for 43% of the 
phenotypic variance of SLE (193). Currently the GWAS data accounts for approximately 28% of 
the heritability of jSLE, leaving almost a third unaccounted for.  This could be explained by 
smaller effect variants, rarer variants not present in common arrays, and epigenetic 
modifications(191). All genome wide association studies (GWAS) in SLE have been in adult 
patients, and consist of multiple large scale studies in European and Asian ethnicities, 
highlighting the need to include children and African patients in these studies (191). 
 
Figure 1-17. GWAS-identified susceptibility genes classed into function pathways as per Tsokos 
et al 2016(192). 
1.4.2.1. Rare monogenic lupus 
There are much rarer monogenic forms of SLE which allow for valuable insights into 
pathogenesis, and equally point to the type 1 IFN pathway as an important in SLE 
pathogenesis. These have been broadly classed by Tsokos et al in a review and shown 
below(Fig.1-18(192)). Many of these include defects in cell debris or nucleic acid clearance 
through complement deficiencies, or abnormalities in the cell nucleic acid clearance 
mechanisms. Many of these defects cause an increased type 1 IFN gene signature, along with 
similar clinical manifestations to SLE.    
Aicardi Goutierres syndrome(AGS) presents clinically with extremely early onset neurological 
disability with intracranial calcifications mimicking intra-uterine infection, fevers, skin ulcers,  a 
type 1 IFN transcription signature and nuclear autoantibodies, similar to those seen in 
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SLE(194). It has been directly linked to defects in intracellular nucleic acid clearance through 
mutations in TREX1, SAMDH, IFIH and RNAse-H2(194). It has provided a direct link between the 
development of systemic inflammation, anti-nuclear antibodies, an abundance of endogenous 
nucleic acid substrate due to decreased clearance and a resulting increase in type 1 IFN 
production and ISG upregulation.   
Similarly, familial chilblain lupus is a rare, autosomal dominant form of SLE with cold-induced 
inflammatory lesions presenting in early childhood. Familial chilblain lupus is usually caused by 
a mutation in TREX1 (3' repair exonuclease 1), similar to AGS and defective clearance of innate 
nucleic acids is implicated. 
These familial defects in nucleic acid clearance that cause an SLE like phenotype with a type 1 
IFN signature provide an important conceptual framework to the hypothesis that the type 1 
IFN pathway may be the initiating pathway in the development of SLE. 
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Figure 1-17. Summary of described monogenic lupus like diseases (From Tsokos et al (192)).  
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1.4.3. The epigenetics of SLE.  
Analysis of the epigenetic processes in SLE have also highlighted the importance of type 1 IFN 
in the pathogenesis. Epigenetic processes govern how genes are expressed in a tissue and 
signal-specific manner(195) 
Epigenetic processes include DNA methylation, histone modification and non-coding RNAs that 
regulate gene expression. These changes correlate with changes in chromatin accessibility and 
transcription factor binding(191).  
In general, methylation in regulatory sequences induces gene silencing, while hypomethylation 
allows for transcriptional chromatin accessibility, and active gene expression when 
transcription factors are available(196). A genome wide methylation study of CD4 T cells in 36 
adult volunteers (18 healthy, 18 SLE) identified significant  hypomethylation in IFN-regulated 
genes in naïve CD4+ T cells from SLE patients, including IFIT1, IFIT3, MX1, STAT1, IFI44L, USP18, 
TRIM22 and BST2(197). 21 out of 35 hypomethylated genes identified were regulated by type I 
IFN, and the hypomethylation of these was not related to disease activity (197). The same 
study included genome wide gene expression, which confirmed overexpression of these 
hypomethylated genes in total, but not naïve CD4+ T cells in SLE, suggesting epigenetic priming 
of IFN-regulated genes, which may lead to future hyper-responsiveness (197). A follow up 
study confirmed that IFN was the most significant unifying canonical pathway (p = 6.41 × 10−8), 
with IFNα as the most significant upstream regulator in these genes (p = 6.77 × 10−23)(198). 
In addition, histone modification has been shown to be altered in SLE(199), and 635 of the 
sites with altered histone H4 hyperactivation, were potential binding sites for IRF1, a 
transcription factor downstream of type 1 IFN, once again linking the epigenetic modifications 
of SLE  back to type 1 IFN. 
1.4.3. The transcriptomics of SLE 
Unlike, the epigenomic and genomic data, the original important transcriptomic description of 
an IFN signature in SLE by Bennett et al  was in data from young people with jSLE (189). RNA 
transcription from 30 young people with jSLE and 9 healthy volunteers was analysed, and 15 
gene transcripts were found to be significantly upregulated after stringent Bonferroni 
correction (Fig. 1-19). Among these, 14 were IFN inducible, or ISG, leading to the coining of the 
term, ‘IFN signature’ in jSLE.  It was established in this relatively small cohort that this IFN 
signature correlated to disease activity, and was extinguished through high dose steroid 
therapy(189). 
The second most commonly differentially expressed genes related to a granulocyte signature, 
which was surprising, as neutrophils are not classically included in the PBMC compartment. 
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Bennet et al then identified a group of smaller, low density granulocytes that co-purify with 
mononuclear cells in jSLE.   
 
Figure 1-19: The IFN gene expression signature in jSLE as first described by Bennet et al(189).  
The second important transcriptome paper in aSLE was published in the same year by Baechler 
et al (200). This confirmed the upregulation of expression of IFN inducible genes, as well as the 
correlation with disease activity. Importantly, in these data they assigned an IFN score to each 
volunteer and found that roughly half of the patients with aSLE displayed an elevated IFN 
score(200). 
Kirou et al confirmed that the IFN induced genes overexpressed in aSLE are those that are 
predominantly induced by IFNα and not type 2 IFNs like IFNγ(201).  
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To complicate matters it has been show that the specific set of ISG upregulated in SLE varies 
widely in each immune cell subtype and in different ethnicities(202). There has been evidence 
that African American patients may be more likely to have an increased ISG upregulation, and 
a wider variation of ISG upregulated in SLE (202-204). 
It has been shown that the upregulation of ISG is present in relatives of patients with jSLE, and 
shows heritability, which argues towards IFNα being a primary event in the pathogenesis of 
SLE(205) 
It has been suggested that transcription profiles may be used to improve stratification of SLE as 
they are used in oncology to direct therapy(192). Recently, Banchereau et al longitudinally 
profiled the blood transcriptome of 158 jSLE patients (206). Using mixed models accounting for 
repeated measurements, demographics, treatment, disease activity, and nephritis class, they 
confirmed a prevalent IFN signature and identified an intermittent plasmablast signature as 
the most robust biomarker of disease activity. They reported gradual enrichment of neutrophil 
transcripts during progression to nephritis. In addition, they have described personalized 
immune-monitoring, which enabled patient stratification into seven groups, supported by 
patient genotypes. These are the first steps towards stratifying jSLE for trial design and 
eventual stratified therapy (206).  
Therefore, transcription data from SLE show a predominant type 1 IFN signature, which is 
correlates with disease activity and may be useful in the stratification of SLE in the future. 
1.4.3. The adaptive immune system in SLE.  
Prior to the discovery of the IFN signature in SLE in the early 2000s, and due to the presence of 
auto-antibodies, it was widely held that SLE was caused by abnormalities in the adaptive 
immune system. Indeed, the type 1 IFN system is not the only deranged pathway in SLE. For 
the sake of completeness, some of the known abnormalities in the adaptive immune system 
will be briefly summarised here.  
Multiple cytokines are deranged in SLE including IL-10, IL-18, B cell activating factor (BAFF), 
TNF, IL4, IL6 and others. The MHC locus is the one of the main genetic susceptibility foci for 
SLE. This underpins the importance of T cells in lupus pathogenesis. T cells subtypes, signalling 
pathways and activation are all known to be disrupted in SLE(192). 
SLE is characterised by antibodies to self, specifically towards DNA, cell nuclei, and 
components of ribonucleoprotein particles(1). This has led to many investigations into the 
trigger of loss of self-tolerance in the adaptive immune system. The autoantibodies produced 
are class switched and of a high affinity, implying T cell help(192). These antibodies may be 
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present for years before the onset of disease and accumulate in the lead up to disease 
presentation (207). It is not only auto-antibodies that are high affinity in SLE, it has been 
shown that SLE patients produce higher affinity antibodies to influenza after vaccination, and 
may produce broadly neutralising antibodies to HIV (208, 209).   
Indeed, targeting the adaptive immune system has led to the landmark U.S. Food and Drug 
Administration approval of belimumab(178), a drug that inhibits B lymphocyte stimulator, as 
well as anecdotal efficacy (despite failing clinical trials) of B cell depleting agents like rituximab 
or T cell activation inhibitors  like abatacept(1). 
Despite these important discoveries through the investigation of the adaptive immune system, 
auto-antibodies are not sufficient to produce disease in isolation. Targeting of the adaptive 
immune system has also only produced partial disease response.  
Multiple investigations have pointed towards type 1 IFN as an early trigger for and crucial to 
the sustained abnormal immune response in SLE. I have shown above, that the anti-viral 
effects of type 1 IFN are ubiquitous within the cells of the immune system. Therefore, there 
have been recent theories that the persistent and excessive production of type 1 IFN and 
activation of molecular events downstream of the IFNΑR are important to the early and 
sustained events in the adaptive immune pathways, and ultimately in lupus pathogenesis(1). 
1.4.4. Type 1 IFN in SLE  
Type 1 IFN has long been associated with the development of SLE. In 1969, Steinberg et al 
reported that in NZBW mice, with a predisposition to develop a lupus like phenotype, injection 
of polyinosinic·polycytidylic acid, a synthetic RNA and IFNα inducer, decreased the time to 
development of lupus features(210). In fact, in the abstract, they proposed a hypothesis, which 
years later we are again considering:  
‘According to this hypothesis, the unusual feature in this disease is not a unique virus, but 
rather the unique genetic susceptibility of the B/W (particularly female) host to immunization 
with nucleic acids. A similar pathogenetic mechanism may be operative in some humans with 
systemic lupus erythematosus’(210) 
IFNα is maintained in serum at miniscule quantities and is not reliably detectable by available 
IFNα assays. For this reason, the direct amounts of ex vivo IFNα has not been reliably reported 
in serum from SLE patients. In 1979, Hooks et al ingeniously used the antiviral nature of IFNα 
to detect it in a vesicular stomatitis virus infection cell assay(211). They showed that IFNα was 
present at relatively higher titres in patients with SLE, and that it correlated with disease 
activity(211). Hua et al repeated this assay in 2006 and confirmed that there was also an 
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upregulation of ISG in the reporter cells, and blocking IFNα (but not IFNγ or IFNβ) abrogated 
this effect (212).  
There have been multiple reports of cases of SLE induced by IFNα therapy (213-215). The 
published literature supports IFNα, as the most abundant type 1 IFN in patients with lupus(1). 
In addition, blocking IFNα (but not IFNγ) in SLE serum in vitro blocks the ability of the serum to 
upregulate ISG similar to blocking the IFNΑR, suggesting that IFNα is responsible for the IFN 
signature in SLE(216). IFNβ and IFNγ are shown to be increased in SLE serum however, and 
their role in the disease has not been fully investigated(216). 
In an important report in 2001 ,Blanco et al noted that monocytes behaved like dendritic cells 
(i.e. induced T cell proliferation) after exposure to serum from jSLE patients(35). They found 
that this effect was dependant on the presence of IFNα in the serum.  
It is argued that in light of these findings, in addition to the genetic, epigenetic and 
transcription data provided above, that IFNα is essential in the pathogenesis of SLE, and may 
even act as the initiating factor. The next obvious question would be whether there is evidence 
of an increased expression of nucleic acid receptors in SLE, and whether, when stimulated, 
these produce an increased amount of IFNα. In addition, it would be important to investigate 
for evidence of increased sources of endogenous nucleic acid in SLE. The data pertaining to 
these questions is scarce, and mostly comes from animal models, but will be summarised 
below to highlight gaps in the literature. 
1.4.5. The source of nucleic acids in SLE  
There are various potential sources of nucleic acid ligand available for sensing and subsequent 
IFNα production in SLE, including apoptosis, increased endogenous retroelement (ERE) activity 
and increased release of neutrophil extracellular traps(NETs). 
1.4.5.1. Apoptosis in SLE  
SLE has been associated with defects in the clearance of apoptotic cell debris(217). The 
characterisation of monogenic complement deficient forms of SLE has also highlighted the 
importance of the clearance of nuclear cell debris in SLE. Apoptotic cell debris can trigger TLRs 
and other nucleic acid sensors, and apoptosis may be further influenced by infection, UV light 
exposure and other cytokines(192).  
1.4.5.2. Endogenous nucleic acids 
ERE comprise a large proportion of the human genome. Non-long terminal repeat (LTR) long 
interspersed nuclear elements (LINE) are the most abundant and represent almost a fifth of 
84 
 
the human genome (218). LINE are capable of autonomous transposition, and contain coding 
regions for RNA polymerase, RNA binding protein, reverse transcriptase and an endonuclease.  
In the absence of virus, it has been proposed that ERE may act as an endogenous source of 
nucleic acid substrate in SLE(219). It has been shown that LINE RNA transfection is capable of 
inducing TLR7 mediated type 1 IFN production (220). In addition, the expression of ERE is 
enriched in patients with SLE and is related to disease activity, although it is unclear whether 
this is primary or associated  with increased IFN, as LINE is IFN inducible(221).  
1.4.5.3. Neutrophils 
In SLE, neutrophils and low density granulocytes  have been shown to readily produce NETS, 
whereby they extrude nuclear material as well as immune-stimulatory anti-microbial 
proteins(222). 
1.4.6. Sensing nucleic acids in SLE 
There is evidence emerging that TLR7 expression and associated nucleic acid sensing is 
enhanced and may be pathogenic in SLE, whereas TLR9 expression may be relatively 
protective. As we have shown, TLR7 specific IFNα production is increased in females, and TLR7 
is coded for on the X chromosome. Given the importance of IFNα in SLE, this naturally leads 
one to question whether TLR7 may be responsible for the sex bias in SLE.  
1.4.6.1. TLR7 and TLR9 in SLE 
It has been well described that self or foreign nucleic acids, bound to antibodies, are capable of 
entering the endosome and triggering IFNα production or ISG transcription via TLR7 or TLR9 
(15, 223, 224).This effect has been shown in vitro to be dependent on FcγRIIa, diminished by 
RNA degradation and increased by NET anti-microbial proteins such as HMGB1 or LL37 (1, 225, 
226). 
When both TLR7 and TLR9 were inhibited in the (NZB × NZW) F1 lupus mouse model, 
development of disease was suppressed (227).  A mutation in Unc93b1, which traffics TLR7 
and TLR9 to endosomes also improved the lupus phenotype in C57VL/6(B6)-Faslpr mice (228). 
In the important BXSB mouse model, male mice develop severe lupus-like autoimmunity (229, 
230). It was shown that this depended on an area on the Y chromosome, named the Y-linked 
autoimmune accelerator (yaa) region which was found to contain a translocation of TLR7 from 
the X chromosome onto the Y chromosome, resulting in a 2 fold increase in expression of TLR7 
in male mice (231-233). It was shown that this increased expression of TLR7 was responsible 
for the disease development.  
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Christensen et al showed that MRL/Mplpr/lpr mice that lacked TLR9, did not develop anti 
chromatin antibodies, but developed more severe disease and early mortality (234). If the 
same mouse model lacked TLR7 however, they did not develop anti RNA binding protein (RBP) 
antibodies, and all features of disease were improved (234). Santiago-Raber et al confirmed 
this with B6.Nba2 mice (235). If TLR9 was absent, the mice developed a markedly accelerated 
form of lupus nephritis, associated with functionally upregulated expression of TLR7.Disease 
exacerbation in TLR9 deficient mice was completely suppressed by the deletion of TLR7(235). 
Recently Celhar et al have confirmed that Sle1TLR9-/- mice develop severe disease, produce 
more class-switched antibodies and have a skewed autoantibody repertoire toward RNA-
containing antigens(236). Sle1TLR9-/- mouse renal DCs were more efficient at TLR7 dependent 
antigen presentation and expressed higher levels of TLR7 protein. Importantly, this increase in 
TLR7 gene expression occurred prior to disease development, indicating a role in the initiation 
stages of disease(236). This has led to the idea that expression of TLR9 may be protective in 
lupus, whereas TLR7 may be pathogenic. These data are from animal models, and this has 
been more difficult to show in humans.  
In humans, the presence of auto-antibodies towards RNA associated proteins in humans (e.g. 
RNA binding protein, RBP), has been associated with a type 1 IFN signature in SLE (201), 
implying that RNA sensing (by TLR7 or others) is important in the production of IFNα and the 
upregulation of ISG.  
Midgley at al showed that human PBMC TLR9 and TLR7 expression was increased in jSLE, but 
TLR7 did not reach statistical significance(237). It is accepted that TLR9 is an ISG, therefore one 
would expect it be increased in SLE, and the actual direction of the expression in SLE cannot be 
measured without correcting for ISG expression. Komatsuda et al also reported that TLR7 and 
TLR9 expression is increased in SLE, but once again, have not corrected for ISGs. In this paper, 
the expression of multiple genes has been tested, without correcting for multiple tests, making 
it unlikely that TLR7 , with its small effect size (p=0.011) was significantly increased(238). 
Another large adult cohort reported the same findings, but once again did not control for the 
effect of ISG (239).  
In 55 adult women and 40 adult men with aSLE, Kelley et al could show no difference in the 
gene copy number of TLR7 when compared to matched healthy volunteers(240) .Other studies 
have shown no difference in TLR7 copy number in jSLE(240) . A recent study of  a large number 
of children in Mexico reported an increased risk of jSLE if the TLR7 copy number variant was 
greater than 1 in males and greater than 2 in females, with an overall increase in TLR7 copy 
number variant in jSLE (241). 
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Therefore, although the animal data indicate that TLR7 gene expression is important in disease 
pathogenesis, the human data are less clear.  
1.4.6.2. Cytoplasmic nucleic acid sensing in SLE 
Information is emerging about the potential role of cytoplasmic nucleic acid sensors in SLE 
(242). Specifically, AGS has been associated with an abnormal sensing of nucleic acid in the 
cytoplasm. This may be due to increased availability of nucleic acids to cytoplasmic RNA or 
DNA sensors due to abnormalities in enzyme pathways responsible for nucleic acid 
degradation such as TREX1, RNaseH2, SAMDH and ADAR1(242). In addition, Aicardi Goutierres 
has been linked directly to a mutation in the MDA5 gene IFIH(243). This gives indirect insight 
into the potential for cytosolic nuclear sensing to be disrupted in SLE.  These cytosolic sensors 
should therefore not be neglected when investigating the production of IFNα in SLE.  
1.4.7. Nucleic acid induced type 1 IFN production in SLE.  
Despite evidence of increased type 1 IFN in SLE, there is little consensus on the source of this 
IFN. In the original study by Blanco et al, when PBMC from jSLE patients were stimulated with 
influenza virus (ssRNA virus and TLR7 agonist), they produced the same amount of IFNα as 
healthy volunteers. In addition, depleting pDC from the system did not fully deplete the IFNα 
producing capacity as it had done in the healthy volunteers(35). It was also shown that herpes 
simplex virus (DsDNA virus and TLR9 agonist) induced pDC IFNα production was reduced in 
SLE(244). 
There have been varying reports about whether TLR7 induced IFNα production is different in 
SLE (35, 244, 245). A recent  large study involving 71 adult  SLE patients and 45 healthy adults 
showed an increase in the TLR7 mediated pDC production of IFNα and TNFα in SLE(245). This 
study included patients with active disease in addition to those with low disease activity and 
reported that the TLR7 mediated pDC production of IFNα correlated with disease activity.  
Therefore, there is evidence that IFNα is increased in SLE. TLR7 gene expression associates 
with the development of SLE in animals, whereas the expression of TLR9 is potentially 
protective. It is unclear whether the expression of TLR7 is increased in humans with jSLE, and 
as TLR9 is a known ISG, it is unclear whether it is truly increased after correcting for IFN 
signature. There is some evidence as to increased TLR7 copy number conferring an increased 
risk to humans in developing SLE. Evidence is conflicting, but there is a possibility that TLR7 
mediated IFNα production may be increased in SLE, and that this may correlate with disease 
activity.  
Therefore, there is a need to examine whether TLR7 and TLR9 gene expression and associated 
IFNα production is different in young people before puberty, which may provide insights into 
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the sex and pubertal bias in jSLE. In addition, there is a need to examine whether TLR7 and 
TLR9 gene expression and associated IFNα production is different between healthy young 
people and those with jSLE, in order to examine whether TLR7 expression and IFNα production 
may be pathogenic in SLE.   
1.4.7. Type 1 IFN centric pathogenesis hypothesis 
The data summarised above has led some researchers, to hypothesise an ‘IFN centric’ view of 
SLE, where numerous polymorphisms in the IFN pathway, associated with environmental 
triggers, set the stage for either endogenous or exogenous nucleic acids to trigger a type 1 IFN 
response(1). This then primes the adaptive immune system (which may have further risk 
polymorphisms in B or T cell function) to promote an anti-nuclear self-reactive environment. 
This leads to the presentation of auto-antibody bound self-nucleic acids through Fc dependant 
presentation to pDC which serves, along with the release of NETs, to further amplify the 
production of type 1 IFN (Fig. 1-20). 
This emphasises the need to explore the effects of TLR7 mediated IFNα production in jSLE, and 
to assess whether these are responsible for the sex and pubertal bias seen in jSLE.  
 
  
pDC-plasmacytoid dendritic cell, Il-interleukin, IFN-IFN, BAFF-B cell activating factor, RIG- retinoic acid-inducible gene, MDA5- Melanoma 
Differentiation-Associated protein 5, cGAS- cyclic GMP-AMP synthase, TLR-toll like receptor, Ag-antigen, MHC-major histocompatibility 
complex, BCR-B cell receptor    
Figure 1-19. Type 1 IFN-centric view of 
SLE pathogenesis from Crow et al(1). 
Polymorphisms in nucleic acid 
degradation or type 1 IFN pathway 
genes, along with environmental stress 
stimuli enhance the activation of the 
type 1 IFN pathway. Endogenous 
nucleic acids activate cytoplasmic PRR 
and induce type 1 IFN which primes an 
adaptive immune response, in a host 
that may be enriched in gene variants 
that lower the threshold for 
lymphocyte activation. Resulting 
autoantibodies target nucleic acids or 
nucleic acid–binding proteins, immune 
complexes form and strongly amplify 
type 1 IFN production, predominantly 
IFNα, through FcR-dependent 
activation of pDCs mediated by 
endosomal TLRs. Neutrophils respond 
to type 1 IFN and immune complex 
exposure with extrusion of nucleic 
acids containing neutrophil 
extracellular traps. Neutrophils and 
pDCs each amplify production of type 1 
IFN by the other cell type, modify the 
function of adaptive immune system 
cells, and amplify autoimmunity. The 
immunologic consequences of this 
sustained viral-like response include 
broad immune dysregulation, 
 1.5. Summary 
Sex and puberty are neglected variables in immunology and data is lacking about their 
contribution to sex biased disease. In addition, the role of X chromosome number and sex 
hormone environment are difficult to separate out in human experiments.  
It is clear that the type 1 IFN pathway is important in the pathogenesis of jSLE, a disease with a 
strong sex bias, which is more common during puberty.  It is known, in adults, that females 
produce more IFNα after TLR7 stimulation. It is not known whether TLR7 gene expression or 
TLR7 mediated IFNα production changes during puberty. There is a need to confirm the role of 
TLR9 and TLR7 in jSLE. There is also a need to investigate whether TLR7 gene expression or 
TLR7 mediated IFNα production changes over puberty, and to examine the relationship to X 
chromosome number and sex hormone, in a manner that may explain the sex and pubertal 
bias in jSLE.  
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Hypothesis  
This thesis aims to test the following hypothesis: 
Puberty associates with an increased TLR7 mediated type 1 IFN production in females. 
Aims  
1. To investigate whether sex and pubertal differences exist in: 
• pDC activation and percentage  
• pDC surface protein expression of known IFN inducible genes  
• TLR7 or TLR9 induced pDC IFNα production  
• pDC IFN pathway gene expression. 
2. To investigate whether the above variables associate with X chromosome number or 
serum sex hormone concentration. 
3. To investigate whether differences exist in the above variables between young people 
with jSLE compared to healthy young volunteers. 
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Chapter 2: Materials and Methods  
2.1. Recruitment.  
Young volunteers were recruited, and informed consent was sought with Research Ethics 
Committee approval REC11/0101. Healthy participants older than 12 years were recruited 
from the local community at science outreach events. Healthy participants less than 12 years 
old were only recruited if blood was being taken for an unrelated clinical indication (e.g. 
surgery for routine, non-inflammatory procedures i.e. dental extraction, circumcision). 
Exclusion criteria included acute or chronic illness and concurrent medication (including oral 
contraceptive).  
Transgender young people on cross-sex hormone therapy (i.e. testosterone in those born 
phenotypically female and oestradiol in those born phenotypically male) and young women 
with TUS were recruited from endocrinology clinics. Exclusion criteria included acute or 
chronic illness. 
Young people with low disease activity jSLE were recruited from rheumatology clinics. jSLE was 
defined as SLE presenting before the age of 16 and diagnosed by the treating clinician. 
Exclusion criteria included a prednisolone dose of >15mg/day and SLEDAI score > 5. SLEDAI 
was calculated for each individual. Briefly a clinical score was calculated based on clinical 
information in the 30 days preceding sample collection. This included a weighted score of 16 
clinical indices and 8 laboratory indices.  
Upon consent, demographic data, clinical data, and peripheral blood was collected. In 
addition, participants older than 13 completed a pubertal self-assessment questionnaire, 
based upon established pubertal developmental phases(100) (Fig 2-1/2-2). If participants were 
younger than 13, their parents either completed the form for the child, or with them if the 
parents thought it appropriate. In further analysis, volunteers were included who were pre-
pubertal or post-pubertal according to self-classification. 
Blood was collected using blood collection vacutainers containing sodium heparin 102IU, (BD  
367876) and silicon containing SSTII tubes containing gel (BD 367954).  Not more than 2ml/kg 
of blood was taken in total from participants. Blood was processed at different times of day 
but all within 2 hours of collection from each volunteer.  
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Confidential self-assessment questionnaire  
Female 
Please indicate below which category best describes what stage of 
puberty you are at. This form is private and will have your study number, 
but not your name.  It is important that you fill it out as truthfully as 
possible.  
Please mark the category that best describes your stage of development in 
the boxes like this  
 
 
 
Figure 2-1. Female self-assessment questionnaire.  
 
 
 
Pre-puberty 
(Tanner stage 1) 
If all of the following: 
 
In Puberty  
(Tanner stage 2-3) 
If any of the following: 
 
Completing Puberty 
(Tanner stage 4-5) 
If all of the following: 
 
-No signs of nipple or 
breast development 
-No pubic hair 
-Any breast enlargement so long as 
nipples also enlarged 
-Any pubic or axillary (armpit) hair 
growth  
Started periods(menarche) with 
breast, pubic and armpit hair 
development 
 
   
   
Adapted from Butler, G, Kirk J. OSH Paediatric Endocrinology and Diabetes 
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Confidential self-assessment questionnaire  
Male 
Please indicate below which category best describes what stage of 
puberty you are at. This form is private and will have your study number, 
but not your name.  It is important that you fill it out as truthfully as 
possible.  
Please mark the category that best describes your stage of development in 
the boxes like this  
Pre-puberty 
(Tanner stage 1) 
If all of the following 
 
In Puberty  
(Tanner stage 2-3)  
If any of the following:  
 
Completing Puberty 
(Tanner stage 4-5) 
 
 
-High voice 
-No growth of testes or penis 
-No pubic hair 
 
 
 -Slight voice deepening 
-Growth of the testicles 
-some growth of the penis  
-Beginnings of pubic or 
armpit hair growth 
 
If any of the following:  
-Voice fully changed 
(broken) 
-Adult size of penis with 
pubic and armpit hair 
growth 
-Moustache and early facial 
hair growth 
   
 
 
Figure 2-2. Male self-assessment questionnaire.  
 
 
 
Adapted from Butler, G, Kirk J. OSH Paediatric Endocrinology and Diabetes 
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2.2. Human blood processing.  
2.2.1. PBMC separation protocol. 
Separation was carried out in a class 2 hood and sterile technique followed at all times. All 
reagents were made up sterile and only opened in the hood. All equipment was sterile, and all 
reagents were endotoxin-free.   
Blood was diluted 1:1 with RPMI 1640 containing L-glutamine and NaHCO3 (Sigma-Aldrich) 
supplemented 100 IU/µg/ml penicillin/streptomycin (Sigma-Aldrich). 
Briefly, 15ml of Ficoll-paque plus (GE-healthcare GE17-1440-03) was added to a SepMate 50 
tube (StemCell 85450), carefully pipetted through to fill the bottom of the tube. A maximum of 
17ml of diluted blood was added slowly to the tube, on top of the Ficoll.  The tube was then 
centrifuged at 1200g for 10 minutes at 20oC with full acceleration and deceleration. The top 
layer was then quickly poured off into a new 50 ml centrifuge tube (Greiner T2318). Media was 
added to the tube to dilute up to 50ml in total. The tube was re-centrifuged at 1800RPM for 10 
minutes at 20 oC at maximum acceleration and deceleration to wash. The cell pellet was re-
suspended in 25ml of media containing RPMI 1640 containing L-glutamine and NaHCO3 (Sigma-
Aldrich) supplemented 100 IU/µg/ml with 10% heat inactivated fetal calf serum (FCS) (Biosera) 
and counted. Cells were then re-suspended at 10 million per ml in freezing media -10% 
dimethyl sulphoxide (Sigma 276855) and 90% heat inactivated FCS at -80° C in cryovials. 
Cryovials were labelled with the allocated sample number, date and cell volume and frozen in 
Nalgen ‘Mr Frosty’ freezing container (controlled freezing rate at 1°C per minute with isopropyl 
alcohol). The samples were stored in liquid nitrogen at 196 °C at no later than 72 hr post initial 
freezing.  
2.2.2. Serum separation protocol 
Whole blood was collected in vacutainers with silicon clotting agents that did not contain 
heparin (BD 367954). The blood was allowed to clot at room temperature for at least 30 min. 
Serum was transferred to sterile Eppendorf tubes (Sigma T2422) and micro-centrifuged at 
10000g for 10 min at room temperature before labelling, freezing and storing at -80°C. 
2.3. PBMC thawing and counting 
PBMC were rapidly thawed in water at 37°C, washed once with RPMI and 10%FCS and re-
suspended in media plus 10% FCS (RPMI 1640 containing L-glutamine and NaHCO3 (Sigma-
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Aldrich) supplemented 100 IU/µg/ml with 10% heat inactivated fetal calf serum (FCS) 
(Biosera)). Cells were counted with a haemocytometer.  
2.4. Cell Culture.  
PBMC were plated in a U bottomed 96 well plate at 1 million cells per well in RPMI 1640 
containing L-glutamine and NaHCO3 (Sigma-Aldrich) supplemented with 10% FCS (Biosera) and 
100 IU/µg/ml penicillin/streptomycin (Sigma-Aldrich). One million cells were each stimulated 
with TLR7 agonist, R848 (Invivogen-tlrl-r848) at 1ug/ml or TLR9 agonist, CpGODN2216 (CpG) 
(Invivogen tlrl-2216) at 1µM or left unstimulated (in RPMI+10%FCS) for 20 hours. Brefeldin A 
(BFA) 5ug/ml (Sigma B7651) was added to the unstimulated and R848-stimulated cells at 0 
hours. BFA was only added to the CpG stimulated cells at 16 hrs. Briefly, after 16 hours, the 
CpG stimulated cells were centrifuged (1800RPM for 3 min), media discarded and re-
suspended in the new media (RPMI+FCS) containing BFA 5ug/ml (Sigma B7651).  
2.4. Flow Cytometry.  
2.4.1. Ex-vivo immune-phenotype flow cytometry. 
Upon thawing, one million PBMC were plated in a 96 well plate. These were centrifuged at 
1800 RPM for 3 min and re-suspended in phosphate buffered saline (PBS), and washed once. 
Thereafter cells were re-suspended in a 50ul mixture of live/dead fixable stain near infrared 
(423105) and the antibodies listed in Table 2-1 and incubated for 30 min in the dark at 4°C. 
Cells were washed once with PBS after incubation and re-suspended in 100ul FoxP3 Fix/perm 
solution (Ebioscience 421403) for 45 minutes in the dark at 4°C before one wash with 
permeability buffer 1:10 (Ebioscience 421403). A mixture of perm buffer and IRF 5 antibody 
(Alexafluor488; ab193245; clone-EPR6094; Abcam; 1.50) was added for 30 minutes in the dark 
before washing with perm buffer once and re-suspending in 100ul FACS buffer (PBS+0.1%FCS 
and 0.01%FCS and 1mM EDTA). Gating was set using isotype controls or full minus one 
samples. Gates illustrated in Fig 2-3 and 2-4. Tetherin is expressed constitutively on many cell 
types including pDC and B cells, and is upregulated with type 1 IFN stimulation(246). For this 
reason, tetherin median fluorescent intensity rather than percentage of cells positive, was 
measured and analysed (247)(Fig 2-5). 
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Antibody Fluorochrome Cat number Clone Company Titre 
Tetherin APC 348410 RS38E Biolegend 1:50 
CD86 PeCy7 305408 IT2.2 Biolegend 1:50 
CD4 BV711 317439 OKT4 Biolegend 1:100 
BDCA2 PE 354203 201A Biolegend 1:50 
CD56 PerCP Cy5.5 318322 HCD56 Biolegend 1:100 
CD11c BV421 301627 3.9 Biolegend 1:100 
CD8  V500 561618 SK1 BD 1:100 
CD14  BUV 737 564444 M5E2 BD 1:100 
CD19  BUV 395 563549 SJ25C1 BD 1:100 
CD3  BUV 805 565515 UCHT1 BD 1:200 
Table 2-1 Cell phenotype surface staining panel.  
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Figure 2-3. PBMC phenotype gating strategy Ex vivo PBMC were analysed by flow cytometry. 
Dead cells and single cells were excluded (not shown) before gating was performed as shown 
for BDCA2+ pDC, CD11c+ cDC, CD14+ monocytes, CD4+ T cells, CD8+ T cells, CD19+ B cells and 
CD56+ NK cells.  
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Figure 2-4. Flow cytometry measurement of CD86 expression in pDC, B cells and monocytes. 
Gates were set using full minus one controls (not shown). 
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Figure 2-5. Tetherin expression. Tetherin was measured by flow cytometry, gates set using 
isotype controls as shown on a. B cells and b. pDC.  
2.4.2. Post culture flow cytometry.  
After culture with R848, CpG or no stimulation, cells were washed once with PBS, and re-
suspended in a 50ul mixture of live/dead fixable stain near infrared (Biolegend, 423105) and 
the antibodies listed in Table 2-2 and incubated for 30 min in the dark at 4°C. Following 
incubation, cells were washed with PBS once before adding 100ul IC fix (Ebioscience IC fix 88-
8824-00) and incubating in the dark at room temperature for 30 min. Thereafter cells were 
washed once with perm buffer before staining with antibody to IFNα (IFNα APC, Miltenyi 
Biotec, 130-092-602, clone:  LT27:295) for 30 min in perm buffer. Cells were then washed once 
with FACS buffer before re-suspending in 100ul FACS buffer.  
2.4.3. Flow cytometry analysis 
Samples were run on an LSRII flow cytometer (BD) and the data were analysed using Flowjo v. 
10. Gating strategy differed depending on whether PBMC were stimulated with CpG or R848. 
Upon CpG stimulation, there was a more pronounced downregulation of BDCA2 on pDC, 
requiring lymphocytes to be gated as lineage negative, CD123 positive, before gating on 
BDCA2 to gain the correct population of pDC. After R848 stimulation however, it was sufficient 
to gate pDC directly from lymphocytes as BDCA2 positive, CD123 positive (Fig. 2-6 and 2-7).  
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Antibody Fluorochrome Cat number Clone Company Titre 
Lineage -
CD3, CD14, 
CD19, CD20, 
CD56 
FITC 348701 UCHT1, 
HCD14, 
HIB19, 2H7, 
HCD56 
Biolegend 1:200 
BDCA2 PE 354203 201A Biolegend 1:25 
CD123 PECy7 306009 6H6 Biolegend 1:100 
Table 2-2 Cultured cells surface staining panel. 
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Figure 2-6. Flow cytometry gating strategy for R848 stimulated PBMC.PBMC were stimulated 
with R848. a.-b. By flow cytometry, lymphocytes and single cells were selected based on size. 
c. Live cells were selected. d. pDC were selected as CD123+; BDCA2+. e. An isotype control was 
used to set the gate for IFNα producing pDC and confirmed in f. unstimulated and g. R848 
stimulated pDC. 
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Figure 2-7. Flow cytometry gating strategy for CpG stimulated PBMC.PBMC were stimulated 
with CpG. a.-b. By flow cytometry, lymphocytes and single cells were gated based on size. c. 
Live cells were selected. d-e. CD123+; Lineage- cells were selected, before gating on BDCA2 to 
select pDC. f. The percentage of pDC producing IFNα was then assessed.  
 
2.5. Cell culture supernatant assay.  
2.5.1. Luminex 
Separately, depending on cell availability, after thawing, PBMC were plated in a U bottomed 96 
well plate at 1 million cells per well in media (RPMI+10%FCS). One million cells were each 
stimulated with TLR7 agonist, R848 (Invivogen-tlrl-r848) at 1ug/ml or TLR9 agonist, 
CpGODN2216 (CpG) (Invivogen tlrl-2216) at 1µM or left unstimulated (in RPMI+10%FCS) for 20 
hours without the addition of BFA. After 20 hours, plates were centrifuged at 1800RPM for 3 
minutes and supernatant was removed and cryopreserved at -80°C. Samples were transferred 
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to UMC Utrecht and strictly kept frozen on dry ice. UMC Utrecht multiplex facility has a ready 
optimised platform for the measurement of many cytokines, and a long term partnership with 
the UCL paediatric rheumatology unit(248, 249) which provided a cost-effective, efficient and 
reliable route for the analysis of these samples.Upon thawing, supernatants were analysed 
immediately by bead-based multiplex assay (Luminex-Thermofisher) at the UMC Utrecht 
facility for the concentrations of IFNα, IFNβ and TNFα (Fig 2-6). TNFα was chosen as a non-IFN 
related cytokine that is produced after TLR signalling to assess whether any response was IFN 
specific(16). Results that were reported as out of range were allocated to the maximum or 
minimum detectable levels represented below in Table 2-3. It was not possible to extrapolate 
out of this range and there was no further sample available to perform dilutions.  The IFNα 
assay was reported by UMC Utrecht to detect all 13 subtypes of IFNα.  
 
 
Table 2-3. Range of detection as reported by UMC Utrecht. 
These data were not normally distributed and the natural log of IFNα, IFNβ and TNFα 
concentration was used when these were analysed by linear regression.  
2.3.2. ELISA 
In early experiments optimising cell culture, supernatant was analysed by ELISA. Human IFN 
Alpha ELISA Kit (TCM) (PBL-411001) was used, according to manufacturer’s instructions and 
reagents.  
Briefly, all components were kept on ice and supernatant was thawed on nice. The exceptions 
were the wash solution and stop solution which were brought to room temperature. 
Standards were prepared with dilution buffer at the 156-5000pg/ml range or the 12.5-
500pg/ml range as required. Samples were diluted in buffer 1:1 and plated in duplicate.100ul 
of sample/standard or blank was added to each well. The plate was covered with a plate sealer 
and incubated for 1 hour at room temperature. After 1 hour, the plate was emptied, and 
washed once with wash buffer. 100ul of antibody solution was added to each well, covered 
with plate sealer and incubated for 1 hour. After 1 hour, the plate was emptied and washed 
with wash buffer 3 times. 100ul of horse-radish protein (HRP) buffer was added to the wells 
and incubated for 1 hour. During this incubation trimethyl benzidine (TMB) substrate was 
brought to room temperature. After an hour, the plate was emptied and washed four times. 
100ul of TMB substrate was added and plate was incubated in the dark for 15 min at room 
temp. After 15 min, stop solution was added to each well and the plate was read on a 
                     Range of detection                              
TNFα               1.34-4962.42 pg./ml           
IFNα                2.82-2499.70 pg./ml           
IFNβ                4.28-13095.05 U/ml            
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microplate reader at 450nm within 5 min of adding stop solution. Optical densities were 
calculated using a 4-parameter fit for the standard curve and the IFNα concentration was 
determined.  
2.6. RNA expression analysis. 
2.6.1. IFNα stimulation. 
Depending on availability, after thawing, PBMC were plated in a U bottomed 96 well plate at 1 
million cells per well in media (RPMI+10%FCS) and washed once. One million cells were each 
stimulated with media (+10%FCS) containing 1000IU/ml IFNα2b (Sigma, SRP4595). After 20 
hours, cells were washed once with media (RPMI+10%FCS) and RNA was extracted as below. 
Cells were incubated for 20 hours to coincide with the 20 hour stimulation of CpG and R848 as 
the experiments were all run together to optimise cell availability and experiment feasibility. A 
time point study was not performed.  
2.6.2. RNA extraction.  
Depending on availability, RNA was extracted from an aliquot of 1 million cells directly upon 
thawing or after 20 hours of stimulation with IFNα as above using the Picopure RNA isolation 
protocol and reagents from this kit (Thermofisher, KIT0214). An RNA free area was designated 
in the lab and RNAse was used in this area.  
Briefly, cells were washed in suspension media (0.9ml 1XPBS; 10%FCS; 0.1ml 0.5M EDTA) and 
suspended in 100ul extraction buffer and incubated at 42°C for 30 minutes. Cells were 
thereafter centrifuged at 3000g before removing supernatant containing RNA and placing in a 
new, labelled 96 well plate and immediately freezing and storing at -80°. 
Later, when needed, supernatant was thawed and 100ul of 70% ethanol was added to each 
well and mixed. Purification columns were pre-conditioned by adding 250ul of conditioning 
buffer to each column and leaving at room temperature for 5 minutes before centrifuging at 
16000g for 1 minute. Samples plus ethanol were added to each purification column and micro-
centrifuged at 100g for 2 minutes, followed by 1 minute at 16000g to bind to the filter. 100ul 
of wash buffer was added and spun at 8000g for 1 minute to remove sediment, this was 
repeated twice. The column was transferred to a new 0.5ml micro centrifuge tube and 11ul of 
elution buffer was directly pipetted onto each membrane. After 1-minute incubation at room 
temperature, each column was spun at 1000g for 1 minute flowed by 16000g for 1 minute to 
elute the RNA. RNA samples were assessed for amount and purity using Nanodrop technology 
and then labelled and stored at -80°C.  
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2.6.3. RNA analysis with Nanostring  
24 genes were selected (including 3 housekeepers) and submitted to Nanostring (Table 2-4). 
Genes were selected to answer the original hypothesis: 
-Known IFN inducible genes to construct an IFN signature (MX1, BST2, IFIT1, ISG15, MCP1) 
-Genes in the TLR signalling pathway ( TLR7/9/IRF5/7) 
-Possible DNA/RNA ligand source, cell death genes (LINE1, TNFR6, TRAIL, Ro60) 
-Intracytoplasmic RNA /DNA sensors ( MDA5, MAVS, DDx41, RIG-1) 
-Hormone receptor genes.   
Nanostring then designed two cDNA probes for each gene (probe A and probe B) which were 
manufactured by Integrated DNA Technologies (IDT, Coralville, IA). Probe A and B each contain 
gene-specific sequence; probe A also has a gene-specific sequence that binds the specific 
barcoded reporter tag, whereas probe B binds to a universal capture tag (Figure 2-8). 
Nucleotide sequences for probes A and B are listed in Table 2-5 and 2-6.  
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. Figure 2-8. Nanostring technology (from Nanostring). NanoString technology uses synthetic 
complementary DNA oligonucleotides to directly bind, capture, and tag RNA molecules of 
interest for fluorescent field counting without reverse transcription or amplification. 
We further extended this technology and plexed multiple samples. Nanostring designed a 
PlexSet, with a unique mix of barcodes for each row of a 96 well plate. This allows the pooling 
of multiple samples in a column, allowing a single run to assess multiple samples (Fig. 2-9). 
Samples were hybridised in individual wells at 67°C for 24 h, and then pooled. Pooled samples 
were then processed using the “High Sensitivity” protocol option on the nCounter Prep Station 
and counted on nCounter Digital Analyzer using maximal data resolution. Data were processed 
with nSolver software (NanoString Technologies, Seattle, WA) which includes quality analysis 
Table 2-4. Nanostring Gene panel   
Gene name Function 
MX1 IFN induced binding protein 1 IFN inducible 
BST2 Tetherin  IFN inducible 
IFIT1 IFN induced protein with tetra repeats 1 IFN inducible 
ISG15 IFN stimulated gene 15  IFN inducible 
MCP1 monocyte chemotactic protein 1 IFN inducible 
IRF5 IFN regulatory factor 5 IRF  
IRF7 IFN regulatory factor 7 IRF  
TLR7 Toll like receptor 7 TLR 
TLR9 Toll like receptor 9 TLR 
TNFR6 Fas cell death 
TRAIL TNF related apoptosis inducing ligand cell death 
L1 LINE-1 Endogenous 
retroelement 
DDX41 Dead box helicase 41 cytoplasmic viral 
sensing  
MDA5 Melanoma differentiated protein 5 cytoplasmic viral 
sensing  
RIG1 Retinoid inducible gene 1 cytoplasmic viral 
sensing  
MAVS Mitochondrial antiviral signalling protein  cytoplasmic viral 
sensing  
TROVE2 Ro60  Ro 60  
ESR1 estrogen receptor alpha hormone receptor 
ESR2 estrogen receptor beta hormone receptor 
AR androgen receptor  hormone receptor 
PGR progesterone receptor hormone receptor 
G6PD housekeeper 
 
POL2RA housekeeper 
 
SDHA housekeeper 
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of the runs. Counts are normalised via six internal positive control sequences and 
predetermined housekeeping genes (SDHA, G6PD and POL2RA). These normalized counts are 
used for downstream analysis. 
A calibration lane was spiked with synthetic manufactured RNA oligonucleotides in order to 
control for variation between PlexSets. 
Nanostring and specifically PlexSet technology has been used before in the study of ISG and 
shown to be reliable and reproducible(250) (251).  
 
 
 
 
 
Figure 2-7. Plexset technology (From Nanostring). PlexSet allows the pooling of multiple 
samples to be analysed in a single run. 
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  Gene number 
 Gene 
name Probe A sequence 
NM_002462 MX1 CCTACAGTTTCCTCTCCTTGCATGAGAGCAGTGATGTCCTGATTAAAGGCCCTCAAGACCTAAGCGACAGCGTGACCTTGTTTCA 
NM_004335 BST2 TACAGCGCTTATCCCCGTCTTCCATGGGCACTCTGCATCCTCTTCTTTTCTTGGTGTTGAGAAGATGCTC 
NM_001548 IFIT1 TGTAGACGAACCCAAGGAGGCTCAAGCTTTCCAGATCTAATGCCTTTCTCCACAATTCTGCGGGTTAGCAGGAAGGTTAGGGAAC 
NM_005101 ISG15 CTCAGAGGTTCGTCGCATTTGTCCACCACCAGCAGGACCTGTTGAGATTATTGAGCTTCATCATGACCAGAAG 
NM_002982 MCP1 CAGTTTGAGAATTGGATGTTTCTGGGTTAGTCTCAGCCTCTCGGTTCCTCCAAAGACGCCTATCTTCCAGTTTGATCGGGAAACT 
NM_002200 IRF5 GTTGGGAGAGTTCTTTCCCTGCTCATGGCTGAATTTCCCGAGAGCCAGCGAACCTAACTCCTCGCTACATTCCTATTGTTTTC 
NM_004029 IRF7 TCGTCATAGAGGCTGTTGGCGCTGGACAGGCAGAGCCAATTTGGTTTTACTCCCCTCGATTATGCGGAGT 
NM_016562 TLR7 GAAAAAGAGCAGGAAGCACTGAAGCAGCAACCACCTGTGTGGTGCCCACACTTTCGGGTTATATCTATCATTTACTTGACACCCT 
NM_017442 TLR9 TTGTTGTAGCTCAGGTTTAGCTCTTCCAGGGTGGGCACAGCAACAGCCACTTTTTTTCCAAATTTTGCAAGAGCC 
NM_000043 TNFR6 CATTCTTGATCTCATCTATTTTGGCTTCATTGACACCATTCTTTCGAACACACCGTGTGGACGGCAACTCAGAGATAACGCATAT 
NM_003810 TRAIL CTGTGAAGATCACGATCAGCACGCAGGTCTGTCCCCCTGGAGTTTATGTATTGCCAACGAGTTTGTCTTT 
U09116 LINE1 CTCTGCACATGAGATGGGTTTCCTGAATACAGCACACTGATGGGTCTTGACAGATAAGGTTGTTATTGTGGAGGATGTTACTACA 
NM_016222 DDX41 ATGACGGGCAACGTGAACACCAGTGTCTTGCCTGAACCCGTGAAAGCGATCTTCCTTCCTGTGTTCCAGCTACAAACTTAGAAAC 
NM_022168 MDA5 CTTCTCCAGATTTGGCTGAACTGTGGTTGAAAGAAGTTGCTCTTCCACTTCATAAAATTGGTTTTGCCTTTCAGCAATTCAACTT 
NM_014314 RIG1 GGTCATTCCTGTGTTCTGATTTGTTTTGCCACGTCCAGTCAATATGCCAGCTGGTCAAGACTTGCATGAGGACCCGCAAATTCCT 
NM_020746 MAVS ACCCCAATGTGTTTCTGGTGTTATTGTAGATAATCTCCCCAACAGTGGGTCTTTCGTTGGGACGCTTGAAGCGCAAGTAGAAAAC 
NM_001042370 TROVE2 CCTCCAGCAAAGGTCTCATTATCAGTGAATACAATGAAGACATCAGCAGGCCAGCAGACCTGCAATATCAAAGTTATAAGCGCGT 
NM_000125 ESR1 AGCATGTCGAAGATCTCCACCATGCCCTCTACACATTTTCCCTGGTTCCTGCCAATGCACTCGATCTTGTCATTTTTTTGCG 
NM_001214903 ESR2 TTCATGGTGGCTGTCTACATAGGAGGAAGGTATGTATATGGAGCCGTGCAAACTGGAGAGAGAAGTGAAGACGATTTAACCCA 
NM_000044 AR CAGAAGAAGACACACGGTGGACAAGATCTGCCCTGCTAGGCTCACAGCGATTGCTGCATTCCGCTCAACGCTTGAGGAAGTA 
NM_000926 PGR AAATCTTCTGAGGTAATGACTCGAAGCTGTATTGTGGGCTCTGGCTGGCTCTGAGGCTGTTAAAGCTGTAGCAACTCTTCCACGA 
NM_000937 G6PD ACTGGCCCAACAGGAAGACAGTAAGCGAAGGAGTCTTTGGCTTCTTGGAACTAGGACGCAAATCACTTGAAGAAGTGAAAGCGAG 
NM_000402 POL2RA CTCAGTGCCAAAGGGCTCCTTGAAGGTGAGGATAACGCAGGCGATGTTGTCCACGCGATGACGTTCGTCAAGAGTCGCATAATCT 
NM_004168 SDHA TAAACCCTGCCTCAGAAAGGCCAAATGCAGCTCGCAAGCCTGCCATTTGGAATGATGTGTACTGGGAATAAGACGACG 
Table 2-5. Probe A sequence design  
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 Gene number 
Gene 
name   Probe B sequence  
NM_002462 MX1 CCTACAGTTTCCTCTCCTTGCATGAGAGCAGTGATGTCCTGATTAAAGGCCCTCAAGACCTAAGCGACAGCGTGACCTTGTTTCA 
NM_004335 BST2 TACAGCGCTTATCCCCGTCTTCCATGGGCACTCTGCATCCTCTTCTTTTCTTGGTGTTGAGAAGATGCTC 
NM_001548 IFIT1 TGTAGACGAACCCAAGGAGGCTCAAGCTTTCCAGATCTAATGCCTTTCTCCACAATTCTGCGGGTTAGCAGGAAGGTTAGGGAAC 
NM_005101 ISG15 CTCAGAGGTTCGTCGCATTTGTCCACCACCAGCAGGACCTGTTGAGATTATTGAGCTTCATCATGACCAGAAG 
NM_002982 MCP1 CAGTTTGAGAATTGGATGTTTCTGGGTTAGTCTCAGCCTCTCGGTTCCTCCAAAGACGCCTATCTTCCAGTTTGATCGGGAAACT 
NM_002200 IRF5 GTTGGGAGAGTTCTTTCCCTGCTCATGGCTGAATTTCCCGAGAGCCAGCGAACCTAACTCCTCGCTACATTCCTATTGTTTTC 
NM_004029 IRF7 TCGTCATAGAGGCTGTTGGCGCTGGACAGGCAGAGCCAATTTGGTTTTACTCCCCTCGATTATGCGGAGT 
NM_016562 TLR7 GAAAAAGAGCAGGAAGCACTGAAGCAGCAACCACCTGTGTGGTGCCCACACTTTCGGGTTATATCTATCATTTACTTGACACCCT 
NM_017442 TLR9 TTGTTGTAGCTCAGGTTTAGCTCTTCCAGGGTGGGCACAGCAACAGCCACTTTTTTTCCAAATTTTGCAAGAGCC 
NM_000043 TNFR6 CATTCTTGATCTCATCTATTTTGGCTTCATTGACACCATTCTTTCGAACACACCGTGTGGACGGCAACTCAGAGATAACGCATAT 
NM_003810 TRAIL CTGTGAAGATCACGATCAGCACGCAGGTCTGTCCCCCTGGAGTTTATGTATTGCCAACGAGTTTGTCTTT 
U09116 LINE1 CTCTGCACATGAGATGGGTTTCCTGAATACAGCACACTGATGGGTCTTGACAGATAAGGTTGTTATTGTGGAGGATGTTACTACA 
NM_016222 DDX41 ATGACGGGCAACGTGAACACCAGTGTCTTGCCTGAACCCGTGAAAGCGATCTTCCTTCCTGTGTTCCAGCTACAAACTTAGAAAC 
NM_022168 MDA5 CTTCTCCAGATTTGGCTGAACTGTGGTTGAAAGAAGTTGCTCTTCCACTTCATAAAATTGGTTTTGCCTTTCAGCAATTCAACTT 
NM_014314 RIG1 GGTCATTCCTGTGTTCTGATTTGTTTTGCCACGTCCAGTCAATATGCCAGCTGGTCAAGACTTGCATGAGGACCCGCAAATTCCT 
NM_020746 MAVS ACCCCAATGTGTTTCTGGTGTTATTGTAGATAATCTCCCCAACAGTGGGTCTTTCGTTGGGACGCTTGAAGCGCAAGTAGAAAAC 
NM_001042370 TROVE2 CCTCCAGCAAAGGTCTCATTATCAGTGAATACAATGAAGACATCAGCAGGCCAGCAGACCTGCAATATCAAAGTTATAAGCGCGT 
NM_000125 ESR1 AGCATGTCGAAGATCTCCACCATGCCCTCTACACATTTTCCCTGGTTCCTGCCAATGCACTCGATCTTGTCATTTTTTTGCG 
NM_001214903 ESR2 TTCATGGTGGCTGTCTACATAGGAGGAAGGTATGTATATGGAGCCGTGCAAACTGGAGAGAGAAGTGAAGACGATTTAACCCA 
NM_000044 AR CAGAAGAAGACACACGGTGGACAAGATCTGCCCTGCTAGGCTCACAGCGATTGCTGCATTCCGCTCAACGCTTGAGGAAGTA 
NM_000926 PGR AAATCTTCTGAGGTAATGACTCGAAGCTGTATTGTGGGCTCTGGCTGGCTCTGAGGCTGTTAAAGCTGTAGCAACTCTTCCACGA 
NM_000937 G6PD ACTGGCCCAACAGGAAGACAGTAAGCGAAGGAGTCTTTGGCTTCTTGGAACTAGGACGCAAATCACTTGAAGAAGTGAAAGCGAG 
NM_000402 POL2RA CTCAGTGCCAAAGGGCTCCTTGAAGGTGAGGATAACGCAGGCGATGTTGTCCACGCGATGACGTTCGTCAAGAGTCGCATAATCT 
NM_004168 SDHA TAAACCCTGCCTCAGAAAGGCCAAATGCAGCTCGCAAGCCTGCCATTTGGAATGATGTGTACTGGGAATAAGACGACG 
Table 2-6. Probe B sequence design  
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2.6.3.1. Nanostring optimisation 
A titration experiment was performed with the aims of optimising  
1) Specific gene detection  
2) Sample input optimisation  
3) Ensuring that maximum saturation and data loss did not occur when plexing samples 
RNA from 2 representative samples was used from healthy teenagers:  
T161-ex vivo RNA  
T 139-Stimulated with IFNα for 20 hours 
3 different input amounts of RNA was used from each subject in duplicate (20ng/100ng/300ng). 
RNA was hybridised with oligonucleotide probe sets and unique reporter and capture tags. These 
were then scanned using a nCounter Flex. Inbuilt positive controls were used to normalise each lane. 
(Fig. 2-10). 
All genes had acceptable expression at 300ng input in stimulated and unstimulated samples except 
for TLR7,9, AR, ESR1, ESR2 and PGR (Fig. 2-11). Among these genes, TLR7 and 9 had low expression 
but good correlation between sample input and count number implying real expression above 
background (R2=0.998 for both). Relatively poor correlation among the steroid receptors implies that 
these may not be expressed in these cell populations at a level high enough for accurate 
quantification (R2<0.982 for all). Therefore increasing the sample input would improve detection of 
TLRs but not necessarily hormone receptors. 
In the final plexset experiment, 8 samples are pooled. It is important to ensure that the counts 
anticipated per sample do not exceed 150000 counts (8x150000 in total after pooling) which is the 
saturation limit for the nCounter Flex system. Maximum sample inputs (T161=2919.56ng; 
T139=1458.49ng) were calculated for each representative sample in this experiment (Fig. 2-12), 
which far exceed the current input of 300-500ng. In addition there is a trend towards plateau in 
detection at 300ng input amount in overall detection, and counts only reach 10% of the saturation 
limit.  
Therefore, all genes were expressed at acceptable levels, except for TLR7/9 and the steroid 
receptors. Increasing sample input to 500ng in certain samples where available should increase 
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detectability of TLR7/9 but not necessarily hormone receptors. In addition, detectability is 
reasonable at these concentrations and there is very little risk of saturation. 
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Figure 2-10: Normalisation of RNA data. Inbuilt positive controls were used to normalise counts across lanes. Normalisation factor is calculate by dividing 
average counts across all lanes by individual lane count. Sample counts are then corrected by lane normalisation factor 
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Figure 2-9: Lane normalised counts of RNA in 600 fields of view. All negative controls showed low mean background counts. Counts highlighted in pink show 
poor detection (using 100 counts as an arbitrary low count number). Mean count number was assessed per input amount per sample. A correlation was 
performed to assess the correlation between input amount and count number. Even though TLR7 and 9 had low expression, there was reasonable 
correlation (r2=0.998 for each), suggesting that the gene is detectable. For the hormone receptors (ESR2, AR, ESR1 and PGR) there is a relatively poor 
correlation, implying less reliable detection of these genes. Therefore, an input higher than 300ng where possible would improve the detection of the low 
expressed genes, but not necessarily the hormone receptors.  
  
Figure 2-12: Linear regression was used to estimate equations to predict the maximum sample 
volume that would exceed 150000 counts. T161-Max sample input =0.0195x150000+1.8969, 
therefore max sample input= 2919.56377ng. T139-Max sample input =0.0097x150000+2.1117 
therefore max sample input= 1458.49435ng 
Therefore, although counts were low, TLR7 and TLR9  expression was reliably measured. This 
was not the case for the steroid receptors (oestrogen, progesterone and androgen receptor) 
whose detection was low, along with a poor correlation with input amounts, implying an 
imprecise measurement. The steroid receptor data was therefore excluded from further 
analysis. Samples with at least 300ng RNA with adequate purity (260/280>1.8 and 
260/230>1.4) were prepared for analysis.  
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2.7. Liquid chromatography/Mass spectrometry.  
Serum sex steroid analysis was performed using clinically optimised liquid chromatography and 
tandem mass spectrometry (LC/MS) at the Biochemistry Department at the Wythenshawe 
Hospital, Manchester University NHS Foundation Trust. Briefly, LC/MS is a technique that 
combines the physical separation capabilities of high performance liquid chromatography with 
the mass analysis capabilities of mass spectrometry. The liquid chromatography effectively 
separates mixtures with multiple components, and the mass spectrometry structurally 
identifies the individual components with high specificity and sensitivity.  
Local clinical and commercially available measurement of sex steroid hormones is performed 
with radio or fluorescent based immunoassays. These do not detect serum steroid hormones 
at low concentrations, for example in young children, and are less specific than LC/MS (252) 
(253).  
The lower detection limits of serum oestradiol using this assay was 10pmol/L, and serum 
testosterone was 0.1nmol/L.  
2.8. Statistical Analysis.  
Data were analysed using linear regression, t-tests or Mann Whitney U tests as statistically 
appropriate. Where necessary, the Benjamini Hochberg or Bonferroni methods of correction 
for multiple hypothesis testing were applied. SPSS software was used for statistical analysis 
(v.24). Graphs were created with SPSS or Biovinci graph software (v.1.3). If outliers were 
present, it was tested if their effect was influential or not. If not found to be influential, it was 
elected to keep them in the analysis. If it was elected to exclude them, it is reported in the 
results chapters below.  
In linear regression, a model is built to predict the variability of the outcome variable (x), by 
using input variables (y1; y2….etc). This builds a model like this: 
X= B1. Intercept + B2.y1+ B2.Y2 … 
The B values represent the coefficients of the predictor variables (y1, y2 etc). They essentially 
represent an equation, where, for every change of 1 in y1, there is a subsequent change of B in 
x, keeping the other predictor variables constant. If a predictor variable is binary (e.g. sex) then 
it is coded 0 or 1. Therefore the B coefficient estimates the predicted change in the outcome 
variable between sexes, holding the other variables in the equation constant. The adjusted r2 
value indicates the amount of variation in the outcome variable (x) that can be predicted by all 
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of the predictor variables (y1, y2, etc) in the model.   Essentially it shows how ‘good’ the model 
is at accounting for the outcome variable of interest. In addition, the adjusted r2 estimates the 
most parsimonious model. This means that the model with the best predictive value, using the 
fewest predictor values is developed.  
In these data, there were many variables that were being analysed. The main predictors were 
sex, puberty, X chromosome number, serum testosterone and oestradiol concentrations. 
These variables required sophisticated modelling in order to assess the true effect of one, 
while correcting for the effects of the others in the equations. Linear regression models with 
more than 2 predictor variables cannot be represented by a 2 dimensional graph, however it 
was important to visually represent these data. Therefore when two variables are represented 
in this thesis, it is with the caveat that this is an illustration of the raw data only, and the p 
values represent the coefficient of the variable shown, holding the other variables in the 
equation constant. In addition, the raw data is represented on the graph, but the p vaue for 
the coefficient of the variable shown actually represents data that has been corrected for the 
other variables in the model. Therefore, it is actually impossible to accurately graphically 
represent  complex models such as these, but the data is shown here and the models have 
been represented as best as they can be on the graphs for the purpose of clarity and probity.  
When other statistical tests are used, ( t-tests, ANOVA , correlation) these are specifically 
mentioned.  
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Chapter 3: Summary of participants 
Participants were recruited as outlined above. In this chapter, key demographic and clinical 
characteristics of the participants that will be relevant to the subsequent main results chapters 
4-7 will be outlined. In addition, the model that will be used in the main results chapters to 
individually evaluate the contributions of serum sex hormone concentration and X 
chromosome number on the measured immune parameters in this thesis will be introduced.  
3.1. Healthy volunteers 
One hundred healthy volunteers were recruited. One 13 year old female was excluded due to 
a serum oestradiol concentration of 2106pmol/L which is outside of the range of normal for 
this age. The ages  and ethnicity of the rest of the volunteers are summarised in Tables 3-1 and 
3-2.  
   Age 
   n Mean  Median Min Max 
Female 
  
Pubertal phase 
  
Pre-pubertal 20 8.8 8.7 6.3 12.01 
Post-pubertal 31 16.39 17.04 12.34 18.32 
Male 
  
Pubertal phase 
  
Pre-pubertal 20 8.93 8.68 6.46 12.43 
Post-pubertal 28 16.7 17.08 13.45 18.8 
Table 3-1. Healthy volunteers (n=99) summarised by pubertal phase, sex and age.  
 
 Ethnicity n  % 
Not reported 4 4.00% 
Black African 5 5.10% 
Black Caribbean 1 1.00% 
East Asian 2 2.00% 
Mixed Background 7 7.10% 
Other 4 4.00% 
South Asian 22 22.20% 
White  54 54.50% 
Table 3-2. Healthy volunteer ethnicity 
All of the volunteers younger than 13 years old were recruited during routine dental or 
orthodontic surgery for caries, extraction or orthodontic procedures. All were reported to be 
well at the time of surgery. Three patients were on asthma and hayfever medication. None of 
the young people were on oral contraceptives and all were asked about current colds and flu 
like symptoms and reported being well at recruitment. Serum sex hormone levels were 
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assessed against self reported pubertal phases, and corresponded with expected normal levels 
in these groups (Fig. 3-1). 
Figure 3-1. Pubertal phase self reporting associated with expected serum sex hormone 
concentrations. (pre=pre-puberty; post=post-puberty) 
3.2. Transgender volunteers 
Sixteen transgender males (Trans M-XX) and 7 transgender females (Trans F-XY) were 
recruited. Three of the transgender males were excluded as they had serum testosterone 
concentrations greater than 60nmol/L which is higher than upper limit of normal for an adult 
male. This may be due to the young people being recruited on the day of their testosterone 
injection, or due to young people intentionally using larger doses than recommended. In any 
case, these young volunteers were excluded as their data influenced the results of the 
investigations including serum testosterone concentration as a variable.  
 All of the transgender volunteers had completed the phase of therapy with pubertal blockers 
(GnRH agonists alone). All volunteers had received at least 3 months of therapy with either 
testosterone or oestradiol. It should be noted that trans female patients remain on GnRH 
agonists during their therapy with alternate sex hormone. The age of transgender volunteers is 
represented in Table 3-3 below.  
 
 
 
 Table 3-3. Transgender volunteers by age 
 
 Age 
n Median Min Max 
Trans Male (XX)  13 18.83 17.63 19.46 
Trans Female (XY)  7 18.61 17.3 19.53 
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3.3. Turner’s syndrome volunteers 
Young women with TUS were recruited from the University College London Hospital (UCLH) 
endocrinology clinic. Young women were recruited regardless of genotype, if they displayed 
the clinical phenotype of TUS. As mentioned in the introduction, TUS manifests phenotypically 
when there is an insufficiency of the second X chromosome. The features and genotype of 
these young volunteers are represented below in Table 3-4.  
Age Therapy Genetic diagnosis 
15.3 Oestradiol Turner variant, deletion of chromosome Xq21.3 
19.6 Oestradiol and growth hormone Turner mosaicism (45,X/46,X,idic(X)(p11.2) 
11.4 Growth hormone Turner syndrome 45,X 
15.2 Oestradiol and growth hormone Turner syndrome 45,X 
18.2 Thyroxine and oestradiol Turner 45,X 
15.9 Growth hormone Turner mosaic (45,X/46,XX) 
15.8 Oestradiol and growth hormone 45,X Turner 
16.7 Vitamin D Turner mosaic 45,X/47,XXX 
13.8 Growth hormone and vitamin D Turner mosaic 47,XXX/45,X 
Table 3-4. Features of young volunteers with Turner’s syndrome. 
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3.4. Building a model to test the effect of X chromosome number vs serum 
sex hormone concentration.  
As discussed in the introduction, it is unknown whether sex differences exist in the TLR7 
mediated production of IFNα before sexual maturity. Serum sex hormone concentration and X 
chromosome number are inherently linked in healthy adults. Therefore, a population model 
was built, using the volunteers recruited above, in order to uncouple the traditional correlation 
between X chromosome number and serum sex hormone concentration. By preventing the 
inherent collinearity in these variables, a regression model was built that allowed for the 
measurement of the individual contributions of X chromosome number, serum oestradiol and 
serum testosterone concentrations to the variability in the outcome measures of interest. The 
premise behind this model is represented in Figure 3-2 which shows a full range of serum 
testosterone and oestradiol concentrations on the background of either one or two X 
chromosomes.  
 
Figure 3-2. Population model. a-b. Serum hormone levels in pre- and post-pubertal healthy, 
transgender and TUS volunteers allowed for a full spectrum of hormone concentration upon 
the background of one or two X chromosomes (n=135). Pre F -Pre pubertal female; post F-post 
pubertal female; Trans M-Transgender Male (XX); Pre M-Prepubertal male; post M -post 
pubertal male; trans M- transgender female (XY); TUS-Turners syndrome 
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3.5. Volunteers with jSLE 
Thirty-nine patients attending the UCLH adolescent rheumatology clinic with jSLE were 
recruited. These included 26 females and 13 males. Median age was 17.2 with a maximum of 
20.7 and a minimum of 14.7. In order to minimise the effect of disease activity and exogenous 
steroid therapy on the IFN based assays, participants with a low disease activity (SLEDAI<5), on 
relatively low doses of steroid therapy were specifically recruited (Table 3-5). Only one female 
and one male had received a dose of intravenous methylprednisolone within 3 months of 
sampling. The ethnicity of one male was unknown. The ethnicities of the group are 
summarised in Table 3-6. In keeping with known trends, in the healthy volunteers above, 54% 
were white, whereas only 25% of the young volunteers with jSLE were white.  
For the purposes of description, the therapies, organ involvement and antibody profiles of the 
volunteers with jSLE are represented in Tables 3-6,7,8. There was only 1 volunteer who was 
newly diagnosed and not on any therapy.  
Table 3-5. Characteristics of young volunteers with jSLE. SLEDAI-Systemic lupus erythematosus 
disease activity index, CRP-C reactive protein, WCC-White cell count, C3/4-complement 3 or 4, 
ESR-Erythrocyte sedimentation rate,  dSDNA –anti-double stranded DNA antibody titre 
 
 
 
 
 Female (n=26) Male (n=13) 
 Median Range Median Range 
Age 16.67 14.7-17.7 18.2 16.4-20.7 
Average SLEDAI 2 0-12 2 0-24 
CRP (mg/L) 0.60 0.06-10.7 1.00 0.6-18 
WCC (x109/L) 4.97 1.0-10.0 4.97 2.75-7.00 
C3 (g/L) 1.07 0.61-1.77 .93 0.33-1.30 
C4 (g/L) .19 0.06-0.43 .14 0-0.27 
ESR (mm/hr.) 11 2.0-29.0 10 0-47 
dsDNA (IU/ml) 26 0-687 62 0-2827 
Median daily dose 
prednisone (mg) 
3 0-15 0 0-15 
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Table 3-6. Ethnic groups of jSLE volunteers.  
 
 
 
 
 
 
 
 
Table 3-7. Therapy at time of recruitment. (Belimumab, Rituximab and cyclophosphamide 
recorded if ever used) 
  FEMALE (26) MALE (13) 
  n % n % 
Skin  23 88.46 12 92.31 
Haematological 12 46.15 6 46.15 
Neurological 2 7.69 0 0.00 
Renal  8 30.77 3 23.08 
Joint  14 53.85 6 46.15 
Cardiac 3 11.54 4 30.77 
Table 3-8. Organ involvement ever recorded.  
 Sex Total (%) 
Female Male 
Ethnic groups  White  7 3 10 (25.6) 
South Asian  5 2 7 (17.9) 
Mixed 3 0 3 (7.7) 
Black 4 4 8 (20.5) 
East Asian 3 3 6 (15.4) 
Other 4 0 4 (10.3) 
Total 26 12 38 
  FEMALE (26) MALE (13) 
  n % n % 
Prednisone 15 57.69 5 38.46 
Steroid pulse in last 3 months 1 3.85 1 7.69 
Mycophenylate 10 38.46 4 30.77 
Methotrexate 1 3.85 1 7.69 
Azathioprine 11 42.31 5 38.46 
Rituximab ever  7 26.92 2 15.38 
Belimumab ever 1 3.85 1 7.69 
Cyclophosphamide ever 3 11.54 1 7.69 
Hydroxychloroquine 26 100.00 12 92.31 
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  FEMALE (26)  MALE (13) 
  n % n % 
Anti-RNP 5 19.23 5 38.46 
Anti-Sm 5 19.23 4 30.77 
Anti-La 3 11.54 2 15.38 
Anti-Ro 12 46.15 4 30.77 
Anti-phospholipid antibodies 1 3.85 1 7.69 
Table 3-9. Antibodies present at time of recruitment. RNP-Ribonucleoprotein, Sm-Smith, 
antiphosphoplipid antibodies may include anti-lupus anticoagulant, anti-β2 glycoprotein or 
anti-cardiolipin.  
3.6 Sample numbers 
There were not always sufficient cell numbers obtained from each volunteer for all of the 
experiments. Although the sample numbers are represented in the graphs below in the results 
chapters,  a summary is provided below of the data numbers for each data type in Table 3-10, 
which will serve as a reference for the results chapters below if necessary.  
Table 3-10. Numbers of data available for each outcome measure. *GE= gene expression 
 
 
 
 
  
  Pubert
y 
Ex 
vivo 
flow 
R848 
%pDC 
IFNα+ 
CpG 
%pDC 
IFNα+ 
R848 
IFNα 
(pg./ml) 
CpG 
IFNα 
(pg./ml) 
Ex 
vivo 
GE 
Post 
stim 
GE 
Serum 
Oestradiol 
Serum 
Testosterone 
Healthy F Pre 19 20 18 18 15 14 9 16 19 
Post 37 31 28 27 24 10 7 14 20 
M Pre 19 20 19 19 17 12 10 13 18 
Post 31 28 25 22 18 14 7 17 22 
TUS F Post 9 9 9 8 6 9 6 7 7 
Trans  
 
M Post 13 13 11 11 6 12 7 11 12 
F Post 7 7 7 6 4 6 5 6 7 
jSLE F Post 19 26 22 16 13 20 9 18 19 
M Post 11 13 9 6 5 9 1 8 8 
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Chapter 4: Plasmacytoid dendritic cell phenotype, sex and 
puberty. 
It is unknown whether sex and pubertal phase associate with significant changes in the 
percentage, activation and tetherin protein expression of pDC and other cell types within 
PBMC in young people. It is also not known whether X chromosome number or sex hormone 
concentration associate with these changes.  
4.1. Sex and pubertal differences in the percentage of PBMC subtypes.  
Aim: To assess whether sex or pubertal differences exist in the percentage of pDC in PBMC in 
healthy young people.  
Sub-aim: To investigate whether sex or pubertal differences exist in the percentages of other 
cell subtypes in healthy young people.  
In healthy volunteers only, ex vivo flow cytometry was performed to assess  for the percentage 
of CD14+ monocytes, CD19+ B cells, CD4+ T cells, CD8 + T cells, BDCA2+ pDC, CD11c+ 
conventional dendritic cells (cDC) and CD56+ NK cells within PBMC .  
The association of sex and pubertal phase, with the variability of the percentage of each cell 
type in the PBMC compartment, was investigated with the following linear regression model:  
%Cell type =Intercept+B1*Sex+B2*Pubertal phase 
Al the data represented by the above model for each variable tested in this chapter is 
summarised in table 4-1.As a regression model with two independent variables was being 
performed for 7 cell types (dependant variable), the significance value of each coefficient for 
sex (B1) and puberty (B2) was corrected for multiple testing by Benjamini Hochberg method 
with a false discovery rate of 0.20 (Table 4-2).  
 
 
 
 
 
 
 Table 4-1. Summary of linear regression models investigating the effect of sex and puberty on PBMC pheontypes.   
 
 Model: y=intercept+B1*Sex+B2*Puberty 
Investigation Dependant variable Model predictive value Model significance Independent Variables 
Sex (F=1; M=0) Puberty(Pre=0; Post=1) 
 
 
% Cells in PBMC 
 Adjusted R
2 p B1 p 95% CI B2 p 95% CI 
%pDC 0.009 0.249 0.005 0.889 -0.064 0.073 -0.059 0.097 -0.129 0.011 
%CD4 0.058 0.024 4.074 0.01 1.003 7.145 1.279 0.418 -1.846 4.405 
%CD14 0.174 0.001 -1.127 0.152 -2.677 0.422 3.596 0.001 2.013 5.179 
%CD11c 0.06 0.043 -0.181 0.025 -0.339 -0.023 0.1 0.221 -0.061 0.262 
 
APC CD86 expression 
%pDC CD86 0.041 0.052 1.88 0.021 0.294 3.465 -0.671 0.413 -2.291 0.949 
%B cell CD86+ 0.088 0.005 0.673 0.181 -0.3191 0.665 -1.586 0.003 -2.6 -0.572 
%CD14 CD86+ 0.06 0.021 0.045 0.303 -0.041 0.132 -0.119 0.009 -0.208 -0.031 
Tetherin expression pDC tetherin 0.053 0.029 75.767 0.011 17.568 133.965 -27.304 0.364 -86.757 32.149 
B cell tetherin 0.039 0.059 54.156 0.023 6.229 84.082 13.238 0.51 -26.527 53.003 
 Dependant and Independent 
variable 
Original p 
value 
Benjamini-Hochberg 
significance 
Benjamini-
Hochberg P-
value 
%CD14 monocytes puberty 0.001 significant 0.014 
%CD4+ T cells sex 0.01 significant 0.07 
%cDC sex 0.025 significant 0.107333333 
% B cells puberty 0.053 significant 0.1855 
%pDC puberty 0.097 not significant 0.38675 
%CD14 monocytes sex  0.154 not significant 0.38675 
% B cells sex  0.21 not significant 0.38675 
%cDC puberty 0.221 not significant 0.38675 
%CD4+ T cells puberty 0.428 not significant 0.665777778 
%CD8+ T cells sex  0.567 not significant 0.775090909 
%NK cell sex 0.609 not significant 0.775090909 
%pDC sex  0.682 not significant 0.778 
%CD8+ T cells puberty 0.74 not significant 0.778 
%NK cell puberty 0.778 not significant 0.778 
Table 4-2. Multiple regression for the association of cell type percentage in PBMC with sex and 
puberty corrected for a false discovery rate of 0.20 by Benjamini Hochberg method. 
Highlighted values are significant after correction. (Benjamini Hochberg p values<0.2 
considered significant)  
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4.1.1. The percentage of pDC in PBMC did not differ significantly between sexes or 
pubertal phases in healthy volunteers. 
There were no significant differences in the percentage of pDC in PBMC between sexes or 
pubertal phases, after correcting for each other (Fig. 4-1a).  
4.1.2. Sex and pubertal differences were seen in the percentage of CD4+ T cell, CD14+ 
monocyte and CD11c+ cDC subpopulations in healthy volunteers. 
The percentage of CD4+ T cells was on average 4% higher in females (B1=4.03; p=0.010; 
CI=0.990, 7.073) (Fig. 4-1b), with no significant association with pubertal phase. There were on 
average 0.18% more conventional CD14-/CD11c+ cDC in males (B2=0.182; p=0.023; CI=0.025, 
0.339) with no association with pubertal phase (Fig 4-1c). Post pubertal healthy volunteers 
had, on average 3.6% more CD14+ monocytes than pre-pubertal volunteers (B2=3.61; p<0.001; 
CI=2.040, 5.179), with no significant association with sex (Fig. 4-1d). No significant sex or 
pubertal differences were seen in the percentage of CD19+ B cells, CD8+ T cells or CD56+ NK 
cells.  
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Figure 4-1. PBMC cell subtype percentage in healthy volunteers. Healthy volunteer PBMC were 
assessed by flow cytometry (n=106:pre F=19; post F=37; pre M =19; Post M=31). p values 
represent the significance of the coefficient the variable shown as estimated by linear 
regression after correcting for the other variable in the model (sex or puberty). a. %BDCA2+ 
pDC did not differ with pubertal phase (p=0.097). b. % CD4+ T cells was higher in females 
(p=0.010). c. %CD14-/CD11c+ cDC was higher in males (p=0.025) d. % CD14+ monocytes was 
higher in post-pubertal volunteers (p=0.001). 
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4.2. Sex and pubertal differences in pDC activation.   
Aim: To investigate whether the expression of the activation marker CD86 on pDC differs 
significantly between sexes or pubertal phases in healthy young people.  
Sub-aim: To investigate whether expression of CD86 on other antigen presenting cells (APC) 
differs significantly between sexes or pubertal phases in healthy young people.  
CD86 is a T cell costimulatory molecule and marker of activation, expressed on APC(254). The 
surface expression of CD 86 was assessed by flow cytometry in healthy volunteers only . 
4.2.1. pDC were significantly more activated in female volunteers than male, regardless 
of pubertal phase.  
pDC were the only cell type which showed a significant sex difference in the surface expression 
of CD86. Females, on average, had 1.9% more pDC expressing CD86 than males (p=1.89; 
p=0.021; CI=0.307, 3.447) (Fig. 4-2a), with no significant association with pubertal phase. 
4.2.2. Monocytes and B cells were significantly less activated in post pubertal 
volunteers, with no sex differences.  
CD19+ B cells (B=-1.531; p=0.004; CI=-2.553, -0.510) (Fig. 4-2b) and CD14+ monocytes (B=-
0.120; p=0.008; CI=-0.208, -0.033) (Fig. 4-2c) both expressed significantly less surface CD86 in 
post pubertal volunteers. There were no significant associations between CD19+ B cell or 
CD14+ monocyte CD86 expression and sex. 
No significant sex or pubertal differences existed in the surface CD86 expression of CD11c+ 
cDC.  
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Figure 4-2. CD86 expression in pDC, B cells and monocytes in healthy volunteers. CD86 
expression was measured on ex-vivo APC by flow cytometry and association with sex or 
pubertal phase was assessed by linear regression (n=106:pre F=19; post F=37; pre M =19; Post 
M=31). a. In females, a higher percentage of pDC expressed CD86 than in males (p=0.021), 
with no significant association with pubertal phase. b. - c.  In post pubertal volunteers, there 
was a significantly lower percentage of B cells (p=0.003) and CD14+ monocytes (p=0.009) 
expressing surface CD86, with no significant association with sex. P values shown represent 
significance of the coefficient for the independent variable shown when analysed by 
linear regression. 
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 4.3. X chromosome and sex hormone associations with pDC activation.  
Aim: To investigate whether pDC CD86 expression associates with X chromosome number, 
serum oestradiol and testosterone concentration in healthy volunteers, transgender and TUS 
volunteers.  
Sub-aim: To investigate whether CD86 expression on other APC associates with X chromosome 
number, serum oestradiol and testosterone concentration in healthy volunteers, transgender 
and TUS volunteers. 
The following regression model was fitted:  
%Cell type CD86+=Intercept+B1*X chromosome number+B2*Testosterone+B3*Oestradiol 
The data from this regression model investigating CD86 expression on APC and B cell and pDC 
tetherin expression (see later) is summarised in table 4-3 below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 Model: y=intercept+B1*X Chromosome number+B2*Testosterone+B3*Oestradiol 
 Model predictive 
value 
Model 
significance 
Independent Variables 
 Dependant 
variable 
Adjusted R2 p 
X chromosome number (1=0;2=1) Testosterone Oestradiol 
B1 p 95% CI B2 p 95% CI B3 p 95% CI 
APC CD86 
expression 
%pDC CD86+ 0.083 0.017 2.406 0.007 0.66 4.152 -0.59 0.05 -0.17 0.05 0.01 0.664 -0.01 0.01 
%B cell CD86+ 0.06 0.043 0.94 0.097 -0.18 2.056 -0.04 0.23 -0.11 0.03 -0.01 0.036 -0.01 0 
Tetherin 
expression 
pDC tetherin 0.044 0.082 68.082 0.073 -6.62 142.783 -3.54 0.13 -8.11 1.04 -0.08 0.465 -0.30 0.14 
B cell tetherin 0.031 0.132 45.874 0.04 2.25 89.498 -1.09 0.42 -3.76 1.58 -0.22 0.731 -0.15 0.11 
Table 4-3. Summary of linear regression models assessing for the effect of X chromosome number, serum testosterone and oestradiol on cell surface  CD86 and 
tetherin expression .
 4.3.1. pDC surface CD86 expression was higher if two X chromosomes were present. 
After correcting for serum sex hormone, it was found that the presence of two X chromosomes 
associated with, on average, 2.4% more pDC expressing surface CD86 (B1=2.406; p=0.007; 
CI=0.660, 4.152) There was no significant association with serum testosterone or oestradiol 
concentration (Fig. 4-3). 
There was a non-significant trend towards a higher percentage of CD19+ B cells expressing 
CD86 in the presence of two X chromosomes (B1=0.940, p=0.097; CI=-0.175, 2.056). CD14+ 
monocyte CD86 expression did not differ significantly with X chromosome number. 
Figure 4-3. pDC CD86 expression was higher if two X chromosome were present. a. The 
percentage of pDC expressing CD86 in healthy, transgender and TUS volunteers was measured. 
a. A linear regression model revealed that the presence of two X chromosomes associated with 
a higher pDC surface expression of CD86 (p=0.007) with no significant association with serum 
testosterone or oestradiol concentration. (n=135; pre F=19; post F=37; Trans M=13; pre M=19; 
post M=31; Trans F=7; TUS=9). P values shown represent significance of the coefficient 
for the independent variable shown when analysed by linear regression. 
4.4. Sex and pubertal differences in the surface expression of an ISG 
product (tetherin protein) in pDC and B cells. 
Aim: To investigate whether pDC tetherin expression is significantly different between sexes or 
pubertal phases in healthy volunteers. 
Sub-aim: To investigate whether B cell tetherin expression is significantly different between 
sexes or pubertal phases in healthy volunteers. 
135 
 
Tetherin is a type 1 IFN inducible antiviral membrane protein constitutively expressed by pDC 
and B cells (255, 256). There is evidence that tetherin may be used as a proxy to ISG 
measurement(257). Within this context, we have used tetherin as an example of an ISG 
product/surface protein to investigate whether differences exist across sex and puberty.  
Tetherin expression was measured by flow cytometry. Linear regression models were fitted to 
evaluate for associations of sex and pubertal phase with B cell or pDC tetherin median 
fluorescent intensity (MFI) as in 4.1.  
 
4.4.1. pDC and B cells from females expressed more tetherin than males, regardless of 
puberty. 
 In healthy females, ex vivo pDC had a significantly higher tetherin MFI than in males 
(B=79.108; p=0.011; CI=21.021, 137.187), with no significant association with pubertal phase 
(Fig. 4-4a).  
In healthy females, ex vivo B cells had a significantly higher tetherin MFI than males (B=45.265; 
p=0.023; CI=6.723, 83.808), with no significant association with pubertal phase (Fig.4-4b).  
 
Figure 4-4. pDC and B cell tetherin expression in healthy volunteers. In healthy females, a. pDC 
(p=0.011) and b. B cells (p=0.023) had a significantly higher tetherin MFI, when compared to 
males, after controlling for pubertal phase. (n=106:pre F=19; post F=37; pre M =19; Post 
M=31). P values shown represent significance of the coefficient for the independent 
variable shown when analysed by linear regression. 
136 
 
4.5. X chromosome and sex hormone associations with pDC and B cell 
expression of tetherin. 
Aim: To investigate whether pDC tetherin expression associates with X chromosome number, 
serum oestradiol and testosterone concentration in healthy, transgender and TUS volunteers.  
Sub-Aim: To investigate whether B cell tetherin expression associates with X chromosome 
number, serum oestradiol and testosterone concentration in healthy, transgender and TUS 
volunteers.  
Linear regression was used as in 4.3. to analyse for associations with X chromosome number, 
serum oestradiol and testosterone concentration. See Table 4-3. 
4.5.1.  There was a non-significant trend towards an increased expression of tetherin 
in pDC if two X chromosomes were present. 
The presence of two X chromosomes associated with a higher pDC tetherin MFI (B=68.082; 
p=0.073; CI=-6.618, 142.783) although this did not reach statistical significance, with no 
significant association with serum testosterone or oestradiol (Fig. 4-5a).  
4.5.2. B cells expressed significantly more tetherin if two X chromosomes were present 
B cell tetherin MFI was significantly higher in the presence of two X chromosomes (B=45.874; 
p=0.040; CI=2.249, 89.498) with no significant association with serum oestradiol or 
testosterone (Fig. 4-5b).  
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Figure 4-5. Tetherin expression in pDC and B cells associates with X chromosome number.a. 
After correcting for serum sex hormone concentration, the presence of two X chromosomes 
tended towards a higher pDC tetherin expression (p=0.073). b. B cell tetherin expression was 
higher in the presence of two X chromosomes (p=0.040). (n=135; pre F=19; post F=37; Trans 
M=13; pre M=19; post M=31; Trans F=7; TUS=9). P values shown represent significance of 
the coefficient for the independent variable shown when analysed by linear regression 
. 
4.6. Differences in pDC percentage, activation and ISG product 
expression between healthy volunteers and those with jSLE.  
Aim: To investigate whether significant differences exist in the relative percentage, CD86 and 
tetherin expression of pDC between healthy volunteers and those with jSLE.  
Sub-Aim: To investigate whether significant differences exist in the relative percentage, CD86 
and tetherin expression of other immune cell types between healthy volunteers and those 
with jSLE.  
pDC and other PBMC type parameters  from patients with jSLE were compared to age and sex 
matched healthy volunteers by t-test or Mann-Whitney U test according to the distribution of 
the parameter.  Five of the volunteers with jSLE had a B cell percentage of less than 2% as they 
had received rituximab therapy. The analysis was performed with and without these 
individuals for sensitivity analysis. Even though the inclusion of these individuals did not alter 
which cell types showed a significant difference between jSLE and healthy volunteers, they 
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were found to influence the relative percentage of other cell types, and therefore the 
estimated differences between the two groups. Therefore, it was decided to exclude them 
from the analysis of cell subtype percentage represented below (Fig. 4-8).  
4.6.1. The percentage of pDC in PBMC was significantly reduced in jSLE 
When compared by t-test, the percentage of BDCA2+ pDC in PBMC from patients with jSLE was 
significantly reduced when compared to healthy volunteers (p=0.01) (Fig. 4-6a) (Table 4-4).  
4.6.2. The percentages of CD4+ T cells, CD8+ T cells, and CD11c+ cDC were significantly 
different in jSLE as compared to healthy volunteers. 
The percentages of the other cell types within the PBMC compartment were analysed by t-test 
to assess for differences between healthy volunteers and those with jSLE. As there were 
multiple t-tests performed simultaneously, the results were checked for multiple testing using 
the Benjamini Hochberg method at a false discovery rate of 0.2 (Table 4-4).  
 The data are summarised in Table 4-4. Of note, there were on average 5.5% more CD4+ T cells 
in jSLE as compared to healthy volunteers (p=0.01) (Fig 4-6b). In the healthy volunteers 
previously analysed in 4.1.2., females had a higher percentage of CD4+ T cells than males. In 
order to confirm that the difference in the percentage of CD4 cells that existed between 
healthy volunteers and those with jSLE was not due to this previously described sex difference, 
a linear regression model was built including sex as a variable with disease status ( Fig. 4-6c). In 
this model, participants with jSLE continued to  have an increased percentage of CD4+ T cells 
regardless of sex (B=5.110; p=0.013; CI=1.115, 9.105) and females continued to have a higher 
percentage of CD4+ T cells regardless of disease status (B=4.88; p=0.009; CI=1.230, -8.53) (Fig. 
4-6c). 
 In addition, the percentage of CD8+ T cells was significantly higher in jSLE (p=0.022) (Fig. 4-6d), 
while the percentage of CD11c+ cDC was significantly lower in jSLE (p=0.049) (Fig 4-6e) when 
compared to healthy volunteers. There were no significant differences in the percentage of 
CD19+ B cells (Fig 4-6f), NK cells or CD14+ monocytes within PBMC between jSLE and healthy 
volunteers. No other cell type showed a significant sex difference when analysed by linear 
regression, including patients with jSLE. 
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Table 4-4. Differences in cell subtype percentage between healthy volunteers and those with 
jSLE. Cell type percentages were compared and corrected for multiple testing using Benjamini 
Hochberg at an FDR of 0.2. Highlighted values are significant. The mean difference and 
confidence intervals of the mean difference are shown.  
 
 
 
 
 
Cell subtype  p-
value 
(t-
test) 
Significance 
after 
multiple 
testing 
Benjamini 
Hochberg 
significance 
value 
Mean 
Differenc
e 
95% Confidence 
Interval of the 
Difference 
%pDC 0.010 significant 0.035 0.101521 0.02514
4 
0.17789
8 
%CD4+ T cell 0.010 significant 0.035 5.4663 1.326 9.606 
CD8+ T cell 0.022 significant 0.05133333
3 
4.1937 0.623 7.763 
%CD11c+ 0.049 significant 0.08575 -0.19681 -0.00088 -0.39275 
%NK cell 0.081 significant 0.1134 0.101297 -0.01271 0.21530
3 
%CD14+ 
monocyte 
0.854 not 
significant 
0.93 0.17345 -1.69028 2.03718 
% B cells 0.930 not 
significant 
0.93 0.08106 -1.73989 1.902 
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Figure 4-6. Differences in cell type percentage between healthy volunteers and those with jSLE 
a. When analysed by t-test, and corrected for multiple testing, volunteers with jSLE (n=30-F-19, 
M-11) had a significantly lower percent of pDC in PBMC compared to post pubertal healthy 
volunteers (n=68, F-37, M-31). b. There was a significantly higher percent of CD4+ T cells in 
jSLE (p=0.01) when analysed by t-test. c. Upon correcting for disease (healthy vs jSLE) by linear 
regression, females still had a higher percentage of CD4+ T cells overall (p=0.009). d.CD8+ T 
cells (p=0.022), and e. CD11c+ cDC (p=0.049) showed significant differences between jSLE and 
healthy volunteers. There were no significant differences seen in the percentage of f. CD19+ B 
cells (p=0.930), CD14+ monocytes or CD56+ NK cells (not shown).                                
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4.6.3. pDC were not significantly more activated in volunteers with jSLE, as compared to 
healthy volunteers.  
There was a trend towards more pDC expressing CD86 in volunteers with jSLE that did not 
reach statistical significance (p=0.078) (Fig.4-7a), when correcting for sex, the trend remained 
(p=0.098). 
4.6.4. CD14+ monocytes were significantly more activated in volunteers with jSLE. 
CD14+ monocytes in volunteers with jSLE expressed significantly more CD86 when analysed by 
t-test (p=0.009). There was no significant difference in B cell CD86 expression between healthy 
volunteers and those with jSLE (p=0.476) (Fig. 4-7b, c).  
 
 
Figure 4-7. Differences in pDC, B cell and CD14+ monocyte activation between healthy 
volunteers and those with jSLE.  a-b. When analysed by t-test, there was no difference in pDC or 
B cell CD86 expression between jSLE and healthy volunteers. c. The percentage of CD14+ 
monocytes expressing CD86 was significantly higher in jSLE than healthy volunteers (p=0.009) 
(n=98- SLE-30, healthy-68). 
4.6.5. Tetherin expression on pDC and B cells was significantly higher in volunteers 
with jSLE. 
 Both pDC (p=0.001) and B cells (p=0.001) from patients with jSLE displayed an increased 
expression of surface tetherin compared to healthy young people when analysed by t-test (Fig. 
4-8a; c). In healthy volunteers, pDC from females tended to express more tetherin (p=0.05), 
whereas this sex difference was lost in young people with jSLE (p=0.623) (t-tests) (Fig. 4-8b). B 
cell tetherin trended towards higher expression in healthy females (p=0.09) whereas this trend 
was not seen in patients with lupus (p=0.799) (Fig 4-8d). 
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Figure 4-8. Differences in expression of the ISG surface protein, tetherin between healthy 
volunteers and those with jSLE. a. Tetherin expression was significantly higher in pDC (p=0.001) 
from volunteers with jSLE as compared to healthy volunteers when analysed by t-test. b. The 
sex difference in pDC tetherin expression was lost in jSLE. c. Tetherin expression was 
significantly higher in B cells (p=0.001) from volunteers with jSLE as compared to healthy 
volunteers. D. There was a trend towards a higher expression of tetherin in female B cells 
(p=0.09) which was not seen in SLE (p=0.799)(n=98-healthy=68, M-31, F=37, jSLE=30, M=11, 
F=19) 
4.7.  Discussion  
In this chapter, it has been shown that, although the percent of pDC does not differ between 
sexes, pDC in females are significantly more activated and express significantly more of the ISG 
encoded surface protein, tetherin, than males. In addition, it has been shown that pDC 
activation and tetherin expression are related to X chromosome number, and not serum 
concentrations of oestradiol or testosterone.  
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It has previously been shown that the percentage of pDC in lymphocytes did not differ 
between healthy adult men and women (16, 120). In the data presented here, full blood 
counts were not available in healthy volunteers in order to confirm whether the absolute 
number of pDC per millilitre of blood was different between sexes, but the data agreed with 
the studies above in adults, in that the percentage of pDC in PBMC was not different between 
sexes. Previous data has shown that pDC percentage in PBMC may decline in the elderly(258). 
In these data, there was no significant difference in pDC percentage between pre and post 
pubertal volunteers. It is therefore proposed that if differences between sexes or pubertal 
phases exist in type 1 IFN production, they are most likely not due to differences in the relative 
quantity of pDC.  
As has been described before(189), there was a decrease in the percentage of BDCA2+ pDC in 
volunteers with jSLE. It has been previously postulated that the decrease in pDC in peripheral 
blood in jSLE may be due to sequestration of pDC into peripheral sites of inflammation (35), 
but this has not been proven. In addition, BDCA2 is expressed highly on immature pDC and is 
downregulated upon TLR ligation of pDC(34). It is therefore possible that there is a decrease in 
the relative percentage of pDC expressing BDCA2, not due to a decrease in numbers of pDC, 
but rather due to a downregulation of BDCA2 in response to increased TLR ligation, or 
peripheral recruitment in jSLE.  
Interestingly, females had a significantly higher percentage of CD4+ T cells than males. This has 
been described before in healthy adults and children (54-56) , as well as new-borns, children 
and adults in the context of HIV infection (57-59).  In these data, this sex difference persisted 
even in patients with jSLE. The observation that females have a higher percentage of CD4+ T 
cells in healthy children, and those with jSLE or HIV infection suggests that this is an inherent 
and persistent difference. HIV and jSLE both have a type 1 IFN phenotype. It may be expected, 
if the sex difference in CD4+ T cell percentage was related to type 1 IFN, that it may be 
abolished in these diseases with an upregulated type 1 IFN. The fact that the sex difference 
persists despite a high background IFN in both sexes, implies that the difference in CD4+ T cell 
percentage is not related to the type 1 IFN pathway.  
To the best of our knowledge, it has not been previously shown that sex differences exist in 
the activation of pDC ex vivo between sexes. In these data, in females, more pDC expressed 
CD86 than in males, regardless of pubertal phase. In addition, when the model was extended 
to include transgender and TUS volunteers, an association was seen with X chromosome 
number and not serum sex hormone concentration. These data imply that pDC are inherently, 
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chromosomally, more activated in females, as compared to males. pDC were the only APC type 
to show a significant sex difference in activation as measured by CD86.  
A trend towards higher activation of pDC was seen in volunteers with jSLE when compared to 
healthy volunteers. The same caveat must be applied as above, in that pDC in jSLE may 
downregulate BDCA2 upon activation, or recruit peripherally, so the pDC that are being 
assessed here may not fully represent the entire quota of mature pDC in jSLE. In addition, the 
patients recruited with jSLE were specifically chosen with low disease activity. Therefore, the 
fact that a borderline insignificant trend towards higher activation of pDC is seen in jSLE should 
be noted.  
Ex vivo tetherin expression was measured on B cells and pDC as a proxy marker for background 
type 1 IFN presence. Interestingly, pDC and B cells in healthy females expressed significantly 
more tetherin than males, regardless of pubertal phase. This too associated with X 
chromosome number and not serum sex hormone. This sex difference in tetherin expression 
has not previously been described. It allows for an intriguing hypothesis that females may have 
a higher expression of IFN inducible or ‘anti-viral’ proteins which may help to explain described 
differences in responses to vaccination or viral infection (17, 43, 45). It can be reasoned that 
the price that females pay for a higher anti-viral or type 1 IFN background, may be an 
increased susceptibility to autoimmune disease like jSLE.  
Indeed, in jSLE, as would be expected of a disease with an abundance of type 1 IFN, pDC and B 
cell tetherin expression was significantly increased when compared to healthy volunteers. 
Intriguingly, the sex difference in pDC tetherin expression that was present in healthy 
volunteers was lost in volunteers with jSLE. This implies that although females have a higher 
propensity towards jSLE, with a higher background IFN phenotype, in males who develop the 
disease, this sex difference may be overwhelmed by the general increase in type 1 IFN.  
4.8. Conclusion 
In healthy females, pDC were more activated and expressed more of the anti-viral or type I IFN 
inducible surface protein, tetherin than males. This associated with X chromosome number 
and not sex hormone. In jSLE, there was an increase in the expression of tetherin on pDC and B 
cells, with a loss of the sex difference that was seen in healthy volunteers. In addition, pDC and 
B cells trended towards higher activation in jSLE.  
After finding these inherent differences in pDC in the resting state, it was next investigated 
whether sex or pubertal differences existed in the pDC production of IFN and other cytokines 
in young people.  
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Chapter 5: Plasmacytoid dendritic cell function, sex and puberty 
After it was shown in chapter 4 that ex vivo female pDC were more activated and trended 
towards expressing more tetherin when compared to males, it was investigated whether sex 
and pubertal differences existed in the ability of TLR7 or TLR9 activated pDC to produce IFNα.  
5.1. Sex and pubertal differences in TLR mediated production of IFNα in 
healthy volunteers.  
Aim: To investigate whether sex and pubertal differences exist in the percentage of pDC 
producing IFNα after R848 or CpG stimulation in healthy young volunteers.  
Sub Aim: To investigate whether sex and pubertal differences exist in the amount of IFNα, IFNβ 
and TNFα produced by PBMC after R848 or CpG stimulation in healthy young volunteers.  
5.1.2. Culture and flow cytometry  
The percentage of IFNα producing pDC was measured in PBMC after stimulation with R848, 
CpG or no stimulation. An early ELISA experiment revealed that significantly more IFNα was 
produced by PBMC if they were stimulated with CpG as compared to R848 (Fig. 5-1). As pDC 
IFNα production after R848 stimulation was the primary outcome of interest, a dose titration 
was performed using 4 healthy volunteers, and it was confirmed that 1ug/ml was an adequate 
stimulation dose for R848 (Fig. 5-2). 
 
Figure 5-1. Preliminary ELISA data. Cells were cultured with CpG ODN 2216 1µM or R848 
1µg/ml for 20 hours without BFA. Supernatant was analyzed by ELISA and it was shown that 
there was significantly more IFNα released after CpG stimulation.  
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Figure 5-2. R848 dose titration. PBMC from 4 healthy adult donors (A, B, C, D) were stimulated 
for 20 hours with R848 at doses of 1µg/ml, 5µg/ml and 10µg/ml and the percentage of pDCs 
expressing IFNα was assessed by flow cytometry. It was found that 1µg/ml was an adequate 
dose for the assessment of IFNα production. 
5.1.3. In healthy young people, there were no differences in background pDC IFNα 
production between sexes or pubertal phases. 
It was first investigated whether any background sex or pubertal differences existed in the 
percentage of unstimulated pDC producing IFNα in healthy participants. The following linear 
regression model was fitted:  
%pDC IFNα+=Intercept+B1*Sex+B2*Pubertal Phase 
It was first established that there were no associations between the percentage of pDC 
producing IFNα and sex (B1= -0.060; p=0.849; CI=-0.682, 0.562) or pubertal phase (B2= -0.217; 
p=0.501; CI=-0.857, 0.423) if cells were not stimulated (Fig. 5-3).  
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In addition, it was confirmed that no sex or pubertal differences existed in the amount of IFNα, 
IFNβ or TNFα produced in supernatant by PBMC without stimulation (not shown).  
Fig. 5-3. Baseline pDC IFNα production did not differ between sexes or pubertal phases in 
healthy volunteers.  No significant sex or pubertal differences existed in the percentage of pDC 
producing IFNα if cells were not stimulated.  
5.1.4. After TLR7 stimulation, a higher percentage of pDC produced IFNα in healthy 
female and post pubertal volunteers.  
PBMC from healthy, pre and post pubertal volunteers were stimulated with R848, and the 
percentage of pDC producing IFNα was measured by flow cytometry. The same linear 
regression analysis was performed as above in 5.1.3. The results are presented in Table 5-1 
below.  
The overall model was significant (p=0.004), and altogether, sex and pubertal phase predicted 
9.2% of the variability in the percentage of pDC producing IFNα after R848 stimulation. 
Females had, on average, 8.3% more pDC producing IFNα after R848 stimulation than males 
after controlling for pubertal phase (p=0.008) (Fig. 5-4a). In addition, post pubertal volunteers 
had on average 6.5% more pDC producing IFNα after R848 stimulation after controlling for sex 
(p=0.039) (Fig. 5-4b).  
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Figure 5-4. The percentage of pDC producing IFNα after R848 stimulation is higher in females 
and after puberty in healthy participants. After stimulation with R848, the percentage of pDC 
producing IFNα was measured and analysed by linear regression (n=99, Pre F=20, Pre M=20, 
Post F=31, Post M=28). a. There was a significantly higher percentage of pDC producing IFNα in 
female (p=0.008) and b. post pubertal volunteers (p=0.039). P values shown represent 
significance of the coefficient for the independent variable shown when analysed by 
linear regression. 
Dependant variable: Percentage pDC producing IFNα after R848 
stimulation.  
Adjusted r
2
=0.092; Model significance p=0.004 
Variables   B coefficient  
(B) 
p 95.0% Confidence 
Interval for B 
(Constant) 27.308 0.000 21.607 33.009 
Sex (F=0; M=1) -8.334 0.008 -14.454 -2.214 
Pubertal phase 
(pre=0; post=1) 
6.569 0.039 0.336 12.802 
Table 5-1. Regression model predicting the percentage of pDC producing IFNα after R848 
stimulation. 
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5.1.5. After TLR7 stimulation, there was a trend towards a higher production of IFNα 
by PBMC in females and post pubertal healthy volunteers. 
To confirm the findings in 5.1.4., PBMC from healthy volunteers were stimulated with R848 
and total IFNα, IFNβ and TNFα in supernatant was measured by Luminex assay. There were 
slightly fewer samples with data (n=86) in this analysis as not all volunteers had sufficient cell 
numbers for all analyses. The same linear regression model was applied as in 5.1.3. As the 
concentration of cytokine data was skewed, the data was transformed using the natural log, in 
order to analyse by linear regression and maintain residuals with a normal distribution. The 
coefficients reported below are all reported as the exponential of the coefficient (Exp B) and 
are, accordingly, multiplicative in nature.  
Overall, sex and puberty predicted 7.4% of the variability in the amount of IFNα produced by 
PBMC. The overall model was significant (r2=0.074; p=0.043). After R848 stimulation, female 
PBMC produced 49% more IFNα than males (ExpB=0.49; p=0.074; CI=0.22-2.01) (Fig. 5-5a) and 
PBMC in post pubertal volunteers produced almost double the amount of IFNα than the pre-
pubertal group (ExpB=1.94; p=0.081; CI=0.89-4.25) (Fig. 5-5b). These coefficients did not reach 
significance as observed in the pDC specific experiment in 5.1.4.  
No significant differences were seen in the production of IFNβ or TNFα in supernatant after 
R848 stimulation.  
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Figure 5-5. There was a non-significant trend towards a higher production of IFNα by PBMC in 
females and post pubertal volunteers after R848 stimulation. After stimulation with R848, the 
amount of IFNα produced by PBMC was measured and analysed by linear regression in healthy 
volunteers (n=86, Pre F=18, Pre M= 19, Post F=27, Post M=22). There was a non-significant 
trend towards higher production in a. female (p=0.074) and b. post pubertal volunteers 
(p=0.081). P values shown represent significance of the coefficient for the independent 
variable shown when analysed by linear regression. 
5.1.6. Sex or pubertal phase did not associate with the production of IFNα after TLR9 
stimulation in healthy young volunteers. 
There were no sex (B=-1.601; p=0.535; CI=-6.711-3.509) or pubertal (B=3.681; p=0.162; CI=-
1.510-8.872) differences in the percentage of pDC producing IFNα in healthy volunteers after 
cells were stimulated with CpG (Fig. 5-6 a,b). Similarly, there were no associations between sex 
and puberty and the production of IFNα (Fig. 5-6c), IFNβ or TNFα by PBMC after CpG 
stimulation.  
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Figure 5-6. Sex or pubertal phase did not associate with the production of IFNα after TLR9 
stimulation in healthy young volunteers.  After stimulation with CpG, the percentage of pDC 
producing IFNα was measured and analysed by linear regression (Pre F=18, Pre M=19, Post 
F=28, Post M =25). There were no significant differences between a. sex (p=0.535) or b. 
pubertal phase (p=0.162). c. There was no sex difference in the amount of IFNα produced by 
PBMC after stimulation with CpG(Pre F=15, Pre M=17, Post F=24, Post M =18). P values 
shown represent significance of the coefficient for the independent variable shown 
when analysed by linear regression. 
5.2.  X chromosome and sex hormone associations with TLR mediated 
production of IFNα and other cytokines. 
Aim: To investigate whether the percentage of pDC producing IFNα after R848 or CpG 
stimulation associates with X chromosome number, serum oestradiol and testosterone 
concentration in healthy, transgender and TUS volunteers.  
Sub Aim: To investigate whether the PBMC production of IFNα, IFNβ and TNFα, after R848 or 
CpG stimulation associates with X chromosome number, serum oestradiol and testosterone 
concentration in healthy, transgender and TUS volunteers.  
152 
 
5.2.1. TLR7 induced pDC IFNα production associated significantly with X chromosome 
number and serum testosterone depending on X chromosome number. 
Transgender volunteers, volunteers with TUS and healthy volunteers were included to 
investigate for associations between the percentage of pDC producing IFNα after R848 
stimulation, X chromosome number, serum oestradiol and testosterone concentrations.  
A linear regression model was fitted. The most parsimonious model, which accounted for the 
most variation in the percentage of pDC producing IFNα, is represented below. It included 
serum testosterone concentration, X chromosome number, an interaction term between the 
two, and serum oestradiol concentration. 
%pDC IFNα+= Intercept + B1*X chromosome + B2*Testosterone + B3*X 
chromosome*Testosterone + B4*Oestradiol 
The coefficients, significance values and confidence intervals for the model are represented 
below in Table 5-2.  Overall, this model accounted for 10 % of the variation in the percentage 
of pDC producing IFNα and was statistically significant (p=0.012). If two X chromosomes were 
present, after controlling for sex hormone concentrations, there were on average 12.41% 
more pDC producing IFNα after R848 stimulation (B=12.407; p=0.003; CI=4.434, 20.380) 
compared to if one X was present (Fig. 5-7a).  The model included a significant association 
between the percentage of pDC producing IFNα after R848 stimulation and serum 
testosterone (B=0.740; p=0.008; CI=0.197, 1.284) and a significant interaction term between X 
chromosome number and serum testosterone (B=-1.315;p=0.002; CI=-2.144, -0.486), which 
improved the predictive value of the model (an illustration of this association, when oestradiol 
is held constant at 5pmol/L, is given in Fig. 5-7b). This implies that there is a positive 
association between the percentage of pDC producing IFNα after R848 stimulation with 
testosterone in the presence of one X, and a negative association in the presence of two X 
chromosomes. This implies that females with high testosterone and males with low 
testosterone should both have a decreased TLR7 induced pDC IFNα production when 
compared to their chromosomal counterparts. To demonstrate this, an ANOVA with a 
Bonferroni adjusted post-hoc test confirmed that  there was a lower percentage of IFNα-
producing pDC in trans males (birth female-two X chromosomes; high testosterone) compared 
to healthy females (mean difference=15.23; p=0.018; 95% CI=1.75, 28.72) and trans females 
(birth males-one X chromosome, low testosterone) when compared to healthy males (mean 
difference=17.41; p=0.047; 95% CI=0.16, 34.66) (Fig. 5-7c).  There was no association between 
serum oestradiol concentration and the percentage of pDC producing IFNα after R848 
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stimulation (B=0.006; p=0.567; CI=-0.014, 0.025), but the inclusion of oestradiol in the model 
improved the predictive value of the model (adjusted r2). 
 
Dependant variable: % pDC IFNα+ after R848 stimulation 
Adjusted r
2
=0.101; Model significance p=0.012 
Variables  B 
coefficient  
p 95.0% Confidence 
Interval for B 
(Constant) 14.753 0.000 8.568 20.938 
X chromosome 
number (1=0; 
2=1) 
12.407 0.003** 4.434 20.380 
Testosterone 
nmol/L 
0.740 0.008* 0.197 1.284 
Test/X 
interaction 
-1.315 0.002** -2.144 -0.486 
Oestradiol 
pmol/L 
0.006 0.567 -0.014 0.025 
Table 5-2. Full linear regression model assessing for associations between X chromosome 
number; sex hormone and the percentage of pDC producing IFNα after R848 stimulation in 
healthy (pre and post puberty), Turner’s and transgender volunteers.* p value <0.05; **p value 
<0.005 
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Fig. 5-7. The percentage of pDC producing IFNα after R848 stimulation associated with 
X chromosome number and serum testosterone depending on X chromosome 
number. Pre- and post-pubertal healthy, transgender and TUS volunteers were 
analysed (n=128 Pre F=20, Post F=31, Trans M=13, Pre M=20, Post M=28, trans F=7, 
Tus=9), p values in a. represent the significance of the coefficient the variable shown 
as estimated by linear regression after correcting for the other variables in the model 
(X chromosome number, serum testosterone and oestradiol). a. If two X chromosomes 
were present, a higher % pDC produced IFNα+ after R848 stimulation (p=0.003). b. % 
pDC IFNα+ after R848 stimulation associated with serum testosterone (p=0.008) with a 
significant interaction term between X chromosome number and serum testosterone 
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(p=0.002) as illustrated, *holding oestradiol constant at 5pmol/L.  c. Trans males 
(p=0.018) and females (p=0.047) both had a lower %pDC IFNα+ after R848 stimulation 
than their chromosomal counterparts when analysed by ANOVA with post hoc 
analysis. 
5.2.2. PBMC IFNα and IFNβ production associated with X chromosome number, and 
serum testosterone depending on X chromosome number. 
To test the pDC-specific findings above, the production of cytokine in supernatant by PBMC 
was measured in healthy, transgender and TUS volunteers. The same regression model as in 
5.2.1. was fitted using the natural log of the total PBMC production of IFNα or IFNβ after R848 
stimulation as the outcome variable (n=111). Please see Tables 5-3 and 5-4 for coefficients, 
significance values and confidence intervals.  
After R848 stimulation, if two X chromosomes were present, after controlling for sex 
hormones, there was on average 2.8 times more IFNα (ExpB=2.84; p=0.017; CI=1.21-6.67(Fig. 
5-8a) and 2.9 times more IFNβ (ExpB=2.94;p=0.030; CI=1.115-7.791)(Fig. 5-8c) produced by 
PBMC than if one X chromosome was present. In addition, after R848 stimulation, serum 
testosterone concentration associated with PBMC IFNα (ExpB=1.08; p=0.032; CI=1.01-1.14) 
and IFNβ production (ExpB=1.08; p=0.030; CI=1.00-1.16). There were significant interaction 
terms between serum testosterone and X chromosome number with IFNα (ExpB=1.12; 
p=0.027; CI=0.80-0.98) (Fig. 5-8b) and IFNβ (B=0.875; p=0.019; CI=0.086-1.023) (Fig. 5-8d) 
concentrations.  
Serum sex hormone or X chromosome number did not associate with the production of TNFα 
in supernatant by PBMC after R848 stimulation.  
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Table 5-3. Full linear regression model assessing for associations between X chromosome 
number; sex hormone and the PBMC production of IFNα after R848 stimulation in healthy (pre 
and post puberty), TUS and transgender volunteers (n=111). * p value <0.05; **p value <0.005 
 
 
 
 
 
 
 
 
 
Table 5-4. Full linear regression model assessing for associations between X chromosome 
number; sex hormone and the PBMC production of IFNβ after R848 stimulation in healthy (pre 
and post puberty), Turner’s and transgender volunteers (n=111) 
 
 
 
Dependant variable: PBMC IFNα (pg./ml) production after R848 
stimulation  
Adjusted r
2
=0.101; Model significance p=0.024 
Variables  ExpB 
coefficient  
p 95.0% Confidence 
Interval for ExpB 
(Constant) 84.77 0.000 43.68 164.35 
X chromosome 
number (1=0; 
2=1) 
2.84 *0.017 1.21 6.66 
Testosterone 
nmol/L 
1.07 *0.024 1.01 1.14 
Oestradiol 
pmol/L 
0.99 *0.047 0.99 1 
Test/X 
interaction 
0.89 *0.028 0.81 0.99 
Dependant variable: PBMC IFNβ (IU/ml) production after R848 
stimulation 
Adjusted r
2
=0.049; Model significance p=0.115 
Variables  ExpB 
coefficient  
p 95.0% Confidence 
Interval for ExpB 
(Constant) 5.51 0.000 2.59 11.75 
X chromosome 
number (1=0; 
2=1) 
2.94 0.030 1.11 7.79 
Testosterone 
nmol/L 
1.08 0.030 1.00 1.16 
Oestradiol 
pmol/L 
0.99 0.634 0.99 1.00 
Test/X 
interaction 
0.87 0.019 0.78 0.97 
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Figure 5-8. X chromosome number and serum testosterone concentration have a significant 
and interactive association with TLR7 induced PBMC IFNα and IFNβ production. PBMC from 
healthy, transgender and TUS volunteers were stimulated with R848 (TLR7/8) and 
concentrations of IFNα, IFNβ and TNFα were measured in supernatant by luminex, p values 
represent significance of the coefficient for the independent variable shown (n=111 Pre F-18, 
Post F=27, Trans M=11, Pre M=19, Post M=22, Trans F=6, TUS=8). a.-d. After R848 stimulation, 
if two X chromosomes were present, PBMC produced more IFNα (p=0.017) and IFNβ (p=0.03) 
with a significant interaction term between testosterone and X chromosome number 
(p=0.028; p=0.019 respectively). 
5.2.3. TLR9 induced pDC IFNα production associated with serum testosterone 
concentration, but not X chromosome number.  
After CpG stimulation, there was no significant association between the percentage of pDC 
producing IFNα and X chromosome number (p=0.243) (Fig. 5-9a). There were no associations 
between the percentage of pDC producing IFNα and X chromosome number or serum 
oestradiol, but an association existed with serum testosterone concentration (B=0.491; 
p=0.007; CI=0.138, 0.845) with no significant interaction term (Fig. 5-9b). After CpG 
stimulation, there were no significant associations with the total PBMC supernatant 
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production of IFNα, IFNβ or TNFα and X chromosome number or serum sex hormone 
concentration. 
 
Fig. 5‐9. The percentage of pDC producing IFNα after CpG stimulation associates with 
serum testosterone concentration. PBMC from healthy, transgender volunteers and 
TUS volunteers were stimulated with CpG (TLR9 agonist) and pDC IFNα production was 
measured by flow cytometry (n=90 Pre F=18, Post F=28, Trans M=9, Pre M=19, Post M=25, 
Trans F=11, TUS=9). P values shown represent significance of the coefficient for the 
independent variable shown when analysed by linear regression. a. After CpG 
stimulation, there were no associations between the percentage of pDC producing 
IFNα and X chromosome number (p=0.243). b. A significant association existed with 
serum testosterone concentration (p=0.007) with no significant interaction terms.  
 
5.3. Differences in TLR mediated production of IFNα and other cytokines 
between healthy young people and those with jSLE.  
Aim: To investigate whether differences exist in the TLR7 or TLR9 mediated production of 
IFNα by pDC between healthy young people and those with jSLE. 
Sub Aim: To investigate whether differences exist in the TLR7 or TLR9 mediated PBMC 
production of IFNα, IFNβ and TNFα between healthy young people and those with jSLE. 
5.3.1. TLR7 mediated production of IFNα by pDC was not different in jSLE and 
maintained a sex bias. 
The percentage of pDC producing IFNα after R848 stimulation was compared between young 
people with jSLE and healthy post pubertal volunteers by t-test and no difference was 
seen(p=0.632) (Fig. 5-10a).  
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In 5.1.4. it was shown that female pDC in healthy young people had a higher percentage of 
pDC producing IFNα after TLR7 stimulation than males. It was found that in jSLE, there was still 
a non-significant trend towards females having a higher percentage of pDC producing IFNα 
after TLR7 stimulation (t-test p=0.057) (Fig. 5-10a). 
5.3.2. TLR7 mediated PBMC production of TNFα but not IFNα or IFNβ was higher in 
jSLE.  
As mentioned above, the distribution of the supernatant cytokine levels was not normal, so 
non-parametric measures (Mann Whitney U test) to compare between 2 groups were used.  
There was no difference in R848 induced PBMC production of IFNα in supernatant between 
healthy, post pubertal volunteers and those with jSLE (p=0.784) (Fig. 5-10b). In addition, there 
was no difference in the R848 induced PBMC production of IFNβ (p=0.699) (Fig. 5-10c). 
Volunteers with jSLE had a higher production of TNFα after stimulation with R848 compared to 
healthy post pubertal volunteers (p=0.001) (Fig. 5-10d).  
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Figure 5-10. TLR7 Induced cytokine production in jSLE a. After R848 stimulation, there was no 
significant difference in the %pDC producing IFNα in jSLE (t-test: p=0.632, n=98-healthy-F=31, 
M=28; jSLE F=26, M=13). Females with jSLE had a trend towards a higher % pDC producing 
IFNα than males with jSLE (p=0.057). b.-c. There were no differences in jSLE in the amount of 
IFNα (p=0.784) or IFNβ (p=0.699) produced by PBMC in supernatant after R848 stimulation d. 
After R848 stimulation here was more TNFα produced in jSLE (p=0.001, n=108). MW=Mann 
Whitney U test 
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5.3.3. TLR9 induced cytokine production was decreased in jSLE. 
In volunteers with jSLE, there was a lower percentage of pDC producing IFNα after TLR9 
stimulation when compared to healthy volunteers (p=0.001) (Fig. 5-11a). In addition, PBMC 
from volunteers with jSLE produced less IFNα (p=0.002), IFNβ (p=0.003) and TNFα (p=0.001) 
than healthy controls after CpG stimulation (Fig. 5-11b-d). 
 
Figure 5-11. TLR9 induced cytokine production is decreased in jSLE. Cells from healthy post 
pubertal volunteers and volunteers with jSLE were stimulated with CpG (TLR9 agonist). a. The 
percentage of pDC producing IFNα was lower in jSLE (t test p=0.001, n=90). b.-d. The PBMC 
production of IFNα (p=0.002); IFNβ (p=0.003) and TNFα (p<0.001) was lower in volunteers with 
jSLE(n=74). MW=Mann Whitney U test 
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5.4. Discussion 
These are the first data investigating the TLR induced pDC production of IFNα in childhood and 
across puberty. It has been observed that, upon TLR7 stimulation, a higher percentage of pDC 
from females produce IFNα than males, regardless of pubertal development. Puberty itself, 
regardless of sex, associated with a higher percentage of pDC producing IFNα after TLR7 
stimulation.  TLR7 induced IFNα production associated with serum testosterone concentration, 
but the direction of this association differed, depending on the number of X chromosomes 
present. These sex and pubertal differences were unique to TLR7 and not TLR9 induced IFNα 
production. Importantly, the differences in sex and pubertal phase were unique to the TLR7 
induced production of IFNα and IFNβ, and not TNFα, suggesting that this was not a ubiquitous 
effect on all TLR7 induced cytokines, but that it was specific to type 1 IFNs. 
Multiple previous studies have shown that a higher percentage of pDC from adult females 
produce IFNα after TLR7 stimulation (16, 120, 123, 259). The only non-adult study ,in 2 month 
old infants, showed that female infants had a higher percentage of pDC producing IFNα after 
TLR7 stimulation compared to male infants(123). They postulated that this sex difference may 
have been due to the surge of testosterone, or ’mini-puberty’ in male infants in the neonatal 
period.  
To the best of our knowledge this, is the first time that this has been studied in children and 
adolescents. The current data show that females have a higher percentage of pDC producing 
IFNα after TLR7 stimulation, regardless of sexual maturity. Sexual maturity however associated 
with a higher percentage of pDC producing IFNα after TLR7 stimulation, regardless of sex. It is 
remarkable that in the linear regression model, two essentially demographic variables (sex and 
pubertal phase) accounted for 10% of the variability in the production of IFNα, a potent 
cytokine, in response to TLR7 stimulation.  
Previous human studies have not been able to separate out the individual effects of sex 
hormones and X chromosome numbers in vivo. When the model in the current study was 
extended to include volunteers with a variation of serum sex hormone on the background of 
one or two X chromosomes, it was seen that the TLR7 induced production of IFNα by pDC was 
substantially and significantly higher if two X chromosomes were present, regardless of serum 
concentration of testosterone or oestradiol. These findings agree with a humanised mouse 
model where male or female human progenitor cells were transplanted into male or female 
NOD-SCID-β2m−/− mice (68). It was seen that regardless of the sex of the recipient mouse, if 
the transplanted human pDC contained two X chromosomes, a higher percentage of them 
produced IFNα after TLR7 stimulation.   
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In our model, it was also noted that the TLR7 mediated pDC production of IFNα associated 
with serum testosterone concentration, and that the direction of this association was different 
depending on the number of X chromosomes present. This finding is novel, and it would not 
have been possible to observe these associations without these unique young volunteers. 
There have been conflicting reports about the associations between TLR7 mediated pDC 
function and sex hormones in vitro and in vivo. In vitro, testosterone has been shown to 
associate with a decrease in the TLR7 induced IFNα production in pDC from adult females, 
whereas oestradiol, or oestradiol antagonism has had no effect on the in vitro assay (16, 124). 
It has previously been shown that  exogenous oestradiol administration in post-menopausal 
women associated with an increase in TLR7 induced pDC production of IFNα and TNFα, but 
these data did not take serum testosterone concentration into account as a confounding 
variable(68).  The current data suggest that testosterone has an important association with 
TLR7 associated pDC IFNα production, but that the direction of this association changes with 
sex. Testosterone therefore, may be a candidate to investigate, in females specifically, to 
potentially modulate the TLR7 mediated pDC IFN response. 
In these data, pDC only represent 0.1-0.9% of total PBMC. Due to small blood volume and cell 
numbers obtainable in children and adolescents, it was not possible to confirm the flow 
cytometry findings by separating sufficient pDC and assessing for the pDC-specific amount of 
IFNα produced in supernatant. Therefore, although less precise, the amount of IFNα produced 
in supernatant by total PBMC after stimulation with R848 was measured as confirmation of the 
pDC specific findings. Despite the main IFNα producing cell type (pDC) representing such a low 
percentage of cells, and there being fewer numbers with the measure available, there were 
still non-significant trends towards increased production in females and post pubertal 
volunteers as had been seen in the pDC specific experiment. When the model was extended 
and the associations with X chromosome number and sex hormone were analysed, the 
production of IFNα and IFNβ but not TNFα associated significantly with X chromosome number 
and serum testosterone as they had done in the pDC specific experiment. In addition, these 
data confirmed a significant interaction term between X chromosome number and serum 
testosterone for both IFNα and IFNβ.   
It is known that R848 is an agonist of both TLR7 and TLR8. Although the effects of TLR8 
stimulation cannot be definitively evaluated from this data, pDC are known to constitutively 
express TLR7 and not TLR8 and therefore the results of R848 stimulation on pDC are most 
likely to represent TLR7 stimulation (260, 261). The indirect effect of TLR8 on other cell types 
however, cannot be excluded. 
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As there were no sex or pubertal associations with the production of any cytokines after CpG 
or TLR9 stimulation, we can conclude that this effect was specific to TLR7, and not ubiquitous 
for nucleic acid sensing by TLRs. As expected after no sex difference was shown, TLR9 induced 
pDC IFNα production did not associate with X chromosome number but did show an 
association with serum testosterone concentration.  Therefore, put together, in these data, a 
lower serum testosterone concentration associated with a lower TLR9 mediated pDC IFNα 
production, regardless of sex, and a higher TLR7 mediated pDC IFNα response in females only.  
As has been stated before, jSLE is a disease with a characteristic type 1 IFN signature. It is not 
clear where the source of this extra IFNα lies. In the current data, there were no difference in 
the production of IFNα after TLR7 stimulation between healthy volunteers and those with jSLE. 
In jSLE, as in healthy volunteers, females still had a higher percentage of pDC producing IFNα 
after TLR7 stimulation. There have been varying reports about whether TLR7 induced IFNα 
production is different in SLE (35, 244, 245). A recent study involving 71 adult  SLE patients and 
45 healthy adults showed an increase in the TLR7 mediated pDC production of IFNα and TNFα 
in SLE(245). This study included patients with active disease in addition to those with low 
disease activity and reported that the TLR7 mediated pDC production of IFNα correlated with 
disease activity. It is possible therefore that the present data do not show a difference, partly 
because the patients were selected to have a low disease activity. Interestingly, the present 
data do show an increase in TNFα production after TLR7 stimulation in jSLE when compared to 
healthy volunteers.  
The TLR9 induced production of IFNα was markedly decreased in jSLE patients, along with the 
PBMC production of IFNα, IFNβ and TNFα. This phenomenon has been widely reported before 
(244, 262, 263). jSLE therefore associates with a significant decrease in TLR9 mediated cytokine 
production, whereas TLR7 mediated cytokine production is reported to be unchanged or 
increased with disease activity. In addition, previous data has shown that pre-stimulation of 
PBMC with IFNα sharply decreases TLR9 mediated cytokine production, but increases TLR7 
mediated cytokine production (245). 
It may stand to reason, that the appropriate response to a high background IFN would be a 
compensatory down-regulation in the IFN producing capacity of TLR to prevent a sustained 
forward feedback loop, as is seen with TLR9 induced IFNα production. Therefore, the 
observation that TLR7 induced IFNα production is not changed may be of importance. Further 
work is needed to assess whether this is appropriate or not in the context of jSLE. From these 
various observations, it might be postulated that the IFNα that drives SLE may be more related 
to TLR7 stimulation, than TLR9, or at least, that a balance exists between the two, which is 
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disrupted in jSLE. This makes the above observation of the effects of serum testosterone 
intriguing. In females, testosterone associates with an increase in TLR9 induced IFNα 
production, and a decrease in TLR7 induced IFNα production, which would make it a logical 
target to reverse the imbalance of these responses that is seen in jSLE. 
 These functional results should be viewed with caution, as all of the patients with jSLE were 
prescribed HCQ, which has the potential to interfere with TLR9 and TLR7 induced cytokine 
production in a manner that is not fully understood in vivo (158, 264). HCQ is almost 
universally used in jSLE and often started at diagnosis. Patients naïve to all treatment are 
difficult to access, therefore it is extremely challenging to obtain such samples and perform 
these experiments in the absence of HCQ.  
5.5. Conclusion  
Females had a higher TLR7 induced pDC IFNα response regardless of puberty. Post pubertal 
volunteers had a higher TLR7 induced pDC IFNα response regardless of sex. If two X 
chromosomes were present, there was a higher TLR7 induced pDC IFNα response, regardless 
of hormonal environment. Testosterone associated with TLR7 induced pDC IFNα response 
differently, depending on the number of X chromosomes present. These findings were specific 
to TLR7 and type 1 IFN production. 
Patients with jSLE showed a universal decrease in cytokine production after TLR9 stimulation, 
but no difference with TLR7 stimulation.   
It was next investigated whether the expression of key genes in the type 1 IFN production 
pathway associated with sex, puberty, X chromosome number or serum sex hormone.  
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Chapter 6: IFN pathway gene expression, sex and puberty 
After observing that female sex and pubertal phase associated with a higher production of 
IFNα after TLR7 stimulation, and that this associated with X chromosome number and 
testosterone, it was next investigated whether the PBMC expression of key genes in the IFN 
sensing and production pathway differed with sex, puberty, X chromosome number or serum 
sex hormone.  
6.1. Gene selection  
A gene panel was designed to test for differences in type 1 IFN production pathway. In 
addition, key gene groups that are known to be over-expressed in jSLE were selected in order 
to investigate whether these were differentially expressed in sex and puberty in a manner that 
may predispose females to develop jSLE(26). Genes are given in Table 2-4 in ‘Methods’. 
6.1.1. IFN score  
Five IFN inducible genes were selected to calculate an ‘IFN score’ (265).  
IFN score = (MX1+BST2+IFIT1+ISG15+MCP1)/5 
As these genes are expressed at varying levels, it was assessed whether normalising them prior 
to calculating an average influenced the findings. There was no difference in the significance of 
results, so it was elected to keep the data in its original form and use the average as calculated 
above and shown in Fig. 6-1. There was one outlier among healthy volunteers with a high IFN 
score. This data point came from a 16-year-old female with no evidence of inter-current viral 
infection on review of her clinical data. Sensitivity analysis was performed, and as this sample 
was not influential, it was elected to include this outlier in the analysis.  
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Figure 6-1. IFN Score.  Five known IFN inducible genes were measured by Nanostring and an 
average score or ‘IFN score’ was calculated. The single outlier was not influential and kept in 
the analysis. 
6.1.2. IFN pathway genes 
Genes were selected from the RNA and DNA sensing and signalling pathway (Fig. 6-2). These 
included endosomal RNA sensor TLR7, intracytoplasmic RNA sensors MDA5 and RIG-1, as well 
as MAVS, a signalling molecule downstream of RIG-1 and MDA5. Endosomal DNA sensor, TLR9, 
and intracytoplasmic DNA sensor, DDX41, were selected. IFN regulatory factors (IRF)5 and 7 
were selected.  
 
Figure 6-2. Gene selection in the DNA and RNA sensing and signalling pathway. 
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6.1.3. Other genes 
In jSLE, there is increased dead/dying cell debris due to increased apoptosis(266). There is a 
theory that this provides an increased load of nucleic acid for sensing and IFN production(1). 
For this reason, Fas (TNFR6) and TNF relate apoptosis inducing ligand (TRAIL) were included in 
the gene panel.  
There has been some investigation into whether ERE nucleic acids may contribute to IFN 
production(219). LINE-1 is the most abundant of these elements and is capable of autonomous 
transposition and has been shown to be differentially expressed in SLE (220). LINE 1 was found 
to be the most abundantly expressed gene out of all the genes measured in the selected panel 
which reflects its ubiquitous nature in cells (Fig. 6-3a). Ro 60 is an RNA binding protein coded 
by the TROVE-2 gene that has been shown to bind endogenous retroelement RNA specifically 
in SLE(267) and was therefore included.  
The gene expression of the following hormone receptors was included: oestrogen receptor 
alpha (ESR1); oestrogen receptor beta (ESR2); progesterone receptor (PGR) and androgen 
receptor (AR). As mentioned in ‘Methods’, the expression of these genes was not high enough 
in PBMC to be accurately measured against the background signal (Fig. 6-3b). Therefore, these 
data were excluded from further investigation.  
Figure 6-3. Relative gene expression in healthy volunteers. a. The corrected and normalised 
counts of gene expression were measured in healthy volunteers. It was noted that LINE1 was 
the most abundantly expressed gene compared to all others. b. Hormone receptor genes for 
oestrogen (ESR1/2), progesterone (PGR), and androgen (AR) were measured but not expressed 
highly enough in PBMC to be accurately measured. These genes are shown here, compared 
arbitrarily to RIG-1 and TROVE which both had a relatively low expression. 
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6.1.4. Statistical analysis  
All the genes measured were analysed by linear regression to assess for associations between 
PBMC gene expression with sex and pubertal phase. A summary of all the models for sex and 
pubertal phase is represented in Table 6-1. In addition, the significance values for each 
coefficient (B) was adjusted for multiple testing using the Benjamini Hochberg method, with a 
false discovery rate of 0.25, as shown in Table 6-2.  
 
 Table 6-1. Linear regression analysis of all genes for associations with sex and pubertal phase. All genes in the panel were assessed for association with sex and 
puberty by linear regression and regression models are summarised here. 
 Model: y=intercept+B1*Sex+B2*Puberty 
Investigation Dependan
t variable 
Model predictive 
value 
Model 
significance 
Independent Variables 
Sex (F=1; M=0) Puberty (Pre=0; Post=1) 
RNA sensing 
 
Adjusted r2 p Coefficient 
B1 
p 95% CI Coefficient 
B2 
p 95% CI 
TLR7 0.055 0.099 5.749 0.091 -0.952 12.45 5.246 0.122 -1.455 11.947 
RIG-1 0.069 0.07 37.739 **0.001 3.595 71.883 -9.316 0.586 -43.462 24.826 
MDA5 0.07 0.069 22.894 *0.022 3.379 42.41 -0.365 0.97 -19.881 19.151 
MAVS 0.079 0.055 9.243 0.127 -2.741 21.227 -10.354 0.089 -22.338 1.631 
DNA sensing TLR9 0.23 0.001 4.566 0.148 -1.676 10.809 -11.156 **0.001 -17.398 -4.913 
DDX41 -0.29 0.733 -6.097 0.462 -22.622 10.427 1.462 0.859 -15.062 17.987 
IRF  IRF5 0.083 0.05 -34.434 0.219 -90.006 21.139 56.229 *0.047 0.656 111.801 
IRF7 -0.01 0.473 56.23 0.391 -74.445 186.904 63.445 0.334 -67.23 194.12 
Cell death TNFR6 -0.023 0.638 15.036 0.352 -17.114 47.185 -0.575 0.971 -32.724 31.575 
TRAIL -0.02 0.594 25.881 0.672 -96.44 148.203 59.502 0.333 -62.82 181.824 
Endogenous 
retroelement  
LINE1 0.191 0.003 -342.498 0.267 -973.068 276.072 -1123.129 **0.001 -1747.699 -498.559 
TROVE 0.088 0.043 28.669 0.071 -2.556 59.893 -24.478 0.121 -55.702 6.747 
IFN Score IFN Score -0.008 0.455 58.776 0.461 -100.47 218.023 87.461 0.274 -71.606 246.888 
Post stim 
IFN Score 
0.316 0.001 -351.992 0.327 -1073.017 369.033 1428.677 **0.001 699.565 2157.789 
  
Table 6-2. Multiple correction of gene coefficients for sex and puberty. Benjamini Hochberg 
method of adjusting for multiple testing was used for the significance values of the coefficients 
for the associations between gene expression, sex and puberty. A false discovery rate of 0.25 
was used.  
 
 
Coefficient Coefficient 
significance 
Benjamini-Hochberg 
significance 
Benjamini-Hochberg 
P-value 
(<0.25=significant) 
RIG-1(Sex) 0.001 significant 0.007 
TLR9 (pub) 0.001 significant 0.007 
LINE1 (pub) 0.001 significant 0.007 
Post stim IFN Score (pub) 0.001 significant 0.007 
MDA5 (sex) 0.022 significant 0.1232 
IRF5 (pub) 0.047 significant 0.219 
TROVE (sex) 0.071 not significant 0.283 
MAVS(Pub) 0.089 not significant 0.283 
TLR7 (sex) 0.091 not significant 0.283 
TROVE (pub) 0.121 not significant 0.296 
TLR7 (pub) 0.122 not significant 0.296 
MAVS (pub) 0.127 not significant 0.296 
TLR9 (sex) 0.148 not significant 0.319 
IRF5 (sex) 0.219 not significant 0.438 
LINE1 (sex) 0.267 not significant 0.479 
IFN Score (pub) 0.274 not significant 0.479 
Post stim IFN Score (sex) 0.327 not significant 0.492 
TRAIL (pub) 0.333 not significant 0.492 
IRF7(pub) 0.334 not significant 0.492 
TNFR6 (pub) 0.352 not significant 0.492 
IRF7 (pub) 0.391 not significant 0.521 
IFN Score (sex) 0.461 not significant 0.562 
DDX41 (sex) 0.462 not significant 0.562 
RIG-1 (pub) 0.586 not significant 0.684 
TRAIL (sex) 0.672 not significant 0.752 
DDX41 (pub) 0.859 not significant 0.925 
MDA5 (pub) 0.97 not significant 0.971 
TNFR6 (pub) 0.971 not significant 0.971 
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6.2. Sex and pubertal differences in PBMC gene expression  
Aim: To investigate whether sex or pubertal phase associate with the expression of selected 
genes in the IFN pathway in healthy young people.  
6.2.1.  The expression of genes coding for RNA sensors was higher in females.  
In healthy females, PBMC expressed significantly more of the genes for intracytoplasmic RNA 
receptors RIG-1 (p=0.001) and MDA5 (p=0.022) (Fig. 6-4, Table 6-1), after controlling for 
pubertal phase. There was no significant difference in the expression of MAVS with sex or 
pubertal phase.  
When assessed by linear regression, there was a higher expression of endosomal RNA sensor 
TLR7, but this did not reach statistical significance (p=0.091). An ANOVA with post hoc analysis 
and Bonferroni correction was performed and revealed that post pubertal females had a 
significantly higher TLR7 expression than post pubertal males (p=0.024; mean 
difference=13.922; 95% CI=1.247, 26.596) and pre-pubertal females (p=0.03; mean 
difference=13.419; 95% CI=0.744, 26.093).  
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Figure 6-4. RNA sensing gene expression was higher in females.  a.-b. The expression of 
intracytoplasmic RNA sensors RIG-1 (p=0.001) and MDA5 (p=0.022) was higher in females than 
males, after controlling for pubertal phase. c. There was a significantly higher expression of 
TLR7 in post pubertal females when compared to post pubertal males (p=0.024) and pre-
pubertal females (p=0.03) respectively. (n=50 Pre F=14, Post F=10, Pre M=12, Post M=14). P 
values shown represent significance of the coefficient for the independent variable 
shown when analysed by linear regression. 
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6.2.2. TLR9 gene expression was decreased in post pubertal healthy volunteers.  
The PBMC gene expression of endosomal DNA sensor, TLR9 was decreased in post pubertal 
volunteers overall (B=-11.156; p=0.001; 95%CI=-17.398, -4.913) with no significant sex 
difference (Fig. 6-5a, Table 6-2). There were no significant sex or pubertal differences in the 
expression of intracytoplasmic DNA sensor DDX41 (Fig. 6-5b, Table 6-1).  
 
Figure 6-5. PBMC TLR9 gene expression was decreased in post pubertal healthy volunteers. a. 
TLR9 gene expression was decreased after puberty when controlling for sex (p=0.001). b. 
DDX41 gene expression was not significantly different between sexes or pubertal phases. 
(n=50 Pre F=14, Post F=10, Pre M=12, Post M=14). P values shown represent significance of 
the coefficient for the independent variable shown when analysed by linear regression. 
6.2.3. IRF5 gene expression was increased in post pubertal volunteers 
In healthy volunteers, there was an increased PBMC gene expression of IRF5 after puberty 
(B=56.229; p=0.047; 95%CI=0.656, 111.801) with no significant sex difference (Fig. 6-6a, Table 
6-1). There were no significant differences in the PBMC gene expression of IRF7 with sex or 
puberty (Fig 6-6b).  
6.2.4. LINE1 gene expression was decreased in post pubertal volunteers 
In healthy volunteers, PBMC LINE1 gene expression was decreased in post pubertal volunteers 
(B=-1123.129; p=0.001; 95%CI=-1747.699, -498.559) with no significant sex difference (Fig. 6-7, 
Table 6-1). There were no significant sex or pubertal differences in the PBMC gene expression 
of TROVE2 (Figure 6-7b). 
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Figure 6-6. IRF5 gene expression was increased in post pubertal volunteers a. In post pubertal 
volunteers, PBMC IRF5 gene expression was increased (p=0.047) with no sex difference. b. No 
significant sex or pubertal differences were seen in PBMC IRF7 gene expression. (n=50 Pre 
F=14, Post F=10, Pre M=12, Post M=14) 
 
Figure 6-7.  LINE1 gene expression was decreased in post pubertal volunteers.  a. Gene 
expression of LINE1 was decreased in post pubertal healthy volunteers (p=0.001) with no 
significant sex difference. b. There was no significant sex or pubertal differences in the PBMC 
expression of TROVE2. (n=50 Pre F=14, Post F=10, Pre M=12, Post M=14). P values shown 
represent significance of the coefficient for the independent variable shown when 
analysed by linear regression 
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6.2.5. Cell death associated genes did not associate with sex or pubertal phase.  
There were no significant differences in PBMC gene expression of cell death associated genes, 
TNFR6 or TRAIL between sexes or pubertal groups (Table 6-1).  
6.2.6. The upregulated IFN score was higher in post pubertal volunteers.  
There was no difference in the ex-vivo baseline PBMC IFN score between sexes or pubertal 
phases (Fig. 6-8a, Table 6-1). PBMC were stimulated with IFNα for 20 hours and IFN score re-
measured (upregulated IFN score). There was a significantly higher upregulated IFN score in 
post pubertal volunteers (B=1428.677; p=0.001; 95% CI=699.565, 2157.789) with no significant 
sex difference (Fig. 6-8b, Table 6-1). The adjusted r2 for this model was 0.316, implying that sex 
and pubertal phase accounted for 32% of the variability seen in the ability of PMBC to 
upregulate the expression of these ISG upon stimulation with IFNα.  
 
Figure 6-8. After exposure to IFNα, the IFN score is higher in post pubertal volunteers. a. The 
baseline IFN score was not significantly different between sexes or pubertal phases in healthy 
volunteers (n=50 Pre F=14, Post F=10, Pre M=12, Post M=14). b. After IFNα stimulation the IFN 
score (upregulated IFN score) was significantly higher in post pubertal volunteers (p=0.001, 
n=33 Pre F=9, Post F=7, Pre M=10, Post M=17). P values shown represent significance of 
the coefficient for the independent variable shown when analysed by linear regression 
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6.3.  X chromosome and sex hormone associations with PBMC gene 
expression of IFN pathway genes.  
After observing that the expression of various genes associated with sex and puberty in 
healthy volunteers, transgender and TUS volunteers were included to test for associations 
between selected PBMC gene expression, X chromosome number, and serum sex hormone.  
Aim: To test for associations between the PBMC gene expression of TLR7; RIG-1; MDA5; TLR9; 
LINE1 and upregulated IFN score with X chromosome number, serum oestradiol and serum 
testosterone concentration.  
6.3.4. The PBMC gene expression of RNA sensor RIG-1, but not MDA5 or TLR7, 
associated with X chromosome number after controlling for sex hormone.  
The expression of RIG-1 was higher if two X chromosomes were present (B=37.342, p = 0.037; 
95% CI=2.272, 72.412) with no association with the concentration of either sex hormone (Fig. 
6-9a). PBMC gene expression of either TLR7 or MDA5 did not associate with X chromosome 
number, serum testosterone or oestradiol concentration (Fig. 6-9b-c). Regression models 
summarised in Table 6-3. 
Figure 6-9. PBMC gene expression of RIG-1 was higher if two X chromosomes were present. a. 
RIG-1 gene expression was higher if two X chromosomes were present (p=0.037) regardless of 
serum sex hormone concentration. b.-c. TLR7 and MDA5 gene expression did not associate 
significantly with X chromosome number or serum sex hormone concentration. (n=77, Pre 
F=14, Post F=10, Trans M=12, Pre M=12, Post M=14, Trans F=6, TUS=9). P values shown 
represent significance of the coefficient for the independent variable shown when 
analysed by linear regression 
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Table 6-3. Linear regression models testing for associations between RNA sensors, X 
chromosome number and serum sex hormone in healthy and transgender volunteers and 
volunteers with TUS. 
6.3.5. The PBMC gene expression of TLR9 and LINE1 was associated with serum 
testosterone.  
PBMC TLR9 and LINE1 gene expression were both decreased in post pubertal volunteers when 
analysed in sub-sections 6.2.2. and 6.2.3. When the expression of these genes was analysed by 
linear regression, for associations with X chromosome number or serum sex hormone, the 
most parsimonious models did not include oestradiol but only serum testosterone 
concentration and X chromosome number (Table 6-4).  By these models, LINE1 and TLR9 PBMC 
gene expression was found not to differ significantly with X chromosome number, but both 
associated negatively with serum testosterone concentration (Fig. 6-10). 
 
Table 6-4. Linear regression model for PBMC gene expression of TLR9 and LINE1. 
Model: y=Intercept+B1*X chromosome number+B2*Testosterone+B3*Oestradiol  
Independent 
Variables 
Dependant variables 
TLR7 RIG-1 MDA5 
B p 95% CI B p 95% CI B p 95% CI 
X 
chromosome 
number 
(1=0; 2=1) 
2.497 0.512 -5.091 10.084 37.342 *0.037 2.272 72.412 8.633 0.347 -9.653 26.919 
Testosterone 
nmol/L 
0.021 0.92 -0.398 0.441 -0.782 0.421 -2.722 1.157 -0.777 0.129 -1.788 0.234 
Oestradiol 
(pmol/L) 
0.001 0.926 -0.02 0.022 -0.029 0.562 -0.127 0.07 0.028 0.284 -0.024 0.079 
Model: y=Intercept+B1*X chromosome number+B2*Testosterone  
Independent Variables Dependant variables 
TLR9  
Adjusted r2=0.078; p=0.024 
LINE1   
Adjusted r2=0.041; p=0.093  
B p 95% CI B p 95% CI 
X chromosome number 
(1=0; 2=1) 
2.693 0.319 -2.654 8.039 -439.502 0.279 -1243.92 364.922 
Testosterone nmol/L -.385 *0.014 -.691 -.079 -46.599 *0.047 -92.57 -.629 
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Figure 6-10. PBMC gene expression of LINE1 and TLR9 was decreased in association with serum 
testosterone. In healthy, TUS and transgender volunteers (n=77, Pre F=14, Post F=10, Trans 
M=12, Pre M=12, Post M=14, Trans F=6, TUS=9), PBMC TLR9 and LINE1 gene expression was 
measured and analysed by linear regression. a.-b. TLR9 expression did not differ with X 
chromosome number(p=0.319) but did associate negatively with serum testosterone 
(p=0.014). c.LINE1 expression did not differ with X chromosome number (p=0.279) but did 
associate negatively with serum testosterone (p=0.047). The lines in b. and d. represent the 
linear regression equation y=Intercept+B1*X chromosome number+B2*Testosterone  
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6.3.6. The upregulated IFN score associated with serum oestradiol concentration.  
The upregulated IFN score was shown above in sub-section 6.2.6 to be higher in post pubertal 
volunteers. When the model was extended to include transgender and TUS volunteers, there 
was a significant association with serum oestradiol concentration, with no significant 
association with X chromosome number or serum testosterone concentration (Table 6-5, Fig. 
6-11). 
Model: y=Intercept+B1*X chromosome number+B2*Testosterone+ 
B3*Oestradiol  
Independent Variables Dependant variable 
Upregulated IFN score 
Adjusted r2=0.247; p=0.015 
B p CI 
X chromosome number 
(1=0; 2=1) 
-522.391 0.189 -1318.90 274.118 
Testosterone nmol/L 29.617 0.253 -22.415 81.649 
Oestradiol pmol/L 3.511 *0.009 .972 6.049 
Table 6-5. Linear regression model testing for associations between upregulated IFN score, X 
chromosome number and serum sex hormone in healthy, TUS and transgender volunteers.  
 
Figure 6-11. Upregulated IFN score associated with serum oestradiol. a. In healthy, TUS and 
transgender volunteers (n=58, Pre F=9, Post F=7, Trans M=7, Pre M=10, Post M=7, Trans F=5, 
TUS=6), the upregulated IFN score did not associate with serum testosterone or the number of 
X chromosomes present but did associate significantly with serum oestradiol (p=0.009) when 
analysd by linear regression. b. *The lines in b. illustrate the equation y=Intercept+B1*X 
chromosome number+B2*Testosterone+ B3*Oestradiol for single and double X chromosomes, 
holding testosterone constant at 0 nmol/L. 
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6.4. PBMC gene expression in jSLE 
Aim: To investigate whether the expression of selected genes in the type 1 IFN pathway differs 
between healthy young people and those with jSLE. 
6.4.1. The IFN score was higher in young people with jSLE and the upregulated IFN score 
was lower. 
In keeping with reported literature(1, 189), it was found that the IFN score was significantly 
higher in young people with jSLE when compared to healthy, post pubertal volunteers by t-test 
(p=0.001, mean difference=679.95; 95% CI=293.10, 1066.80) (Fig. 6-12a). A mean IFN score 
was calculated from the healthy post-pubertal volunteers only. Greater than 2 standard 
deviations (SD) above the mean was considered IFN positive (IFN+) and less than 2SD above 
the mean was considered IFN negative (IFN-)(26) (Fig. 6-12b). 14/29 (48%) of young people 
with jSLE were IFN+, vs 1/39 healthy volunteers.  
The upregulated IFN score was lower in young people with jSLE as compared to healthy 
volunteers, although this did not reach statistical significance (t test: p=0.070; mean 
difference=1039.74; 95% CI=-91.67, 2171.16) (Fig 6-12c).  
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Figure 6-12. The IFN score was higher in young people with jSLE. a. Young people with jSLE had 
a higher IFN score when compared to healthy volunteers (t test p=0.001, n=79-jSLE=29, 
healthy=50). b. A normal range was calculated from healthy volunteers. <2SD above the 
healthy mean=IFN negative and >2SD above the healthy mean =IFN positive.  c. Volunteers 
with jSLE had a lower upregulated IFN score than healthy volunteers (t test: p=0.07, n=23 
healthy=14; jSLE=9) although this did not reach statistical significance.  
6.4.2. Measuring IFN inducible genes. 
jSLE is a disease with an inherent IFN signature. Therefore, to assess whether differences 
existed in the expression of various genes in the IFN pathway, it needed to be established 
whether individual genes were IFN inducible. In the healthy, post pubertal volunteers only, 
PBMC gene expression was measured at baseline (ex vivo) and after 20 hours of stimulation 
with IFNα and significance values were adjusted for multiple testing by Bonferroni method 
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(Fig. 6-13).  It was established that many of the genes measured in the panel were IFN 
inducible, all except for DDX41, TLR7, TRAIL and IRF5.  
For this reason, when measuring for differences between healthy volunteers and those with 
jSLE in the expression of genes shown to be IFN inducible, a correction for the IFN score was 
included to account for the inherent upregulation of ISG in jSLE.    
 
Figure 6-13. IFN inducible gene assay. PBMC from healthy volunteers were analysed for gene 
expression before and after stimulation with IFNα. All p values are adjusted for multiple testing 
by Bonferroni method. p<0.003 indicates that the gene was significantly upregulated by IFNα 
stimulation and was therefore considered IFN inducible (ISG). Any comparison of ISG in jSLE 
patients must therefore contain a correction for background IFN score. Values of 0.000000 
represent values less than 0.000001. 
 
 
 
 
Gene      Corrected p value 
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6.4.3. Among the gene expression of the selected RNA sensors, RIG-1 was 
downregulated in jSLE, whereas TLR7 showed no difference.  
There was no difference in the PBMC expression of TLR7 between healthy volunteers and 
those with jSLE (B=3.194; p=0.442; CI=-5.080, 11.467) (Table 6-6). The other RNA sensors 
MDA5, RIG-1 and signalling protein MAVS, were all IFN inducible and were analysed including a 
correction for IFN score (Table 6-6).After correcting for IFN score, jSLE associated with a 
decreased PBMC gene expression of RIG-1 (B=-44.576; p=0.033; 95%CI=-85.286, -3.866) but no 
significant difference in expression of MDA5 or MAVS was observed (not shown). 
 It was shown in 6.2.1. that TLR7 gene expression was higher in post pubertal healthy females 
as compared to males (p=0.02). In young people with jSLE there was no difference in TLR7 
expression between sexes (t-test, p=0.44). There was a significantly higher expression of TLR7 
in males with jSLE as compared to healthy males (t-test, p=0.045, Fig. 6-14). 
Table 6-6. Linear regression models testing for differences in RNA sensing pathway gene 
expression between healthy volunteers and those with jSLE. (n=79) As TLR7 was not IFN 
inducible, there was no correction for IFN score as there was in RIG-1 and MDA5. After 
correcting for IFN score, it was found that RIG-1 was downregulated in jSLE (p=0.033). *p<0.05 
 
 
 
Model: y=Intercept+B1*type+B2*IFN score  
Independ
ent 
Variables 
Dependant variables 
TLR7 Adjusted 
 r2=-0.008, p=0.442 
RIG-1 Adjusted r2=0.646, 
p=0.001 
MDA5 Adjusted r2=0.770, 
p=0.001 
B p 95% CI B p 95% CI B P 95% CI 
Type 
(0=health
y; 1=jSLE) 
3.1
94 
0.4
42 
-
5.0
8 
11.4
67 
-
44.57
6 
*0.0
33 
-
85.28
6 
-
3.86
6 
19.6
16 
0.12
8 
-
5.85
2 
45.0
85 
IFN score     0.127 0.00
1 
0.100 0.15
3 
0.92 0.00
1 
0.07
5 
0.10
8 
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Figure 6-14. PBMC TLR7 gene expression sex difference was lost in jSLE. The gene expression of 
TLR7 was significantly higher in healthy, post pubertal females as compared to males (p=0.02) 
when analysed by t-test. This difference was lost in jSLE (p=0.44), and males with jSLE 
expressed significantly more TLR7 gene in PBMC than healthy males (p=0.045) ( Healthy M=14, 
Healthy F=10, jSLE F =20, jSLE M=9 ). 
6.4.4. The expression of TLR9 was decreased in jSLE, after controlling for IFN score.  
 There was a relatively decreased gene expression of TLR9 in jSLE (B= -6.076; p=0.038; 95% CI=-
11.801, -0.352) after controlling for IFN score (Table 6-7, Fig. 6-15). There was a relatively 
decreased PBMC gene expression of DDX41 in jSLE after controlling for IFN score, but this did 
not reach statistical significance (B=-13.051; p=0.093; 95% CI=-29.314, 2.311).  
 In addition, there was no significant difference in expression of IRF5 (B=-11.591; p= 0.739; 95% 
CI= -81.031, 57.850) and IRF7 (controlling for IFN score) (B=65.726; p= 0.245; 95% CI=-
46.538, 177.989) in jSLE as compared to healthy volunteers (data not shown).  
Table 6-7. Linear regression models testing for differences in TLR9 and DDX41 PBMC gene 
expression between healthy volunteers and those with jSLE. *p<0.05 
 
Model: y=Intercept+B1*type+B2*IFN score  
Independent Variables Dependant variables 
TLR9 Adjusted r2=0.07, p=0.061 DDX41 Adjusted r2=0.209, p=0.001 
B p 95% CI B p 95% CI 
Type (0=healthy; 
1=jSLE) 
-
6.076 
*0.03
8 
-
11.801 
-
0.352 
-
13.051 
0.093 -
29.314 
2.31
1 
IFN score 0.004 0.052 0.00 0.007 0.020 **0.00
1 
0.010 0.03
1 
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Figure 6-15. TLR9 expression is relatively decreased in jSLE. After controlling for IFN score by 
linear regression, it was shown that TLR9 expression was relatively decreased in jSLE (p=0.038) 
(jSLE=29, healthy=24) 
6.4.5. The expression of LINE1 trended towards being increased in jSLE, after 
controlling for IFN score.  
The PBMC gene expression of LINE1 was higher in jSLE (B=621.642; p=0.093; 95% CI=-107.270, 
1350.554) after correcting for IFN score, although this did not reach statistical significance (Fig. 
6-16). There was no difference in PBMC TROVE-2 gene expression between jSLE and healthy 
volunteers, controlling for IFN score (B=4.669, p=0.794; 95% CI=-31.119, 40.457).   
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Figure 6-16. LINE1 gene expression trended towards an increase in jSLE after correcting for IFN 
score. After correcting for IFN score by linear regression, there was a non-significant trend for 
LINE1 expression to be higher in jSLE as compared to healthy volunteers (p=0.093) (jSLE=29, 
healthy=24). 
6.4.6. There was no difference in gene expression of TRAIL or TNFR6 in jSLE. 
 There was no difference in the expression of apoptosis related genes TRAIL (B=45.689; p= 
0.588; 95% CI= -122.643, 214.022) or TNFR6 (correcting for IFN score-B= 24.545; p=0.147; 95% 
CI=-8.929, 58.018) in jSLE. 
6.5. Discussion  
In this chapter, it was seen that females in general, had a higher gene expression of the 
intracytoplasmic RNA sensors, RIG-1 and MDA5. Post-pubertal females specifically had a higher 
gene expression of TLR7, an endosomal RNA sensor. In further analysis, it was shown that at 
least RIG-1 gene expression was significantly related to X chromosome number, and that none 
of the genes encoding these RNA sensors associated with serum sex hormone concentrations.  
Females are known to have an increased response against RNA viruses such as HIV (43)and 
influenza (268), as well as an increased risk of developing jSLE(4). It is shown here that females 
expressed more of these RNA sensors than males, which may contribute to our understanding 
of this sex difference.  
Interestingly, TLR7 was the only gene out of these RNA sensors that is located on the X 
chromosome. Recent work has shown that TLR7 may escape X inactivation in a significant 
proportion of B cells, monocytes and pDC in healthy women and men with Klinefelter’s 
syndrome (XXY)(127). In the same study, B cells that were bi-allelic for TLR7, after stimulation 
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with a TLR7 agonist, showed a preferential enrichment for plasma cells and increased Ig class 
switching. This has led researchers to speculate as to whether TLR7 may escape X inactivation 
in females, which predisposes them to develop SLE. It is therefore intriguing that, in the 
healthy young volunteers, TLR7 was significantly increased in post pubertal females, but did 
not relate statistically to either X chromosome number, serum testosterone or oestradiol.  
There are other puberty associated hormones, which were not tested here, such as LH or FSH, 
and many other non-hormonal parameters that may associate with this rise in TLR7 expression 
in females after puberty. It would be interesting to investigate in the future, whether the 
increase in TLR7 gene expression in post pubertal females relates to an increase in the bi-allelic 
expression of TLR7 on the X chromosome over puberty. This may be due to epigenetic 
mechanisms that associate with puberty. 
In this study, no difference was seen in the PBMC gene expression of TLR7 between healthy 
volunteers and those with jSLE. Gene expression of TLR7 in B cells has been reported to be 
increased in jSLE(237). Whole blood gene expression of TLR7 and TLR9 have been reported to 
be increased in adult patients with active SLE(239, 269). Among this low disease activity group 
however, there was no significant difference in TLR7 expression.  
The sex difference in TLR7 gene expression that was seen in healthy young people was not 
seen in jSLE and there was a significantly higher expression of TLR7 in males with jSLE as 
compared to healthy males.  The BXSB lupus model is a recombinant inbred mouse strain 
produced from a cross of C57BL/6J (B6) and SB/Le mice(229, 230). Male BXSB mice develop 
severe lupus-like autoimmunity, which depends on the presence of the y-linked autoimmune 
accelerator (yaa) region, on the background of other autoimmune susceptibility genes. It has 
been demonstrated that yaa contains a translocation of TLR7 from the X chromosome onto the 
Y chromosome, resulting in a 2-fold increase in expression of TLR7 which is sufficient to induce 
the phenotype in males. Another study showed that human adult males with a TLR7 SNP, 
associated with an increased expression of TLR7,  had a higher risk of developing SLE as  
compared to females with the same mutation(270). Altogether, these data all seem to indicate 
that an increased TLR7 expression associates more with SLE in males, which is perplexing, 
given that it is coded for on the X chromosome and would provide a logical explanation for the 
female predominance of SLE. Indeed, the finding that healthy females had an increased 
expression of TLR7 after puberty does suggest that it may relate to the increased prevalence of 
jSLE in females upon sexual maturity, but TLR7 gene expression was not directly increased in 
females with jSLE. Perhaps, the increased expression of TLR7 in healthy females after puberty 
contributes to their increased risk of jSLE, whereas it may be more likely to pathogenic if raised 
in males. 
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Conversely, it was seen that the PBMC TLR9 gene expression was decreased in post pubertal 
volunteers. Various murine lupus models have demonstrated that TLR9 expression may be 
protective against disease development, whereas TLR7 gene expression mediated 
inflammation, IFNα production and disease progression (234, 235, 271, 272). Importantly, 
despite no baseline difference in IFN score, the upregulated IFN score was significantly higher 
in the post pubertal volunteers, which associated significantly with serum oestradiol, after 
correcting for X chromosome number and serum testosterone. This too may predispose 
females with a higher oestradiol to develop jSLE after puberty, with a more rigorous gene 
response to IFN stimulation.  
 Perhaps, the combination of a pubertal decrease in TLR9 gene expression, regardless of sex, 
along with an increased ability to upregulate ISG after puberty, linked specifically to oestradiol, 
may contribute to the increased risk of developing jSLE after puberty. Additionally, the specific 
increase in TLR7 expression after puberty in healthy females may account for at least some of 
the increased susceptibility seen in young women.  
Interestingly, in jSLE, as expected, the baseline IFN score was significantly higher than healthy 
volunteers, but the upregulated IFN score trended towards being lower than healthy 
volunteers. This suggests perhaps that PBMC in jSLE may have a level of exhaustion or relative 
downregulation in their ability to upregulate ISG in response to further IFN challenge.  
A limitation of these data is that the gene expression is not specific to a certain cell type but is 
from PBMC. It was not possible to get enough PBMC to separate out specific cells types (e.g. 
pDC) and assess their individual gene expression, which would be more informative.  
When studying gene expression in jSLE, it is difficult to tease out true differences, as many 
genes that may be of interest, are inherently over-expressed simply because they are ISG. In 
this study, the IFN score was used to control for the effect of background ISG upregulation 
when investigating the pattern of expression of individual ISG of interest in jSLE. This has not 
been done previously in other studies, and probably represents more accurate results. Indeed, 
genes such as TLR9 and RIG-1, which are ISG and have been reported to be upregulated in jSLE 
were relatively downregulated when the IFN score was controlled for.   
The ERE, LINE1 is known to be abundant in the human genome, compromising 17% of human 
DNA (218). Indeed, in this study, the expression of LINE1 gene was higher than any other gene 
included in the panel. In the absence of virus, it has been proposed that ERE may act as an 
endogenous source of nucleic acid substrate in SLE(219). It has been shown that LINE1 RNA 
transfection is capable of inducing TLR7 mediated type 1 IFN production (220). In addition, the 
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expression of ERE has been shown to be enriched in patients with SLE and is related to disease 
activity, although it is unclear whether this is due to primary disease or is due to an increased 
IFN signature, as LINE1 is known to be IFN inducible(221). In these data, it was shown that 
LINE1 gene expression trended towards being higher in jSLE, after correcting for IFN score. 
Even though this didn’t reach statistical significance, LINE1 was the only IFN inducible gene 
that showed a relative increase when correcting for ISG. This is important, as due to its 
abundance, LINE1 activity may be a logical target for future investigation for use in therapy of 
jSLE.  
6.6.  Conclusion  
 In this chapter, it was shown that in females, there was a higher PBMC gene expression of the 
RNA sensors, RIG-1 and MDA5 in general, and an increased expression of TLR7 in post pubertal 
females specifically. PBMC gene expression of TLR9 and LINE1 was lower in post pubertal 
volunteers with no sex difference observed, whereas the upregulated IFN score was 
significantly enhanced in post pubertal volunteers. There was no overall difference in PBMC 
TLR7 gene expression between healthy volunteers and those with jSLE, but males with jSLE did 
have a significantly higher TLR7 gene expression than healthy males. After correcting for the 
IFN score, PBMC gene expression of TLR9 was relatively decreased in jSLE, whereas LINE1 gene 
expression trended towards an increase.  
It was next investigated whether stratifying volunteers with jSLE as IFN positive or negative, 
revealed any further differences which were not evident when studying jSLE as a uniform 
group.  
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Chapter 7: Stratifying jSLE by IFN score  
It was reported in chapter 6 that 48% of young people with jSLE were IFN+. It was therefore 
investigated in a post hoc analysis, whether stratifying jSLE by IFN score showed further 
differences in immune phenotype, pDC function and PBMC gene expression.   
7.1. Clinical differences between IFN + and IFN – jSLE.  
 
Aim: To investigate whether clinical differences exist between young people with IFN+ and 
IFN- jSLE.  
Sub aims: 
i. To assess whether demographic differences (sex and ethnicity) exist between 
young people with IFN+ and IFN- jSLE. 
ii. To assess whether differences exist in disease activity, auto-antibody presence, 
drug therapy and organ involvement between young people with IFN+ and IFN- 
jSLE. 
 
7.1.1. Demographics 
7.1.1.2. Sex 
Fourteen out of twenty-nine (48%) patients with jSLE were IFN + (>2SD above the healthy 
mean). Nine out of eleven (45%) females were IFN+ vs five out of nine (55%) males. There was 
no significant sex difference in the percentage IFN+ when assessed by Chi squared test 
(p=0.599, Table 7-1.). The odds of being IFN+ were not significantly different between sexes 
when analysed by logistic regression (ExpB=1.528; p=0.60; 95% CI=0.314, 7.437). 
 IFN score Total 
Negative 
(<2SD) 
Positive 
(>2SD) 
Sex Female 11 9 20 
Male 4 5 9 
Total  15 14 29 
Table 7-1. There was no sex difference in the number of jSLE patients who were IFN+ or -. 
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 7.1.1.3. Ethnicity  
There was no significant difference in the likelihood of having a positive IFN score between 
ethnicities when analysed by logistic regression (Table 7-2).  Although not significant, probably 
due to small numbers (only 6 black patients in total) it should be noted that black patients had 
a 6-fold increase in the likelihood of being IFN+ than white patients (ExpB =6; p=0.152; 95% 
CI=0.516, 69.754).  
 IFN score Total Significance 
of B (p 
value) 
Exp 
(B) 
  
Negative 
(<2SD) 
Positive 
(>2SD) 
95% CI Exp (B) 
Ethnic 
groups  
White* 4 3 7     
South 
Asian 
3 2 5 0.839 0.800 0.093 6.848 
Mixed 1 0 1 1.000 0.000 0.000  
Black 1 5 6 0.152 6.000 0.516 69.754 
East 
Asian 
3 2 5 0.839 0.800 0.093 6.848 
Other 
** 
2 2 4     
Total  14 14 28     
Table 7-2. There were no significant differences in likelihood of being jSLE IFN+ or – based on 
ethnicity*White was reference category in model so no coefficient displayed. ** Other not 
included in logistic regression model as only 2 values. 
7.1.2. Disease activity 
 There were no significant differences in prednisone dose, SLEDAI, or clinical markers of 
disease activity (ESR, CRP, DsDNA, WCC or serum complement components, C3 or C4) between 
young people with jSLE who were IFN+ or IFN- when analysed by Mann Whitney U test.  
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Table 7-3. There were no significant differences in prednisone dose or clinical markers of 
disease activity between patients with jSLE who were IFN+ or IFN-.  
7.1.3. Auto-antibodies 
After correcting for all the measured auto-antibodies, if a patient had auto-antibodies towards 
RNP, the IFN score was on average 1010.94 counts higher than if they did not (p=0.044, 95% CI 
= 27.84, 1993.99) (Table 7-4, Fig. 7-1). By t-test (i.e. without correcting for the presence of 
other auto-antibodies), this translated to a mean difference in titre of 859 (p=0.018; 95% 
CI=162.57, 1555.94). When classifying IFN score into binary (+vs-) based on 2SD from the 
healthy mean, the presence of auto-antibodies towards RNP increased the odds of being IFN+ 
nearly 5 times (Exp B=4.875; p=0.089; 95% CI=0.785, 30.29) although this effect did not reach 
statistical significance.   
 IFN- (n=15) IFN+ (n=14)  
 Median Range Median Range Mann 
Whitney 
u test p-
value 
Prednisone 
(mg/day) 
0.0 0-10 4.0 0-15 0.310 
SLEDAI 2 0-10 3 0-24 0.635 
dsDNA 
(IU/ml) 
31 0-546 48 48-2827 0.905 
ESR 
(mm/hr) 
8 2-29 9 2-47 0.210 
CRP (mg/L) 0.60 0.6-3.1 0.8 0.6-3.7 0.880 
White cell 
count 
(x109/ml) 
4.90 3.5-10.7 5.16 1.07-7.28 0.830 
C3 (g/L) 1.07 0.71-1.44 0.98 0.33-1.7 0.804 
C4 (g/L) 0.14 0.06-0.29 0.185 0.0-0.43 0.301 
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Figure 7-1. IFN score was significantly higher if antibodies towards RNP were present. When 
analysed by t-test there was a significantly higher IFN score in the group that were RNP 
positive (p=0.018).  
Antibody (positive vs negative) B p 95% CI 
RNP 1010.914 *0.044 27.841 1993.988 
Ro 216.805 0.581 -585.323 1018.933 
La 689.093 0.194 -376.736 1754.923 
Sm 81.334 0.876 -986.268 1148.936 
dsDNA -131.130 0.765 -1027.691 765.431 
 Table 7-4. RNP associated significantly with IFN score after correcting for the presence of 
other auto-antibodies. A linear regression model was fitted to investigate for associations of 
the presence of auto-antibodies to IFN score. Only autoantibodies towards RNP associated 
significantly with IFN score after controlling for the presence of the other measured 
autoantibodies. 
7.1.4. Organ involvement  
Current or previous organ involvement in young people with jSLE was recorded. Only two 
patients had either neurological or cardiac disease respectively, and only two patients did not 
have skin disease.  Therefore skin, neurological and cardiac involvement were excluded from 
the analysis as they skewed results.  
When assessed by linear regression, the presence of renal, haematological or joint disease did 
not associate significantly with the IFN score (Table 7-5). 
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Table 7-5. Linear regression showed that IFN score did not associate with the presence of 
haematological, renal or joint disease. 
7.1.5. Drug therapy  
Only one patient was treatment naïve. This patient was newly diagnosed and had a high IFN 
score and a high disease activity. This individual was found to be highly influential in analysis of 
associations between drugs and IFN score so was excluded from these analyses (Fig. 7-2). No 
significant associations were seen between IFN score, mycophenylate dosage (B=0.255; 
p=0.453; 95% CI=-0.445, 0.96), azathioprine dosage (B=5.797; p=0.254; 95% CI=-4.57, 16.16) or 
hydroxychloroquine dosage (B=-1.669; p=0.53; 95% CI=-7.16, 3.82, Fig. 7-2.) when analysed by 
multiple linear regression.   
 
 
 
 
 
 
Organ system Involved? Count IFN Score  B p 
IFN+ IFN- Mean 95% CI 
   
Skin no 2.00 0.00 411.48 -
1244.5 
2067.48   
yes 12.00 14.00 1330.74 969.68 1691.79 
Haematological no 10.00 6.00 1041.21 746.30 1336.12 583.32 0.130 
yes 5.00 8.00 1473.73 767.85 2179.61 
Neurological no 13.00 14.00 1296.55 942.46 1650.64   
yes 2.00 0.00 405.48 281.91 529.04 
Renal no 9.00 12.00 1373.87 925.34 1822.41 -
390.55 
0.351 
yes 6.00 2.00 870.81 493.59 1248.03 
Arthritis no 7.00 4.00 1227.35 513.76 1940.94 164.24 0.656 
yes 5.00 9.00 1371.37 886.74 1856.00 
Cardiac no 13.00 11.00 1184.08 849.12 1519.03   
yes 2.00 3.00 1479.99 -
217.44 
3177.43 
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Figure 7-2. HCQ dose did not associate with IFN score. After an influential treatment naïve 
outlier was excluded, it was found that HCQ did not associate significantly with IFN score 
(p=0.53) by linear regression. 
7.2. Differences in immune cell phenotype in jSLE stratified by IFN score.  
It was previously shown in chapter 4 that the percentage of BDCA2+ pDC and CD11c+ cDC in 
PBMC was significantly lower in young people with jSLE, while there was a higher percentage 
of CD4+ and CD8+ T cells in jSLE. In addition, B cells and pDC from volunteers with jSLE 
expressed more of the IFN inducible surface marker, tetherin, when compared to healthy 
volunteers. It was investigated whether stratifying patients with jSLE showed any further 
differences in PBMC subset percentage or tetherin expression.  
Aim: To investigate whether differences exist in immune cell phenotype when jSLE is stratified 
by IFN score.  
Sub-Aims:  
i. To investigate whether differences exist in the percentage of each PBMC cell 
subtype when jSLE is stratified by IFN score.  
ii. To investigate whether differences exist in the expression of tetherin by pDC, CD4+ 
T cells, CD8+ T cells and B cells, when jSLE is stratified by IFN score.  
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7.2.1. B cell depletion did not associate with IFN score.  
Four of the patients with jSLE were B cell depleted (<2% of PBMC). There was no association 
between the percentage of CD19+ B cells in PBMC and the IFN score (B=-1.424; p=0.956; CI=-
54.66, 51.82, Fig. 7-3). Due to their influence on the relative expression of other cell types 
however, these volunteers were excluded from further analysis of cell subtype percentage.  
 
Figure 7-3. IFN score did not associate with the percentage of CD19+ B cells in PBMC. Analysed 
by linear regression.  
7.2.2. PBMC subtypes when jSLE was stratified by IFN score.  
The percentage of individual PBMC cell types were analysed by ANOVA with post hoc testing 
and Bonferroni adjustment for multiple correction. There was a decrease in the percentage of 
BDCA2+ pDC (ANOVA p=0.072) between IFN+ jSLE, IFN- jSLE and healthy volunteers, although 
this did not reach statistical significance (Fig 7-4a). There were no overall significant 
differences in the percentage of CD19+ B cells (ANOVA p=0.323); CD4+ T cells (ANOVA 
p=0.507); CD8+ T cells (ANOVA p=0.139) and CD14+ monocytes ( ANOVA p=0.298) between 
groups (Fig. 7-4b,c,d,f). There was a significant difference in the percentage of CD11c+ cDC 
between healthy volunteers and those with IFN+ jSLE (p=0.035) (Fig 7-4e).  
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Figure 7-4. PBMC cell subtype stratified by IFN score. There was no significant difference in the 
percentage of a. pDC, b. CD19+ B cells, c. CD4 T cells, d. CD8 T cells or f. CD14+ monocytes 
when stratified by IFN score by ANOVA with Bonferroni correction . e. There was a significantly 
higher %CD11c+ DC between healthy volunteers and IFN- jSLE ( adjusted post hoc p=0.035). 
(Healthy=22; jSLE IFN-=14, IFN+=8). 
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7.2.3. Tetherin expression when jSLE was stratified by IFN score.  
Surface tetherin expression was measured by flow cytometry on all cell types in the 
lymphocyte compartment and compared by ANOVA with post hoc analysis and Bonferroni 
correction for multiple testing (analysis summarised Table 7-6, Fig. 7-5).  
Tetherin expression was significantly higher in IFN+ vs IFN- jSLE in CD4+ T cells (p=0.006) and 
CD8+ T cells (p=0.007) (Fig 7-5a, b.). Tetherin expression was higher in IFN+ jSLE than healthy 
controls in CD4+ T cells (p=0.077); CD8+ T cells (p= 0.012); pDC (p=0.004) and B cells (p=0.034).  
 
Cell type Post hoc test P value 
(corrected) 
Mean 
difference 
95% CI 
CD4+ T cell 
tetherin MFI 
healthy vs 
IFN+  
0.077 33.7 4.624 122.653 
IFN- vs IFN+  *0.006 92.714 22.968 162.46 
CD8+ T cell 
tetherin MFI 
healthy vs 
IFN+  
*0.012 143.663 26.076 261.250 
IFN- vs IFN+  *0.007 164.536 37.569 291.502 
pDC tetherin 
MFI 
healthy vs 
IFN+  
**0.004 284.326 80.089 488.562 
IFN- vs IFN+  0.121 187.071 33.456 407.599 
B cell 
tetherin MFI 
healthy vs 
IFN+  
*0.034 154.16 9.02 299.3 
Table 7-6.  PBMC cell type tetherin expression. PBMC cell type tetherin expression was 
measured and compared by ANOVA with Bonferroni post hoc correction.  
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Figure 7-5. CD4+ T cell tetherin surface expression was higher in IFN+ jSLE.  a. CD4+ T cell 
tetherin was higher in IFN+ vs IFN- jSLE (p=0.006). b.CD8+ T cell tetherin was higher in IFN+ vs 
IFN- jSLE (p=0.007). c-d. B cell (p=0.560) or pDC (p=0.141) tetherin expression was not 
significantly different between IFN+ vs IFN- jSLE. ANOVA was performed and p values are all 
corrected by Bonferroni method. (Healthy=22; jSLE IFN-=14, IFN+=8). 
7.2.4. CD4+ T cell tetherin expression correlated strongly with IFN score.  
After noting that CD4+ T cell expression was significantly higher in IFN+ vs IFN- jSLE, it was 
investigated how well surface tetherin expression on CD4+ T cells correlated with IFN score in 
volunteers with jSLE only. CD4+ T cell tetherin expression correlated strongly with IFN score in 
jSLE (Pearson R2=0.878; p=0.001, Fig. 7-6.). There was one jSLE patient with a high IFN score 
and CD4+ T cell tetherin expression. When this patient was excluded, there was still a 
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significant correlation (Pearson R2=0.634; p=0.005), implying that this individual was not 
influential.  
There were significant correlations between IFN score and surface tetherin expression on CD8+ 
T cells (Pearson R2=0.617; p=0.002); pDC (Pearson R2=0.423; p=0.050) and B cells (Pearson 
R2=0.601; p=0.003) although none reached the same strength of correlation as CD4+ T cell 
tetherin expression.  
Figure 7-6. There was a strong correlation between CD4+ T cell tetherin expression and PBMC 
IFN score in jSLE. n=20 
7.3. TLR induced pDC IFNα production in jSLE stratified by IFN score. 
In chapter 5, it was seen that there was no difference in the TLR7 induced production of IFNα 
between volunteers with jSLE and healthy volunteers. It was investigated whether differences 
existed when jSLE was stratified according to IFN score.  
7.3.1. There were no differences in TLR7 induced pDC IFNα production when jSLE was 
stratified by IFN score.  
There were no significant differences in the percentage of pDC producing IFNα after R848 
stimulation between healthy volunteers and those with jSLE (either IFN+ or IFN-) when 
analysed by ANOVA with post hoc testing and Bonferroni adjustment (Fig 7-7a). There was a 
significantly lower percentage of pDC producing IFNα after CpG stimulation in IFN+ (p=0.019; 
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mean difference=15.677; 95% CI=1.410, 19.434) and IFN- (p=0.002; mean difference=10.422; 
95% CI= 1.41, 19.434) jSLE when compared to healthy volunteers (Fig. 7-7b). There was no 
significant difference in the percentage of pDC producing IFNα between IFN+ and IFN- jSLE 
however (p=0.709; mean difference=5.225; 95% CI=-5.67, 16.187). 
Patients with jSLE are often lymphopenic and volunteers with jSLE frequently had fewer PBMC 
per ml of blood. For this reason, only 3 volunteers with jSLE who were IFN+ had sufficient cells 
to stimulate with CpG or R848 and measure the PBMC production of cytokine into 
supernatant. For this reason, these data were not analysed in the post hoc stratification of jSLE 
by IFN score.  
 
Figure 7-7. IFN+ jSLE volunteers have significantly less pDC producing IFNα after CpG 
stimulation.    a. There were no significant differences in the percentage of pDC producing IFNα 
between healthy volunteers and IFN+ or IFN- jSLE after R848 stimulation when analysed by 
ANOVA with Bonferroni correction. b. After CpG stimulation there was significantly lower 
percentage of pDC producing IFNα in IFN- (p=0.019) and IFN+ (p=0.002) jSLE when compare to 
healthy volunteers(Healthy=24; jSLE IFN-=15, IFN+=14). 
 
7.4. Gene expression in jSLE stratified by IFN score.   
 In chapter 5 it was shown that there was no significant difference in PBMC gene expression of 
TLR7 in jSLE as compared to healthy volunteers. After correcting for IFN score, there was a 
relative decrease in TLR9 and RIG-1 gene expression and a relative increase in LINE1 gene 
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expression in jSLE. A post hoc analysis was performed to assess for differences in gene 
expression when jSLE was stratified by IFN score. 
7.4.1. TLR7 gene expression was significantly higher in IFN+ jSLE.   
 TLR7 had been confirmed to not be significantly IFN inducible in 6.4.2. and was therefore 
analysed by ANOVA with Bonferroni corrected post hoc analysis, without correcting for IFN 
score. 
There was a significantly higher PBMC gene expression of TLR7 in IFN+ jSLE than healthy 
volunteers (p=0.022; mean difference=12.615; 95% CI=1.4-23.773; Figure 7-8). Patients with 
jSLE who were IFN+ had a significantly higher PBMC TLR7 gene expression than IFN- jSLE 
(p=0.002; mean difference=18.214; 95% CI=5.883, 30.54). 
 
Figure 7-8. PBMC TLR7 gene expression was significantly higher in patients with IFN+ jSLE. 
Volunteers with IFN+ jSLE had a higher PBMC TLR7 gene expression than healthy volunteers 
(p=0.002) and those with IFN- jSLE (p=0.002) when analysed by linear regression, controlling 
for IFN score. (Healthy=24; jSLE IFN-=15, IFN+=14). P values shown represent significance of 
the coefficient for the independent variable shown when analysed by linear regression 
7.4.2. TLR9 and RIG-1 gene expression were not increased in IFN+ or IFN- jSLE after 
controlling for IFN score.  
It was shown in 6.4.2. that TLR9 and RIG-1 were both ISG. Therefore, when analysing for 
differences in expression of these genes, the effect of IFN score was controlled for through use 
of linear regression modelling. This showed that there was significantly less PBMC TLR9 gene 
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expression in IFN- jSLE when compared to healthy volunteers (B=-6.602; p=0.027; 95% CI=-
12.420, -0.784) after controlling for IFN score. There was no significant difference between 
healthy volunteers and IFN+ jSLE (B-=-2.236; p=0.604; 95% CI= -0.849, 6.378). RIG-1 expression 
was lower in both IFN- (B=-34.879; p=0.111; 95% CI=-78.065, 8.307) and IFN+ (B=-64.669; 
p=0.048; 95% CI=-128.599, -0.738) jSLE when compared to healthy volunteers, but only 
reached statistical significance in IFN+ jSLE.  
7.4.3. LINE1 gene expression was higher in IFN+ jSLE after controlling for IFN score. 
After correcting for IFN score and assessing by linear regression, it was seen that IFN+ jSLE had 
a significantly higher expression of LINE1 than healthy volunteers (B=1564.395; p=0.007; 95% 
CI= 450.007, 2678.783) (Fig 7-9). There was no significant difference between healthy 
volunteers and IFN- jSLE (B= 473.585; p=0.212; 95% CI=-279.190, 1226.361).  
Figure 7-9. PBMC LINE1 gene expression was significantly higher in patients with IFN+ jSLE. 
Volunteers with IFN+ jSLE had a higher PBMC LINE1 gene expression than healthy volunteers 
(p=0.007) when analysed by linear regression, controlling for IFN score. (Healthy=24; jSLE IFN-
=15, IFN+=14). P values shown represent significance of the coefficient for the 
independent variable shown when analysed by linear regression 
7.5. Discussion 
There is an overabundance of ISG expression in jSLE which correlates with disease 
activity(189). More recently, ISG expression has been used to successfully stratify patients in 
trials of the anti- IFNα monoclonal antibody, sifalimumab (170) and the type 1 IFN receptor 
antagonist, anifrolumab(186) . These phase II trials have both shown a differential effect of 
therapy depending on whether the patient is ‘IFN high’ or ‘IFN low’.  
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In this study, patients with low disease activity were specifically recruited. In this group, only 
half of the patients with jSLE were IFN+, by the relatively strict (and arbitrary) criteria of being 
>2SD from the mean of healthy individuals of roughly the same age. This is lower than previous 
studies in children which have reported that up to 80% of jSLE expresses an overall 
‘upregulated IFN signature’(189). This may be due to the deliberate selection of patients with 
low disease activity, but also due to the stringent criteria for an IFN+ classification in this study. 
Adult studies using this same criteria  vary from a prevalence of 50% IFN+ patients in low 
disease activity studies, up to 75% ‘IFN high’ patients in moderate to severe disease activity 
studies(273). 
It has been reported previously that jSLE is more prevalent, with a worse clinical phenotype 
and damage scores in non-white population groups (138, 140, 274, 275). In addition, there is a 
trend among adult studies that include stratification by IFN score for non-white SLE patients to 
be ‘IFN-high’ (273) and among gene expression data for there to be an increased IFN signature 
in non-white patients (200, 276, 277). The problem is that these studies, like the current data, 
are performed in Western cohorts and have proportional under-representation of non-white 
ethnic groups, despite the disease being least prevalent in white populations. Indeed, in these 
data, there was a non-significant trend for black patients to be 6 times more likely to be IFN+ 
as compared to white patients, which is interesting given that there were only 6 black patients 
recruited. If indeed there is a clinical difference in the therapeutic efficiency of drugs based on 
IFN score, then these ethnic differences will become important in therapeutic decision making 
and warrant further research. This finding needs to be confirmed in a larger cohort, which 
includes more non-white participants. 
The only clinical variable that associated significantly with IFN score was the presence or 
absence of autoantibodies towards RNP in fitting with previous literature (201). Previous 
clinical associations have been seen between IFN score and disease activity measures such as 
SLEDAI(189). These were not seen in this study, probably due to the deliberate selection of low 
disease activity patients.  
The IFN gene expression signature is difficult and time consuming to measure and standardise. 
In addition, serum IFNα cannot be measured in a clinical laboratory with any level of accuracy 
currently. If IFN score is to be used as a routine stratification measure in jSLE, there is a need 
for an easier, accurate measure of IFN activity. Tetherin is an anti-viral protein is expressed 
constitutively only on pDC and B cells but expressed widely upon IFN stimulation. In jSLE 
patients, among the tetherin expression in cells in the lymphocyte compartment, we found a 
strong correlation between CD4+ T cell tetherin expression and the IFN signature. CD4+ T cell 
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tetherin expression therefore may be a good target for future investigation as a clinical 
biomarker to distinguish between IFN high or IFN low jSLE, and more research is warranted in 
the future. 
In addition to the clinical implications of stratifying jSLE patients by IFN score, we investigated 
whether stratification may lead to any further insights into type 1 IFN associated pathways in 
jSLE. To this end, it was seen that there were no significant differences in the percentage of 
pDC producing IFNα when stimulated with a TLR7 agonist, regardless of IFN stratification. 
There was still a significant decrease in the percentage of pDC producing IFNα upon TLR9 
stimulation as compared to healthy controls, regardless of IFN score stratification. Once again, 
all these patients were on hydroxychloroquine, which may interfere with TLR7 and 9 functions. 
Regardless of that, stratification by IFN score did not change the trend seen in chapter 5, for a 
decreased pDC IFNα production in jSLE after TLR9 stimulation, but an unchanged production in 
jSLE after TLR7 stimulation.  
There was however a difference in the PBMC gene expression of TLR7 when stratified by IFN 
score. In chapter 6, it was reported that there was no significant difference in TLR7 gene 
expression in jSLE as compared to healthy volunteers. Upon stratification however, a 
significantly higher TLR7 gene expression was seen in IFN+ jSLE patients as compared to 
healthy volunteers and IFN- jSLE. It was confirmed in chapter 6 that TLR7 was not IFN 
inducible, so this effect can be assumed to be not due to the general upregulation of ISG in 
jSLE. There is a well described pathogenic link between TLR7 expression and SLE in mouse 
models (231, 232). These data raise the question of whether there is TLR7 gene expression 
may be a pathological influence in SLE, depending on whether the disease is IFN+ or IFN-. TLR7 
may be a logical target for investigation in jSLE, but a stratified approach may be necessary.  
Lastly, the significant over-expression of LINE1 in IFN+ jSLE and not in IFN- jSLE, after correcting 
for IFN score was interesting. As stated in chapter 6, there is potential to target ERE RNA in 
jSLE to decrease the amount of RNA substrate available for TLR7 stimulation. This also adds 
insight into the importance of stratifying this approach, based on the IFN score of the patient.   
7.6. Conclusion  
jSLE is a heterogeneous disease and stratifying by IFN gene expression score may be useful in 
assessing the pathophysiology of disease, as well as designing therapeutic targets. These data 
show that among baseline, relatively inactive disease, on relatively low steroid dose, roughly 
half of young people with jSLE have an IFN gene expression score that is significantly higher 
than healthy volunteers. Stratifying by IFN score has allowed us to show an over-expression of 
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TLR7 and LINE1 RNA expression in IFN+ patients, which was not obvious when investigating the 
patients as a homogenous group.  
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Chapter 8: Conclusion and future work  
This brief chapter will summarise the most important findings of this work and mention their 
importance, limitations and relevance to the field. New research questions arising from this 
work and future aims will be explored. 
8.1. pDC were inherently more activated and expressed more anti-viral 
surface protein, tetherin in females as compared to males. 
These data demonstrated for the first time in healthy young people that pDC were more 
activated in females (Fig. 4-3) and expressed more tetherin surface protein (Fig. 4-6). In this 
population, this related to the number of X chromosomes present, and not serum oestradiol or 
testosterone concentrations (Fig 4-4; 4-7). This is a remarkable observation, in ex-vivo cells 
from healthy young volunteers, where a basic demographic variable such as sex might not be 
expected to show a significant difference in the activation and priming of such a potent cell 
type. This underpins the importance of sex as a variable in biology and may explain some of 
the increased response of females to viral infection, vaccination and their predisposition 
towards jSLE. These findings now need to be confirmed in a separate population. In addition, 
pDC specific gene expression may be explored to assess whether these trends exist in the gene 
expression of pDC specifically.  
8.2. Female pDC inherently produced more IFNα after TLR7 stimulation 
regardless of puberty. 
These data show, for the first time in children and adolescents, that females had a higher 
percentage of pDC producing IFNα after TLR7 stimulation than males, regardless of pubertal 
status (Fig. 5-6). This effect was significant and substantial, especially given that these were 
healthy volunteers. It was demonstrated for the first time in humans, that the TLR7 induced 
production of type 1 IFN was significantly and substantially associated with the presence of 
two X chromosomes, regardless of serum oestradiol or testosterone concentrations (Fig. 5-9). 
The unique young human volunteers in this study allowed for a model that could uncouple the 
relationship between sex steroid and X chromosome number in humans. This implies that 
female pDC are not only inherently more activated than males, but also produce more type 1 
IFN after TLR7 stimulation. This increased potential to react to RNA ligands adds to our 
understanding of why females have an enhanced antiviral and vaccine immune response. In 
jSLE, there is emerging opinion from the literature that an enhanced response to type 1 IFN 
may underpin pathogenesis. Therefore, if female pDC are inherently more capable of 
producing IFNα after RNA ligand stimulation, this may contribute to female’s predisposition to 
develop jSLE.  
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8.3. Puberty and testosterone associated with more pDC producing IFNα 
after TLR7 stimulation  
Remarkably, healthy volunteers who had completed puberty also showed a significant increase 
in the pDC production of IFNα specific to TLR7 stimulation when controlling for sex (Fig. 5-6). 
The human model revealed that serum testosterone associated positively with the TLR7 
induced production of type 1 IFN in the presence of two X chromosomes, and negatively in the 
presence of one. Oestradiol has often been assumed to be responsible for sex differences in 
immunity, but in this population, controlling for oestradiol, testosterone showed the more 
significant effect. This is the first time that all of these variables  have been analysed together 
in this manner and allow for the intriguing possibility that sex hormone may associate with 
immunity differently, depending on the number of X chromosomes present. These findings 
need to be confirmed in a separate, larger population group.  
8.4. Females expressed more of the genes coding for RNA sensors than 
males 
 After observing that females had more activated pDC, with a higher tetherin expression, and 
produced more IFNα after TLR7 stimulation, it was further demonstrated that females 
expressed more of the genes coding for RNA-sensors RIG-1 and MDA5 (Fig. 6-4). This fits with 
the observation above that females seem more primed to detect RNA ligand than males. TLR7 
gene expression was increased in females, but only after puberty (Fig. 6-4). Surprisingly, RIG-1 
and MDA5 gene expression associated with the number of X chromosomes whereas TLR7, 
which is coded for on the X chromosome, did not (Fig. 6-9). No explanation for this can be 
provided. Future research aims to focus on the pDC specific gene copy number of TLR7 in 
females across puberty, to assess whether puberty associates with a dynamic increase in bi-
allelic pDC expression of TLR7, and if true, explore underlying factors that may associate with 
this.  
Conversely TLR9 gene expression was lower in the post pubertal volunteers and associated 
with testosterone (Fig 6-5). TLR7 gene expression has been shown to be important for lupus 
pathogenesis in murine models, whereas TLR9 gene expression may be relatively protective. 
The observed increase in TLR7 gene expression in females after puberty, along with a decrease 
in TLR9 gene expression may contribute to the increased risk of females to develop jSLE 
around puberty.   
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8.5. TLR7 and TLR9 behave differently in jSLE 
It was observed that TLR9 induced production of all measured cytokines, including IFNα, was 
decreased in jSLE as compared to healthy volunteers (Fig 5-13). Similarly, the relative gene 
expression of TLR9 in jSLE was decreased after correcting for the IFN score (Fig. 7-8). Indeed, 
when jSLE was stratified by IFN score, there was a further significant decrease in the amount of 
IFNα produced after TLR9 stimulation in IFN+ patients (Fig. 7-7), suggesting negative feedback 
between TLR9 induced cytokine production and background IFNα. This is the first time that IFN 
gene expression score has been controlled for when assessing individual gene expression in 
this manner. 
Conversely, the TLR7 induced production of IFNα was not different in low disease activity jSLE, 
although the TLR7 induced production of TNFα was increased (Fig. 5-12). In addition, the 
expression of TLR7 gene was higher in males with jSLE compared to healthy males, but not 
altogether increased in low disease activity jSLE (Fig. 6-14). Interestingly, when stratified by IFN 
score, it was shown that IFN+ patients expressed significantly more TLR7 gene than healthy 
volunteers or IFN- jSLE patients (Fig. 7-8). These experiments need to be extended to include 
patients with moderate to severe jSLE, to assess whether TLR7 induced IFNα production and 
TLR7 gene expression remains the same or is increased as compared to healthy volunteers. It 
may stand to reason, that the appropriate response to a high background IFN would be a 
compensatory down-regulation in the expression and IFN producing capacity of TLR to prevent 
a sustained forward feedback loop, as is seen with TLR9. Therefore, the observation that TLR7  
gene expression is not changed overall, and increased in IFN+ jSLE is important. Future work is 
needed to assess whether TLR7 gene expression and TLR7 induced IFNα production is 
appropriate in jSLE, given the high background IFN, and to explore whether TLR7 may be a 
valid target for future therapies. 
8.6. Stratifying jSLE by IFN score  
These data are the first to actively stratify young people with low disease activity based on 
background IFN induced gene expression score. It was observed that roughly half of the young 
people with jSLE were IFN+ based on this classification (Fig. 6-12), which was similar to adults 
with low to moderate disease activity SLE. It has previously been reported that jSLE shows an 
almost universal upregulated IFN gene signature, but this has not been observed here. In 
addition, stratifying by IFN score allowed for the observation that TLR7 gene expression was 
increased in IFN+ disease, which was not the case for jSLE as a whole. Interestingly, the only 
ISG that was not relatively down-regulated in jSLE upon correcting for IFN score was the 
endogenous retroelement LINE1 (Fig. 6-16; Fig. 7-9). This serves as an interesting pathway to 
investigate whether targeting the activity of LINE1 may be beneficial in jSLE.  
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It was also shown that CD4 T cell tetherin surface protein expression correlated strongly with 
IFN score, and future work is necessary to assess whether this may serve as a useful biomarker 
for background type 1 IFN activity (Fig. 7-6).  
Limitations of this study include the fact that these data were from a large population group 
and are broad and associative in nature. Further specific functional work, as mentioned above, 
is necessary to dissect these findings. 
8.7. Conclusion 
The original hypothesis to be tested was:  
‘Puberty associates with an increased TLR7 mediated type 1 IFN production in females.’ 
It has been shown that puberty and female sex associate with an increased TLR7 mediated 
type 1 IFN production in females and that this is related to X chromosome number and serum 
testosterone. Although the data suggests that TLR7 gene expression and function is important 
in jSLE, a direct causal link has not been shown here. The role of TLR7 and TLR9 in jSLE, and the 
potential of TLR7 as a therapeutic target underpin future research in jSLE.  
8.8 Future work.  
 
• Establish whether pDC specific gene expression of ISG and other genes in the type 1 
IFN pathway associate with sex and puberty, and change in jSLE, using the ongoing 
cohort of young people recruited to the Arthritis Research UK Centre for Adolescent 
Rheumatology. Briefly, pDC will be separated from PBMC by bead based magnetic cell 
separation and analysed for RNA gene expression using the same Nanostring assay. 
• Investigate whether puberty associates with an increase in bi-allelic TLR7 gene 
expression in pDC in healthy females and assess for underlying chromosomal and 
hormonal factors that may associate with this. This would involve young people 
recruited to the above cohort and use allele-specific KASP (KBiosciences) PCR (as used 
in Souyris et al(127)) to discriminate the relative abundance of cells that are mono-
allelic or bi-allelic for TLR7. 
• Assess whether TLR7 induced IFNα production and TLR7 gene expression is increased 
in severe to moderate disease activity jSLE as compared to healthy volunteers. This 
would include recruiting young people with higher disease activity jSLE from the above 
cohort and analysing by Nanostring. 
• Assess whether background IFN stimulation associates with a change in TLR7 induced 
IFNα production and TLR7 gene expression in healthy volunteers. This experiment 
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would include pre-stimulating PBMC with various dosages of IFNα for varying times, to 
assess whether this influences the subsequent production of IFNα or expression of 
TLR7 gene.  
• Investigate whether LINE1 copy number and retrotransposition is increased in jSLE by 
performing RNA sequencing on a larger cohort of young people with jSLE. 
• Investigate, in a larger population of young people with jSLE, whether CD4 surface 
tetherin expression (as measured by flow cytometry) serves as a useful biomarker for 
high IFN signature disease.  
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